

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 00/23588

(51) International Patent Classification ⁷ :

C12N 15/12, C07K 14/705, 16/28, G01N
33/53, C12Q 1/68, A61K 31/70, 38/17,
A01K 67/027

A2

(11) International Publication Number:

(43) International Publication Date:

27 April 2000 (27.04.00)

(21) International Application Number: PCT/US99/24368

(22) International Filing Date: 18 October 1999 (18.10.99)

(30) Priority Data:
09/173,869 16 October 1998 (16.10.98) US
Not furnished 18 October 1999 (18.10.99) US

(71) Applicant (for all designated States except US): MILLEN-
NIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney
Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GLUCKSMANN, Maria,
Alexandra [AR/US]; 33 Summit Road, Lexington, MA
02173 (US). WEICH, Nadine, S. [US/US]; 70 Park Street
#53, Brookline, MA 02446 (US).

(74) Agents: BROWN, Anne et al.; Alston & Bird LLP, P.O. Drawer
34009, Charlotte, NC 28234-4009 (US).

(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ
(Utility model), DE, DE (Utility model), DK, DK (Utility
model), DM, EE, EE (Utility model), ES, FI, FI (Utility
model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO
patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN,
TD, TG).

Published

Without international search report and to be republished
upon receipt of that report.

(54) Title: G-PROTEIN COUPLED RECEPTORS

(57) Abstract

The present invention relates to newly identified receptors belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptors. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

G-PROTEIN COUPLED RECEPTORS

FIELD OF THE INVENTION

The present invention relates to newly identified receptors belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptors. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated or -related disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.

BACKGROUND OF THE INVENTION

15

G-protein coupled receptors

G-protein coupled receptors (GPCRs) constitute a major class of proteins responsible for transducing a signal within a cell. GPCRs have three structural domains: an amino terminal extracellular domain, a transmembrane domain containing seven transmembrane segments, three extracellular loops, and three intracellular loops, and a carboxy terminal intracellular domain. Upon binding of a ligand to an extracellular portion of a GPCR, a signal is transduced within the cell that results in a change in a biological or physiological property of the cell. GPCRs, along with G-proteins and effectors (intracellular enzymes and channels modulated by G-proteins), are the components of a modular signaling system that connects the state of intracellular second messengers to extracellular inputs.

25

GPCR genes and gene-products are potential causative agents of disease (Spiegel *et al.* (1993) *J. Clin. Invest.* 92:1119-1125; McKusick *et al.* (1993) *J. Med.*

(*Genet.* 30 1-26) Specific defects in the rhodopsin gene and the V2 vasopressin receptor gene have been shown to cause various forms of retinitis pigmentosum (Nathans *et al.* (1992) *Annu. Rev. Genet.* 26 403-424), and nephrogenic diabetes insipidus (Holtzman *et al.* (1993) *Hum. Mol. Genet.* 2 1201-1204). These receptors
5 are of critical importance to both the central nervous system and peripheral physiological processes. Evolutionary analyses suggest that the ancestor of these proteins originally developed in concert with complex body plans and nervous systems.

The GPCR protein superfamily can be divided into five families. Family I, receptors typified by rhodopsin and the β 2-adrenergic receptor and currently
10 represented by over 200 unique members (Dohlman *et al.* (1991) *Annu. Rev. Biochem.* 60 653-688); Family II, the parathyroid hormone/calcitonin/secretin receptor family (Juppner *et al.* (1991) *Science* 254:1024-1026, Lin *et al.* (1991) *Science* 254:1022-1024; Family III, the metabotropic glutamate receptor family (Nakanishi (1992)
15 *Science* 258 597-603); Family IV, the cAMP receptor family, important in the chemotaxis and development of *D. discoideum* (Klein *et al.* (1988) *Science* 241:1467-1472); and Family V, the fungal mating pheromone receptors such as STE2 (Kurjan (1992) *Annu. Rev. Biochem.* 61:1097-1129).

There are also a small number of other proteins which present seven putative
20 hydrophobic segments and appear to be unrelated to GPCRs; they have not been shown to couple to G-proteins. *Drosophila* expresses a photoreceptor-specific protein, bride of sevenless (boss), a seven-transmembrane-segment protein which has been extensively studied and does not show evidence of being a GPCR (Hart *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:5047-5051). The gene frizzled (*fz*) in
25 *Drosophila* is also thought to be a protein with seven transmembrane segments. Like boss, *fz* has not been shown to couple to G-proteins (Vinson *et al.* (1989) *Nature* 338:263-264).

G proteins represent a family of heterotrimeric proteins composed of α , β and γ subunits, that bind guanine nucleotides. These proteins are usually linked to cell
30 surface receptors, e.g., receptors containing seven transmembrane segments. Following ligand binding to the GPCR, a conformational change is transmitted to the G protein, which causes the α -subunit to exchange a bound GDP molecule for a GTP molecule and to dissociate from the $\beta\gamma$ -subunits. The GTP-bound form of the α -subunit typically functions as an effector-modulating moiety, leading to the

production of second messengers, such as cAMP (e.g., by activation of adenylyl cyclase), diacylglycerol or inositol phosphates. Greater than 20 different types of α -subunits are known in humans. These subunits associate with a smaller pool of β and γ subunits. Examples of mammalian G proteins include Gi, Go, Gq, Gs and Gt. G proteins are described extensively in Lodish *et al. Molecular Cell Biology*, (Scientific American Books Inc., New York, N.Y., 1995), the contents of which are incorporated herein by reference. GPCRs, G proteins and G protein-linked effector and second messenger systems have been reviewed in *The G-Protein Linked Receptor Fact Book*, Watson *et al.* eds., Academic Press (1994).

10

Purinoceptors

Purines, and especially adenosine and adenine nucleotides, have a broad range of pharmacological effects mediated through cell-surface receptors. For a general review, see Adenosine and Adenine Nucleotides in *The G-Protein Linked Receptor Facts Book*, Watson *et al.* (Eds.) Academic Press 1994, pp. 19-31.

15

Some effects of ATP include the regulation of smooth muscle activity, stimulation of the relaxation of intestinal smooth muscle and bladder contraction, stimulation of platelet activation by ADP when released from vascular endothelium, and excitatory effects in the central nervous system. Some effects of adenosine include vasodilation, bronchoconstriction, immunosuppression, inhibition of platelet aggregation, cardiac depression, stimulation of nociceptive afferents, inhibition of neurotransmitter release, pre- and postsynaptic depressant action, reducing motor activity, depressing respiration, inducing sleep, relieving anxiety, and inhibition of release of factors, such as hormones.

20

Distinct receptors exist for adenosine and adenine nucleotides. Clinical actions of such analogs as methylxanthines, for example, theophylline and caffeine, are thought to achieve their effects by antagonizing adenosine receptors. Adenosine has a low affinity for adenine nucleotide receptors, while adenine nucleotides have a low affinity for adenosine receptors.

25

There are four accepted subtypes of adenosine receptors, designated A₁, A_{2A}, A_{2B}, and A₃. In addition, an A₄ receptor has been proposed based on labeling by 2-phenylaminoadenosine (Cornfield *et al.* (1992) *Mol. Pharmacol.* 42:552-561).

30

P_{2X} receptors are ATP-gated cation channels (See *Neuropharmacology* 36 (1977)). The proposed topology for P_{2X} receptors is two transmembrane regions, a large extracellular loop, and intracellular N and C-termini.

Numerous cloned receptors designated P_{2Y} have been proposed to be members of the G-protein coupled family. UDP, UTP, ADP, and ATP have been identified as agonists. To date, P_{2Y1-7} have been characterized although it has been proposed that P_{2Y7} may be a leukotriene B₄ receptor (Yokomizo *et al.* (1997) *Nature* 387:620-624). It is widely accepted, however, that $P_{2Y1, 2, 4, \text{ and } 6}$ are members of the G-protein coupled family of P_{2Y} receptors.

At least three P_2 purinoceptors from the hematopoietic cell line HEL have been identified by intracellular calcium mobilization and by photoaffinity labeling (Akbar *et al.* (1996) *J. Biochem.* 271:18363-18567).

The A_1 adenosine receptor was designated in view of its ability to inhibit adenylyl cyclase. The receptors are distributed in many peripheral tissues such as heart, adipose, kidney, stomach and pancreas. They are also found in peripheral nerves, for example intestine and vas deferens. They are present in high levels in the central nervous system, including cerebral cortex, hippocampus, cerebellum, thalamus, and striatum, as well as in several cell lines. Agonists and antagonists can be found on page 22 of *The G-Protein Linked Receptor Facts Book* cited above, herein incorporated by reference. These receptors are reported to inhibit adenylyl cyclase and voltage-dependent calcium channels and to activate potassium channels through a pertussis-toxin-sensitive G-protein suggested to be of the G_i/G_o class. A_1 receptors have also been reported to induce activation of phospholipase C and to potentiate the ability of other receptors to activate this pathway.

The A_{2A} adenosine receptor has been found in brain, such as striatum, olfactory tubercle and nucleus accumbens. In the periphery, A_2 receptors mediate vasodilation, immunosuppression, inhibition of platelet aggregation, and gluconeogenesis. Agonists and antagonists are found in *The G-Protein Linked Receptor Facts Book* cited above on page 25, herein incorporated by reference. This receptor mediates activation of adenylyl cyclase through G_s .

The A_{2B} receptor has been shown to be present in human brain and in rat intestine and urinary bladder. Agonists and antagonists are discussed on page 27 of *The G-Protein Linked Receptor Facts Book* cited above, herein incorporated by reference. This receptor mediates the stimulation of cAMP through G_s .

The A₃ adenosine receptor is expressed in testes, lung, kidney, heart, central nervous system, including cerebral cortex, striatum, and olfactory bulb. A discussion of agonists and antagonists can be found on page 28 of *The G-Protein Linked Receptor Facts Book* cited above, herein incorporated by reference. The receptor
5 mediates the inhibition of adenylyl cyclase through a pertussis-toxin-sensitive G-protein, suggested to be of the G_i/G_o class.

The P_{2Y} purinoceptor shows a similar affinity for ATP and ADP with a lower affinity for AMP. The receptor has been found in smooth muscle, for example, taeni caeci and in vascular tissue where it induces vasodilation through endothelium-
10 dependent release of nitric oxide. It has also been shown in avian erythrocytes. Agonists and antagonists are discussed on page 30 of *The G-Protein Linked Receptor Facts Book* cited above, herein incorporated by reference. The receptor function through activation of phosphoinositide metabolism through a pertussis-toxin-insensitive G-protein, suggested to be of the G_i/G_o class.

15 Accordingly, GPCRs, and especially purinoceptors, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown GPCRs. The present invention advances the state of the art by providing a previously unidentified human GPCR having homology to purinoceptors.

20

SUMMARY OF THE INVENTION

It is an object of the invention to identify novel GPCRs.

It is a further object of the invention to provide novel GPCR polypeptides that
25 are useful as reagents or targets in receptor assays applicable to treatment and diagnosis of GPCR-mediated disorders.

It is a further object of the invention to provide polynucleotides corresponding to the novel GPCR receptor polypeptides that are useful as targets and reagents in receptor assays applicable to treatment and diagnosis of GPCR-mediated disorders
30 and useful for producing novel receptor polypeptides by recombinant methods.

A specific object of the invention is to identify compounds that act as agonists and antagonists and modulate the expression of the novel receptors.

A further specific object of the invention is to provide compounds that modulate expression of the receptors for treatment and diagnosis of GPCR- related disorders

The invention is thus based on the identification of novel GPCRs, designated
5 the 2838, 14618, and 15334 receptors

The invention provides isolated 2838 receptor polypeptides including a polypeptide having the amino acid sequence shown in SEQ ID NO:1

The invention provides isolated 14618 receptor polypeptides including a polypeptide having the amino acid sequence shown in SEQ ID NO:3.

10 The invention provides isolated 15334 receptor polypeptides including a polypeptide having the amino acid sequence shown in SEQ ID NO:5

The invention also provides isolated 2838 receptor nucleic acid molecules having the sequence shown in SEQ ID NO:2

The invention also provides isolated 14618 receptor nucleic acid molecules
15 having the sequence shown in SEQ ID NO:4

The invention also provides isolated 15334 receptor nucleic acid molecules having the sequence shown in SEQ ID NO:6

The invention also provides variant polypeptides having an amino acid sequence that is substantially homologous to the amino acid sequence shown in SEQ
20 ID NO:1.

The invention also provides variant polypeptides having an amino acid sequence that is substantially homologous to the amino acid sequence shown in SEQ ID NO:3.

The invention also provides variant polypeptides having an amino acid
25 sequence that is substantially homologous to the amino acid sequence shown in SEQ ID NO:5.

The invention also provides variant nucleic acid sequences that are substantially homologous to the nucleotide sequence shown in SEQ ID NO:2.

The invention also provides variant nucleic acid sequences that are
30 substantially homologous to the nucleotide sequence shown in SEQ ID NO:4

The invention also provides variant nucleic acid sequences that are substantially homologous to the nucleotide sequence shown in SEQ ID NO:6

The invention also provides fragments of the polypeptide shown in SEQ ID NO.1 and nucleotide sequence shown in SEQ ID NO.2, as well as substantially homologous fragments of the polypeptide or nucleic acid.

5 The invention also provides fragments of the polypeptide shown in SEQ ID NO.3 and nucleotide sequence shown in SEQ ID NO.4, as well as substantially homologous fragments of the polypeptide or nucleic acid.

The invention also provides fragments of the polypeptide shown in SEQ ID NO.5 and nucleotide sequence shown in SEQ ID NO.6, as well as substantially homologous fragments of the polypeptide or nucleic acid.

10 The invention further provides nucleic acid constructs comprising the nucleic acid molecules described above. In a preferred embodiment, the nucleic acid molecules of the invention are operatively linked to a regulatory sequence.

The invention also provides vectors and host cells for expressing the receptor nucleic acid molecules and polypeptides and particularly recombinant vectors and
15 host cells.

The invention also provides methods of making the vectors and host cells and methods for using them to produce the receptor nucleic acid molecules and polypeptides.

20 The invention also provides antibodies or antigen-binding fragments thereof that selectively bind the receptor polypeptides and fragments.

The invention also provides methods of screening for compounds that modulate expression or activity of the receptor polypeptides or nucleic acid (RNA or DNA).

The invention also provides a process for modulating receptor polypeptide or nucleic acid expression or activity, especially using the screened compounds.
25 Modulation may be used to treat conditions related to aberrant activity or expression of the receptor polypeptides or nucleic acids.

The invention also provides assays for determining the presence or absence of and level of the receptor polypeptides or nucleic acid molecules in a biological sample, including for disease diagnosis.

30 The invention also provides assays for determining the presence of a mutation in the receptor polypeptides or nucleic acid molecules, including for disease diagnosis.

In still a further embodiment, the invention provides a computer readable means containing the nucleotide and/or amino acid sequences of the nucleic acids and polypeptides of the invention, respectively.

DESCRIPTION OF THE DRAWINGS

Figure 1 shows a comparison of the 2838 receptor against the Prosite data base of protein patterns, specifically showing a high score against the seven transmembrane segment rhodopsin superfamily. The underlined area shows a GPCR signature, and specifically the position of an arginine residue, conserved in GPCRs. The most commonly conserved sequence is an aspartate, arginine, tyrosine (DRY) triplet. DRY is implicated in signal transduction. Arginine is invariant. Aspartate is conservatively placed in several GPCRs. In the present case, the arginine is found in the sequence DRF, which matches the position of DRY or invariant arginine in GPCRs of the rhodopsin superfamily of receptors.

Figure 2 shows an analysis of the 2838 amino acid sequence: α turn and coil regions; hydrophilicity; amphipathic regions; flexible regions; antigenic index; and surface probability plot.

Figure 3 shows a 2838 receptor hydrophobicity plot. The amino acids correspond to 1-319 and show the seven transmembrane segments.

Figure 4 shows an analysis of the 2838 open reading frame for amino acids corresponding to specific functional sites. A glycosylation site is found at amino acids 5-8 which corresponds to the amino terminal extracellular domain. A second glycosylation site is found at amino acids 171-174 which corresponds to the second extracellular loop. A protein kinase C phosphorylation site is found at amino acids 134-136 which is in the second intracellular loop. A second protein kinase C phosphorylation site is found at amino acids 178-180 which is in the second extracellular loop. A casein kinase II phosphorylation site is found at amino acids 6-9 which is in the carboxy terminal intracellular domain. A second casein kinase II phosphorylation site is found at amino acids 95-98 which is in the first extracellular loop. An N-myristoylation site is found at amino acids 34-39 which is in the first transmembrane segment. A second N-myristoylation site is found at amino acids 107-112 which is in the third transmembrane segment. A third N-myristoylation site is found at amino acids 140-145 which is in the fourth transmembrane segment. An

amidation site is found at amino acids 209-212 which spans the fifth transmembrane segment and third intracellular loop. In addition, amino acids corresponding in position to the GPCR signature and containing the invariant arginine are found in the sequence DRF at amino acids 118-120.

5

Figure 5 shows a comparison of the 14618 receptor against the Prosite data base of protein patterns, specifically showing a high score against the seven transmembrane segment rhodopsin superfamily. The underlined area shows a GPCR signature, and specifically the position of an arginine residue, conserved in GPCRs.

10 The most commonly conserved sequence is an aspartate, arginine, tyrosine (DRY) triplet. DRY is implicated in signal transduction. Arginine is invariant. Aspartate is conservatively placed in several GPCRs. In the present case, the arginine is found in the sequence DRF, which matches the position of DRY or invariant arginine in GPCRs of the rhodopsin superfamily of receptors.

15

Figure 6 shows an analysis of the 14618 amino acid sequence: α turn and coil regions; hydrophilicity; amphipathic regions; flexible regions; antigenic index; and surface probability plot.

20

Figure 7 shows a 14618 receptor hydrophobicity plot. The amino acids correspond to 1-337 and show the seven transmembrane segments.

Figure 8 shows an analysis of the 14618 open reading frame for amino acids corresponding to specific functional sites. A glycosylation site is found at amino acids 6-9 which corresponds to the amino terminal extracellular domain. A second glycosylation site is found at amino acids 169-172 which corresponds to the second extracellular loop. A third glycosylation site is found at amino acids 180-183 which also corresponds to the second extracellular loop. A fourth glycosylation site found at amino acids 224-227 which corresponds to the third intracellular loop. A fifth glycosylation site is found at amino acids 262-265 which corresponds to the third extracellular loop. A cAMP- and cGMP-dependent protein kinase phosphorylation site is found at amino acids 304-307, 310-313, and 323-326, all in the carboxy terminal intracellular domain. A protein kinase C phosphorylation site is found at amino acids 136-138 which corresponds to the second intracellular loop. Second and

third protein kinase C phosphorylation sites are found at amino acids 220-222 and 227-229, both corresponding to the third intracellular loop. A fourth protein kinase C phosphorylation site is found at amino acids 308-310, corresponding to the carboxy terminal intracellular domain. Casein kinase II phosphorylation sites are found at amino acids 13-16 and 17-20, both in the amino terminal extracellular domain. A third casein kinase II phosphorylation site is found at amino acids 326-329 corresponding to the carboxy terminal intracellular domain. A microbodies C-terminal targeting signal is found at amino acids 335-338, corresponding to the carboxy terminal intracellular domain. In addition, amino acids corresponding in position to the GPCR signature and containing the invariant arginine are found in the sequence FRC at amino acids 120-122.

Figure 9 shows a comparison of the 15334 receptor against the Prosite data base of protein patterns, specifically showing a high score against the seven transmembrane segment rhodopsin superfamily. The underlined area shows a GPCR signature, and specifically the position of an arginine residue, conserved in GPCRs. The most commonly conserved sequence is an aspartate, arginine, tyrosine (DRY) triplet. DRY is implicated in signal transduction. Arginine is invariant. Aspartate is conservatively placed in several GPCRs. In the present case, the arginine is found in the sequence DRY, which matches the position of DRY or invariant arginine in GPCRs of the rhodopsin superfamily of receptors.

Figure 10 shows an analysis of the 15334 amino acid sequence: α turn and coil regions; hydrophilicity; amphipathic regions; flexible regions; antigenic index; and surface probability plot.

Figure 11 shows a 15334 receptor hydrophobicity plot. The amino acids show the seven transmembrane segments.

Figure 12 shows an analysis of the 15334 open reading frame for amino acids corresponding to specific functional sites. Glycosylation sites are found at amino acids 4-7 and 9-12, which are in the amino terminal extracellular domain. A glycosylation site is also found at amino acids 251-254, which is in the sixth transmembrane segment. A further glycosylation site is found from amino acid 323-

326, which is in the carboxy terminal domain. A cAMP- and cGMP-dependent protein kinase phosphorylation site is found at amino acids 229-232, which is in the third intracellular loop. Protein kinase C phosphorylation sites are found from amino acids 21-23, which corresponds to the amino terminal domain, 211-213, 226-228, and 232-234, which corresponds to the third intracellular loop, and 307-309 and 332-334, which corresponds to the carboxy terminal intracellular domain. A casein kinase II phosphorylation site is found from amino acids 178-181, which is in the second extracellular loop and from 342-345, which is in the carboxy terminal intracellular domain. N-myristoylation sites are found at amino acids 36-41, which is in the amino terminal extracellular domain, 258-263, which spans the sixth transmembrane segment and third extracellular loop, and 324-329, which corresponds to the carboxy terminal intracellular domain. In addition, a GPCR signature, DRY, is found at amino acids 118-120, which is in the second intracellular loop.

Figure 13 shows expression of the 14618 receptor in various normal human tissues.

Figure 14 shows the 14618 receptor expression in various tissues and in cells of the hematopoietic system.

Figure 15 shows expression of the 2838 receptor in various cells and tissues, including cells of the hematopoietic system.

Figure 16 shows expression of the 15334 receptor in normal human tissues.

Figure 17 shows expression of the 15334 receptor in various tissues and in cells of the hematopoietic system.

Figure 18 shows expression of the 15334 receptor in various hematopoietic cells/cell lines, including erythroid and megakaryocyte cells.

Figure 19 shows expression of the 15334 receptor in various hematopoietic cells or cell lines, including erythroid and megakaryocyte cells.

DETAILED DESCRIPTION OF THE INVENTION

Receptor function/signal pathway

The 2838, 14618, and 15334 receptor proteins are GPCRs that participate in signaling pathways. As used herein, a "signaling pathway" refers to the modulation (e.g., stimulation or inhibition) of a cellular function/activity upon the binding of a ligand to the GPCR (2838, 14618, or 15334 protein). Examples of such functions include mobilization of intracellular molecules that participate in a signal transduction pathway, e.g., phosphatidylinositol 4,5-bisphosphate (PIP₂), inositol 1,4,5-triphosphate (IP₃) and adenylate cyclase; polarization of the plasma membrane; production or secretion of molecules; alteration in the structure of a cellular component; cell proliferation, e.g., synthesis of DNA, cell migration, cell differentiation; and cell survival. Since the 2838 receptor protein is expressed in thymus, lymph node, spleen, testes, colon, and peripheral blood lymphocytes including but not limited to activated T helper cells-1, activated T-helper cells-2, CD3(both CD4 and CD8), activated B cells, and granulocytes, cells participating in a 2838 receptor protein signaling pathway include, but are not limited to, these tissues and cells. Since the 14618 receptor protein is expressed in breast, skeletal muscle, thyroid, lymph node, spleen, and peripheral blood lymphocytes including, but not limited to, CD34⁺ cells, resting B cells, and megakaryocytes, cells participating in a 14618 receptor protein signaling pathway include, but are not limited to, cells derived from these tissues and cells. Since the 15334 receptor protein is expressed in colon, pancreas, tonsil, lymph node, spleen, thymus, adrenal gland, heart, and peripheral blood cells, including but not limited to those shown in Figure 17, megakaryocytes, and erythroblasts, cells participating in a 15334 receptor protein signaling pathway include, but are not limited to, cells derived from these tissues and cells.

The response mediated by the receptor protein depends on the type of cell. For example, in some cells, binding of a ligand to the receptor protein may stimulate an activity such as release of compounds, gating of a channel, cellular adhesion, migration, differentiation, etc., through phosphatidylinositol or cyclic AMP metabolism and turnover while in other cells, the binding of the ligand will produce a different result. Regardless of the cellular activity/response modulated by the receptor protein, it is universal that the protein is a GPCR and interacts with G proteins to produce one or more secondary signals, in a variety of intracellular signal

transduction pathways, e.g., through phosphatidylinositol or cyclic AMP metabolism and turnover, in a cell

As used herein, "phosphatidylinositol turnover and metabolism" refers to the molecules involved in the turnover and metabolism of phosphatidylinositol 4,5-bisphosphate (PIP₂) as well as to the activities of these molecules. PIP₂ is a phospholipid found in the cytosolic leaflet of the plasma membrane. Binding of ligand to the receptor activates, in some cells, the plasma-membrane enzyme phospholipase C that in turn can hydrolyze PIP₂ to produce 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP₃). Once formed IP₃ can diffuse to the endoplasmic reticulum surface where it can bind an IP₃ receptor, e.g., a calcium channel protein containing an IP₃ binding site. IP₃ binding can induce opening of the channel, allowing calcium ions to be released into the cytoplasm. IP₃ can also be phosphorylated by a specific kinase to form inositol 1,3,4,5-tetraphosphate (IP₄), a molecule which can cause calcium entry into the cytoplasm from the extracellular medium. IP₃ and IP₄ can subsequently be hydrolyzed very rapidly to the inactive products inositol 1,4-bisphosphate (IP₂) and inositol 1,3,4-triphosphate, respectively. These inactive products can be recycled by the cell to synthesize PIP₂. The other second messenger produced by the hydrolysis of PIP₂, namely 1,2-diacylglycerol (DAG), remains in the cell membrane where it can serve to activate the enzyme protein kinase C. Protein kinase C is usually found soluble in the cytoplasm of the cell, but upon an increase in the intracellular calcium concentration, this enzyme can move to the plasma membrane where it can be activated by DAG. The activation of protein kinase C in different cells results in various cellular responses such as the phosphorylation of glycogen synthase, or the phosphorylation of various transcription factors, e.g., NF-kB. The language "phosphatidylinositol activity", as used herein, refers to an activity of PIP₂ or one of its metabolites.

Another signaling pathway in which the receptor may participate is the cAMP turnover pathway. As used herein, "cyclic AMP turnover and metabolism" refers to the molecules involved in the turnover and metabolism of cyclic AMP (cAMP) as well as to the activities of these molecules. Cyclic AMP is a second messenger produced in response to ligand-induced stimulation of certain G protein coupled receptors. In the cAMP signaling pathway, binding of a ligand to a GPCR can lead to the activation of the enzyme adenyl cyclase, which catalyzes the synthesis of cAMP. The newly synthesized cAMP can in turn activate a cAMP-dependent protein kinase.

This activated kinase can phosphorylate a voltage-gated potassium channel protein, or an associated protein, and lead to the inability of the potassium channel to open during an action potential. The inability of the potassium channel to open results in a decrease in the outward flow of potassium, which normally repolarizes the membrane of a neuron, leading to prolonged membrane depolarization.

Polypeptides

The invention is based on the discovery of novel G-coupled protein receptors. Specifically, an expressed sequence tag (EST) was selected based on homology to G-protein-coupled receptor sequences. This EST was used to design primers based on sequences that it contains and used to identify a 2838 cDNA from a B cell cDNA library, a 14618 cDNA from a liver and spleen cDNA library, and a 15334 cDNA from a spleen cDNA library. Positive clones were sequenced and the overlapping fragments were assembled. Analysis of the assembled sequences revealed that the three cloned cDNA molecules encode G-protein coupled receptors.

The invention thus relates to a novel GPCR having the deduced amino acid sequence shown in SEQ ID NO:1.

The invention also thus relates to a novel GPCR having the deduced amino acid sequence shown in SEQ ID NO:3.

The invention also thus relates to a novel GPCR having the deduced amino acid sequence shown in SEQ ID NO:5.

The Sequence Listing shows the 2838 nucleotide sequence (SEQ ID NO:2) and the deduced 2838 amino acid sequence (SEQ ID NO:1). It is predicted that amino acids 1 to about 24 constitute the amino terminal extracellular domain, amino acids about 25-292 constitute the region spanning the transmembrane domain, and amino acids about 293-319 constitute the carboxy terminal intracellular domain. The transmembrane domain contains seven transmembrane segments, three extracellular loops and three intracellular loops. The transmembrane segments are found from about amino acid 25 to about amino acid 49, from about amino acid 56 to about amino acid 79, from about amino acid 100 to about amino acid 117, from about amino acid 138 to about amino acid 159, from about amino acid 187 to about amino acid 210, from about amino acid 224 to about amino acid 248, and from about amino acid 268 to about amino acid 292. Within the region spanning the entire transmembrane domain are three intracellular and three extracellular loops. The three intracellular

loops are found from about amino acid 50 to about amino acid 55, from about amino acid 118 to about amino acid 137, and from about amino acid 211 to about amino acid 223. The three extracellular loops are found at from about amino acid 80 to about amino acid 99, from about amino acid 160 to about amino acid 186, and from about amino acid 249 to about amino acid 267.

The Sequence Listing shows the 14618 nucleotide sequence (SEQ ID NO:4) and the deduced 14618 amino acid sequence (SEQ ID NO:3). It is predicted that amino acids 1 to about 28 constitute the amino terminal extracellular domain, amino acids about 29-297 constitute the region spanning the transmembrane domain, and amino acids about 298-337 constitute the carboxy terminal intracellular domain. The transmembrane domain contains seven transmembrane segments, three extracellular loops and three intracellular loops. The transmembrane segments are found from about amino acid 29 to about amino acid 49, from about amino acid 60 to about amino acid 84, from about amino acid 103 to about amino acid 127, from about amino acid 142 to about amino acid 161, from about amino acid 194 to about amino acid 217, from about amino acid 231 to about amino acid 247, and from about amino acid 276 to about amino acid 297. Within the region spanning the entire transmembrane domain are three intracellular and three extracellular loops. The three intracellular loops are found from about amino acid 50 to about amino acid 59, from about amino acid 128 to about amino acid 141, and from about amino acid 218 to about amino acid 230. The three extracellular loops are found at from about amino acid 85 to about amino acid 102, from about amino acid 162 to about amino acid 193, and from about amino acid 248 to about amino acid 275.

The Sequence Listing shows the 15334 nucleotide sequence (SEQ ID NO:6) and the deduced 15334 amino acid sequence (SEQ ID NO:5). It is predicted that amino acids 1 to about 25 constitute the amino terminal extracellular domain, amino acids about 26-299 constitute the region spanning the transmembrane domain, and amino acids about 300-372 constitute the carboxy terminal intracellular domain. The transmembrane domain contains seven transmembrane segments, three extracellular loops and three intracellular loops. The transmembrane segments are found from about amino acid 26 to about amino acid 48, from about amino acid 56 to about amino acid 77, from about amino acid 99 to about amino acid 115, from about amino acid 140 to about amino acid 157, from about amino acid 188 to about amino acid 209, from about amino acid 235 to about amino acid 259, and from about amino acid

277 to about amino acid 299. Within the region spanning the entire transmembrane domain are three intracellular and three extracellular loops. The three intracellular loops are found from about amino acid 49 to about amino acid 55, from about amino acid 116 to about amino acid 139, and from about amino acid 210 to about amino acid 234. The three extracellular loops are found at from about amino acid 78 to about amino acid 98, from about amino acid 158 to about amino acid 187, and from about amino acid 260 to about amino acid 276.

The "2838 receptor polypeptide" or "2838 receptor protein" refers to the polypeptide in SEQ ID NO:1. The "14618 receptor polypeptide" or "14618 receptor protein" refers to the polypeptide in SEQ ID NO:3. The "15334 receptor polypeptide" or "15334 receptor protein" refers to the polypeptide in SEQ ID NO:5. The term "receptor protein" or "receptor polypeptide", however, further includes the numerous variants of 2838, 14618, or 15334 polypeptides described herein, as well as fragments derived from the full length 2838, 14618, or 15334 polypeptides and variants.

The present invention thus provides isolated or purified 2838, 14618, and 15334 receptor polypeptides and variants and fragments thereof.

The 2838 polypeptide is a 319 residue protein exhibiting three main structural domains. The amino terminal extracellular domain is identified to be within residues 1 to about 24 in SEQ ID NO:1. The transmembrane domain is identified to be within residues from about 25 to about 292 in SEQ ID NO:1. The carboxy terminal intracellular domain is identified to be within residues from about 293 to 319 in SEQ ID NO:1. The transmembrane domain contains seven segments that span the membrane. The transmembrane segments are found from about amino acid 25 to about amino acid 49, from about amino acid 56 to about amino acid 79, from about amino acid 100 to about amino acid 117, from about amino acid 138 to about amino acid 159, from about amino acid 187 to about amino acid 210, from about amino acid 224 to about amino acid 248, and from about amino acid 268 to about amino acid 292. Within the region spanning the entire transmembrane domain are three intracellular and three extracellular loops. The three intracellular loops are found from about amino acid 50 to about amino acid 55, from about amino acid 118 to about amino acid 137, and from about amino acid 211 to about amino acid 223. The three extracellular loops are found at from about amino acid 80 to about amino acid 99, from about amino acid 160 to about amino acid 186, and from about amino acid 249 to about amino acid 267.

The transmembrane domain includes a GPCR signal transduction signature, DRF, at residues 118-120. The sequence includes an arginine at residue 119, an invariant amino acid in GPCRs.

Based on a BLAST search, highest homology was shown to purinoceptors.

5 The 14618 polypeptide is a 337 residue protein exhibiting three main structural domains. The amino terminal extracellular domain is identified to be within residues 1 to about 28 in SEQ ID NO:3. The transmembrane domain is identified to be within residues from about 29 to about 297 in SEQ ID NO:3. The carboxy terminal intracellular domain is identified to be within residues from about 298 to 337 in SEQ ID NO:3. The transmembrane domain contains seven segments that span the membrane. The transmembrane segments are found from about amino acid 29 to about amino acid 49, from about amino acid 84 to about amino acid 60, from about amino acid 103 to about amino acid 127, from about amino acid 142 to about amino acid 161, from about amino acid 194 to about amino acid 217, from about amino acid 15 231 to about amino acid 247, and from about amino acid 276 to about amino acid 297. Within the region spanning the entire transmembrane domain are three intracellular and three extracellular loops. The three intracellular loops are found from about amino acid 50 to about amino acid 59, from about amino acid 128 to about amino acid 141, and from about amino acid 218 to about amino acid 230. The three extracellular 20 loops are found at from about amino acid 85 to about amino acid 102, from about amino acid 162 to about amino acid 193, and from about amino acid 248 to about amino acid 275.

The transmembrane domain includes a GPCR signal transduction signature, FRC, at residues 121-123. The sequence includes an arginine at residue 122, an invariant amino acid in GPCRs.

Based on a BLAST search, highest homology was shown to purinoceptors.

30 The 15334 polypeptide is a 372 residue protein exhibiting three main structural domains. The amino terminal extracellular domain is identified to be within residues 1 to about 25 in SEQ ID NO:5. The transmembrane domain is identified to be within residues from about 26 to about 299 in SEQ ID NO:5. The carboxy terminal intracellular domain is identified to be within residues from about 300 to 372 in SEQ ID NO:5. The transmembrane domain contains seven segments that span the membrane. The transmembrane segments are found from about amino acid 26 to about amino acid 48, from about amino acid 56 to about amino acid 77, from about

amino acid 99 to about amino acid 115, from about amino acid 140 to about amino acid 157, from about amino acid 188 to about amino acid 209, from about amino acid 235 to about amino acid 259, and from about amino acid 277 to about amino acid 299. Within the region spanning the entire transmembrane domain are three intracellular and three extracellular loops. The three intracellular loops are found from about amino acid 49 to about amino acid 55, from about amino acid 116 to about amino acid 139, and from about amino acid 210 to about amino acid 234. The three extracellular loops are found at from about amino acid 78 to about amino acid 98, from about amino acid 158 to about amino acid 187, and from about amino acid 260 to about amino acid 276.

The transmembrane domain includes a GPCR signal transduction signature, DRY, at residues 118-120. The sequence includes an arginine at residue 119, an invariant amino acid in GPCRs.

Based on a BLAST search, highest homology was shown to purinoceptors.

As used herein, a polypeptide is said to be "isolated" or "purified" when it is substantially free of cellular material when it is isolated from recombinant and non-recombinant cells, or free of chemical precursors or other chemicals when it is chemically synthesized. A polypeptide, however, can be joined to another polypeptide with which it is not normally associated in a cell and still be considered "isolated" or "purified."

The receptor polypeptides can be purified to homogeneity. It is understood, however, that preparations in which the polypeptide is not purified to homogeneity are useful and considered to contain an isolated form of the polypeptide. The critical feature is that the preparation allows for the desired function of the polypeptide, even in the presence of considerable amounts of other components. Thus, the invention encompasses various degrees of purity.

In one embodiment, the language "substantially free of cellular material" includes preparations of the receptor polypeptide having less than about 30% (by dry weight) other proteins (*i.e.*, contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the receptor polypeptide is recombinantly produced, it can also be substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, less than about 10%, or less than about 5% of the volume of the protein preparation.

A receptor polypeptide is also considered to be isolated when it is part of a membrane preparation or is purified and then reconstituted with membrane vesicles or liposomes.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the receptor polypeptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the polypeptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

In one embodiment, the receptor polypeptide comprises the amino acid sequence shown in SEQ ID NO:1. However, the invention also encompasses sequence variants. Variants include a substantially homologous protein encoded by the same genetic locus in an organism, *i.e.*, an allelic variant. The receptor maps to chromosome 2, in close proximity to WI-7921. Variants also encompass proteins derived from other genetic loci in an organism, but having substantial homology to the 2838 receptor protein of SEQ ID NO:1. Variants also include proteins substantially homologous to the 2838 receptor protein but derived from another organism, *i.e.*, an ortholog. Variants also include proteins that are substantially homologous to the 2838 receptor protein that are produced by chemical synthesis. Variants also include proteins that are substantially homologous to the 2838 receptor protein that are produced by recombinant methods. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

In another embodiment, the receptor polypeptide comprises the amino acid sequence shown in SEQ ID NO:3. However, the invention also encompasses sequence variants. Variants include allelic variants. Variants also encompass proteins derived from other genetic loci in an organism, but having substantial homology to the 14618 receptor protein of SEQ ID NO:3. Variants also include substantially homologous orthologs. Variants also include proteins that are substantially homologous to the 14618 receptor protein that are produced by chemical synthesis. Variants also include proteins that are substantially homologous to the 14618 receptor protein that are produced by recombinant methods. It is understood,

however, that variants exclude any amino acid sequences disclosed prior to the invention

In another embodiment, the receptor polypeptide comprises the amino acid sequence shown in SEQ ID NO 5. However, the invention also encompasses sequence variants. Variants include allelic variants. The receptor maps to chromosome 12 in close proximity to SHGC-30262. Variants also encompass proteins derived from other genetic loci in an organism, but having substantial homology to the 15334 receptor protein of SEQ ID NO 5. Variants also include substantially homologous orthologs. Variants also include proteins that are substantially homologous to the 15334 receptor protein that are produced by chemical synthesis. Variants also include proteins that are substantially homologous to the 15334 receptor protein that are produced by recombinant methods. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention

As used herein, two proteins (or a region of the proteins) are substantially homologous to the 2838 protein when the amino acid sequences are at least about 40-45%, 45-50%, 50-55%, 55-60%, typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more homologous. A substantially homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence hybridizing to the nucleic acid sequence, or portion thereof, of the sequence shown in SEQ ID NO 2 under stringent conditions as more fully described below

As used herein, two proteins (or a region of the proteins) are substantially homologous to the 14618 protein when the amino acid sequences are at least about 35-40%, 40-45%, 45-50%, 55-60%, typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more homologous. A substantially homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence hybridizing to the nucleic acid sequence, or portion thereof, of the sequence shown in SEQ ID NO 4 under stringent conditions as more fully described below

As used herein, two proteins (or a region of the proteins) are substantially homologous to the 15334 protein when the amino acid sequences are at least about 40-45%, 45-50%, 50-55%, 55-60%, typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more homologous. A

substantially homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence hybridizing to the nucleic acid sequence, or portion thereof, of the sequence shown in SEQ ID NO 6 under stringent conditions as more fully described below.

- 5 To determine the percent homology of two amino acid sequences, or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When
10 a position in one sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence, then the molecules are homologous at that position. As used herein, amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity". The percent homology between the two sequences is a function of the number of identical positions shared
15 by the sequences (*i.e.*, per cent homology equals the number of identical positions/total number of positions times 100).

The invention also encompasses polypeptides having a lower degree of identity but having sufficient similarity so as to perform one or more of the same functions performed by the 2838, 14618, or 15334 polypeptides. Similarity is
20 determined by conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Conservative substitutions are likely to be phenotypically silent. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl
25 residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie *et al.* (1990) *Science* 247:1306-1310.

30

TABLE 1 Conservative Amino Acid Substitutions

| | |
|-------------|---|
| Aromatic | Phenylalanine Tryptophan Tyrosine |
| Hydrophobic | Leucine Isoleucine Valine |
| Polar | Glutamine Asparagine |
| Basic | Arginine Lysine Histidine |
| Acidic | Aspartic Acid Glutamic Acid |
| Small | Alanine Serine Threonine Methionine Glycine |

Both identity and similarity can be readily calculated (*Computational*
5 *Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988,
Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press,
New York, 1993, *Computer Analysis of Sequence Data, Part 1*, Griffin, A.M., and
Griffin, H.G., eds., Humana Press, New Jersey, 1994, *Sequence Analysis in Molecular*
Biology, von Heinje, G., Academic Press, 1987, and *Sequence Analysis Primer*,
10 Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991)

A preferred, non-limiting example of such a mathematical algorithm is described in Karlin *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing
5 BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. In one embodiment, parameters for sequence comparison can be set at score= 100, wordlength=12, or can be varied (e.g., W=5 or W=20).

In a preferred embodiment, the percent identity between two amino acid
10 sequences is determined using the Needleman *et al.* (1970) (*J. Mol. Biol.* 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a BLOSUM 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between
15 two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux *et al.* (1984) *Nucleic Acids Res.* 12(1):387) (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.

Another preferred, non-limiting example of a mathematical algorithm utilized
20 for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the CGC sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional
25 algorithms for sequence analysis are known in the art and include ADVANCE and ADAM as described in Torellis *et al.* (1994) *Comput. Appl. Biosci.* 10:3-5; and FASTA described in Pearson *et al.* (1988) *PNAS* 85:2444-8.

A variant polypeptide can differ in amino acid sequence by one or more substitutions, deletions, insertions, inversions, fusions, and truncations or a
30 combination of any of these.

Variant polypeptides can be fully functional or can lack function in one or more activities. Thus, in the present case, variations can affect the function, for example, of one or more of the regions corresponding to ligand binding, membrane association, G-protein binding and signal transduction.

Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. Functional variants can also contain substitution of similar amino acids which result in no change or an insignificant change in function. Alternatively, such substitutions may positively or
5 negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

As indicated, variants can be naturally-occurring or can be made by
10 recombinant means or chemical synthesis to provide useful and novel characteristics for the receptor polypeptide. This includes preventing immunogenicity from pharmaceutical formulations by preventing protein aggregation.

Useful variations further include alteration of ligand binding characteristics. For example, one embodiment involves a variation at the binding site that results in
15 binding but not release, or slower release, of ligand. A further useful variation at the same sites can result in a higher affinity for ligand. Useful variations also include changes that provide for affinity for another ligand. Another useful variation includes one that allows binding but which prevents activation by the ligand. Another useful variation includes variation in the transmembrane G-protein-binding/signal
20 transduction domain that provides for reduced or increased binding by the appropriate G-protein or for binding by a different G-protein than the one with which the receptor is normally associated. Another useful variation provides a fusion protein in which one or more domains or subregions is operationally fused to one or more domains or subregions from another G-protein coupled receptor.

25 Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.* (1989) *Science* 244:1081-1085). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as receptor binding or *in vitro*, or
30 *in vitro* proliferative activity. Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.* (1992) *J. Mol. Biol.* 224:899-904, de Vos *et al.* (1992) *Science* 255:306-312).

Substantial homology can be to the entire nucleic acid or amino acid sequence or to fragments of these sequences.

The invention thus also includes polypeptide fragments of the 2838 receptor protein. Fragments can be derived from the amino acid sequence shown in SEQ ID
5 NO 1. However, the invention also encompasses fragments of the variants of the 2838 receptor protein as described herein.

The invention thus also includes polypeptide fragments of the 14618 receptor protein. Fragments can be derived from the amino acid sequence shown in SEQ ID
10 NO:3. However, the invention also encompasses fragments of the variants of the 14618 receptor protein as described herein.

The invention thus also includes polypeptide fragments of the 15334 receptor protein. Fragments can be derived from the amino acid sequence shown in SEQ ID
NO:5. However, the invention also encompasses fragments of the variants of the 15334 receptor protein as described herein.

15 The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed prior to the present invention.

Fragments can retain one or more of the biological activities of the protein, for example the ability to bind to a G-protein or ligand, as well as fragments that can be
20 used as an immunogen to generate receptor antibodies

Biologically active fragments of 2838 receptor (peptides which are, for example, 8, 12, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) can comprise a domain or motif, e.g., an extracellular or intracellular domain or loop, one or more transmembrane segments, or parts thereof, G-protein binding
25 site, or GPCR signature, glycosylation sites, protein kinase C and casein kinase II phosphorylation sites, N-myristoylation and amidation sites. Such domains or motifs can be identified by means of routine computerized homology searching procedures.

Possible fragments include, but are not limited to: 1) soluble peptides comprising the entire amino terminal extracellular domain from amino acid 1 to about
30 amino acid 24 of SEQ ID NO 1, or parts thereof; 2) peptides comprising the entire carboxy terminal intracellular domain from about amino acid 293 to amino acid 319 of SEQ ID NO 1, or parts thereof; 3) peptides comprising the region spanning the entire transmembrane domain from about amino acid 25 to about amino acid 292, or parts thereof; 4) any of the specific transmembrane segments, or parts thereof, from

about amino acid 25 to about amino acid 49, from about amino acid 56 to about amino acid 79, from about amino acid 100 to about amino acid 117, from about amino acid 138 to about amino acid 159, from about amino acid 187 to about amino acid 210, from about amino acid 224 to about amino acid 248, and from about amino acid 268 to about amino acid 292, 5) any of the three intracellular or three extracellular loops, or parts thereof, from about amino acid 50 to about amino acid 55, from about amino acid 118 to about amino acid 137, from about amino acid 211 to about amino acid 223, from about amino acid 80 to about amino acid 99, from about amino acid 160 to about amino acid 186, and from about amino acid 249 to about amino acid 267.

10 Fragments further include combinations of the above fragments, such as an amino terminal domain combined with one or more transmembrane segments and the attendant extra or intracellular loops or one or more transmembrane segments, and the attendant intra or extracellular loops, plus the carboxy terminal domain. Thus, any of the above fragments can be combined. Other fragments include the mature protein

15 from about amino acid 6 to 319. Other fragments contain the various functional sites described herein, such as phosphorylation sites, glycosylation sites, and myristoylation sites and a sequence containing the GPCR signature sequence. Fragments, for example, can extend in one or both directions from the functional site to encompass 5, 10, 15, 20, 30, 40, 50, or up to 100 amino acids. Further, fragments

20 can include sub-fragments of the specific domains mentioned above, which sub-fragments retain the function of the domain from which they are derived. Fragments also include amino acid sequences greater than 7 amino acids from amino acid 1 to about amino acid 264. Fragments also include antigenic fragments and specifically those shown to have a high antigenic index in Figure 2.

25 Accordingly, possible fragments include fragments defining a ligand-binding site, fragments defining a glycosylation site, fragments defining membrane association, fragments defining phosphorylation sites, fragments defining interaction with G proteins and signal transduction, and fragments defining myristoylation sites. By this is intended a discrete fragment that provides the relevant function or allows

30 the relevant function to be identified. In a preferred embodiment, the fragment contains the ligand-binding site.

Biologically active fragments of 14618 receptor (peptides which are, for example, 9, 12, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) can comprise a domain or motif, e.g., an extracellular or intracellular domain

or loop, one or more transmembrane segments, or parts thereof, G-protein binding site, or GPCR signature, glycosylation sites, and cAMP- and cGMP-dependent protein kinase C, and casein kinase II phosphorylation sites.

Possible fragments include, but are not limited to: 1) soluble peptides comprising the entire amino terminal extracellular domain about amino acid 1 to about amino acid 28 of SEQ ID NO.3, or parts thereof; 2) peptides comprising the entire carboxy terminal intracellular domain from about amino acid 298 to amino acid 337 of SEQ ID NO.3, or parts thereof; 3) peptides comprising the region spanning the entire transmembrane domain from about amino acid 29 to about amino acid 297, or parts thereof; 4) any of the specific transmembrane segments, or parts thereof, from about amino acid 29 to about amino acid 49, from about amino acid 60 to about amino acid 84, from about amino acid 103 to about amino acid 127, from about amino acid 142 to about amino acid 161, from about amino acid 194 to about amino acid 217, from about amino acid 231 to about amino acid 247, and from about amino acid 276 to about amino acid 297; 5) any of the three intracellular or three extracellular loops, or parts thereof, from about amino acid 50 to about amino acid 59, from about amino acid 128 to about amino acid 141, from about amino acid 218 to about amino acid 230, from about amino acid 85 to about amino acid 102, from about amino acid 162 to about amino acid 193, and from about amino acid 248 to about amino acid 275. Fragments further include combinations of the above fragments, such as an amino terminal domain combined with one or more transmembrane segments and the attendant extra or intracellular loops or one or more transmembrane segments, and the attendant intra or extracellular loops, plus the carboxy terminal domain. Thus, any of the above fragments can be combined. Other fragments include the mature protein from about amino acid 6 to 337. Other fragments contain the various functional sites described herein, such as phosphorylation sites, glycosylation sites, and a sequence containing the GPCR signature sequence. Fragments, for example, can extend in one or both directions from the functional site to encompass 5, 10, 15, 20, 30, 40, 50, or up to 100 amino acids. Further, fragments can include sub-fragments of the specific domains mentioned above, which sub-fragments retain the function of the domain from which they are derived. Fragments also include amino acid sequences greater than 8 amino acids from amino acid 1 to about amino acid 244.

Fragments also include antigenic fragments and specifically those shown to have a high antigenic index in Figure 2.

Accordingly, possible fragments include fragments defining a ligand-binding site, fragments defining a glycosylation site, fragments defining membrane association, fragments defining phosphorylation sites, fragments defining interaction with G proteins and signal transduction, and fragments defining myristoylation sites.

- 5 By this is intended a discrete fragment that provides the relevant function or allows the relevant function to be identified. In a preferred embodiment, the fragment contains the ligand-binding site.

- Biologically active fragments (peptides which are, for example, 8, 12, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) can comprise a
10 domain or motif, e.g., an extracellular or intracellular domain or loop, one or more transmembrane segments, or parts thereof, G-protein binding site, or GPCR signature, glycosylation sites, cAMP, cGMP, protein kinase C, and casein kinase II phosphorylation sites, and N-myristoylation sites

- Possible fragments include, but are not limited to: 1) soluble peptides
15 comprising the entire amino terminal extracellular domain about amino acid 1 to about amino acid 23 of SEQ ID NO:5, or parts thereof; 2) peptides comprising the entire carboxy terminal intracellular domain from about amino acid 300 to amino acid 372 of SEQ ID NO:5, or parts thereof; 3) peptides comprising the region spanning the entire transmembrane domain from about amino acid 26 to about amino acid 299, or
20 parts thereof; 4) any of the specific transmembrane segments, or parts thereof, from about amino acid 26 to about amino acid 48, from about amino acid 56 to about amino acid 77, from about amino acid 99 to about amino acid 115, from about amino acid 140 to about amino acid 157, from about amino acid 188 to about amino acid 209, from about amino acid 235 to about amino acid 259, and from about amino acid
25 277 to about amino acid 299; 5) any of the three intracellular or three extracellular loops, or parts thereof, from about amino acid 49 to about amino acid 55, from about amino acid 78 to about amino acid 98, from about amino acid 116 to about amino acid 139, from about amino acid 158 to about amino acid 187, from about amino acid 210 to about amino acid 234, and from about amino acid 260 to about amino acid 276
30 Fragments further include combinations of the above fragments, such as an amino terminal domain combined with one or more transmembrane segments and the attendant extra or intracellular loops or one or more transmembrane segments, and the attendant intra or extracellular loops, plus the carboxy terminal domain. Thus, any of the above fragments can be combined. Other fragments include the mature protein

from about amino acid 6 to 372. Other fragments contain the various functional sites described herein, such as phosphorylation sites, glycosylation sites, and myristoylation sites and a sequence containing the GPCR signature sequence. Fragments, for example, can extend in one or both directions from the functional site to encompass 5, 10, 15, 20, 30, 40, 50, or up to 100 amino acids. Further, fragments can include sub-fragments of the specific domains mentioned above, which sub-fragments retain the function of the domain from which they are derived. Fragments also include amino acid sequences greater than 7 amino acids.

Fragments also include antigenic fragments and specifically those shown to have a high antigenic index in Figure 2.

These regions can be identified by well-known methods involving computerized homology analysis.

Accordingly, possible fragments include fragments defining a ligand-binding site, fragments defining a glycosylation site, fragments defining membrane association, fragments defining phosphorylation sites, fragments defining interaction with G proteins and signal transduction, and fragments defining myristoylation sites. By this is intended a discrete fragment that provides the relevant function or allows the relevant function to be identified. In a preferred embodiment, the fragment contains the ligand-binding site.

The invention also provides 2838 receptor fragments with immunogenic properties. These contain an epitope-bearing portion of the 2838 receptor protein and variants. These epitope-bearing peptides are useful to raise antibodies that bind specifically to a receptor polypeptide or region or fragment. These peptides can contain at least 8, 12, at least 14, or between at least about 15 to about 30 amino acids

The invention also provides 14618 receptor fragments with immunogenic properties. These contain an epitope-bearing portion of the 14618 receptor protein and variants. These epitope-bearing peptides are useful to raise antibodies that bind specifically to a receptor polypeptide or region or fragment. These peptides can contain at least 9, 12, at least 14, or between at least about 15 to about 30 amino acids

The invention also provides 15334 receptor fragments with immunogenic properties. These contain an epitope-bearing portion of the 15334 receptor protein and variants. These epitope-bearing peptides are useful to raise antibodies that bind specifically to a receptor polypeptide or region or fragment. These peptides can contain at least 8, 12, at least 14, or between at least about 15 to about 30 amino acids

Non-limiting examples of antigenic polypeptides that can be used to generate antibodies include peptides derived from the amino terminal extracellular domain or any of the extracellular loops. Regions having a high antigenicity index are shown in Figures 2, 6, and 10.

5 The epitope-bearing receptor and polypeptides may be produced by any conventional means (Houghten (1985) *Proc. Natl. Acad. Sci. USA* 82:5131-5135). Simultaneous multiple peptide synthesis is described in U.S. Patent No. 4,631,211.

 Fragments can be discrete (not fused to other amino acids or polypeptides) or can be within a larger polypeptide. Further, several fragments can be comprised
10 within a single larger polypeptide. In one embodiment a fragment designed for expression in a host can have heterologous pre- and pro-polypeptide regions fused to the amino terminus of the receptor fragment and an additional region fused to the carboxyl terminus of the fragment.

 The invention thus provides chimeric or fusion proteins. These comprise a
15 receptor protein operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the receptor protein. "Operatively linked" indicates that the receptor protein and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the receptor protein.

20 In one embodiment the fusion protein does not affect receptor function *per se*. For example, the fusion protein can be a GST-fusion protein in which the receptor sequences are fused to the C-terminus of the GST sequences. Other types of fusion proteins include, but are not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions and Ig fusions.
25 Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant receptor protein. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence. Therefore, in another embodiment, the fusion protein contains a heterologous signal sequence at its N-terminus.

30 EP-A-O 464 533 discloses fusion proteins comprising various portions of immunoglobulin constant regions. The Fc is useful in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). In drug discovery, for example, human proteins have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists. Bennett *et al.*

(1995) *J. Mol. Recog.* 8:52-58 and Johanson *et al.* (1995) *J. Biol. Chem.* 270, 16:9459-9471. Thus, this invention also encompasses soluble fusion proteins containing a receptor polypeptide and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclass (IgG, IgM, IgA, IgE).
5 Preferred as immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. For some uses it is desirable to remove the Fc after the fusion protein has been used for its intended purpose, for example when the fusion protein is to be used as antigen for immunizations. In a particular embodiment, the Fc part can be removed in a simple
10 way by a cleavage sequence which is also incorporated and can be cleaved with factor Xa.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another
15 embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel *et al.*, (1992) *Current*
20 *Protocols in Molecular Biology*). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A receptor protein-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the receptor protein.

Another form of fusion protein is one that directly affects receptor functions.
25 Accordingly, a receptor polypeptide is encompassed by the present invention in which one or more of the receptor domains (or parts thereof) has been replaced by homologous domains (or parts thereof) from another G-protein coupled receptor or other type of receptor. Accordingly, various permutations are possible. The amino terminal extracellular domain, or subregion thereof, (for example, ligand-binding) can
30 be replaced with the domain or subregion from another ligand-binding receptor protein. Alternatively, the entire transmembrane domain, or any of the seven segments or loops, or parts thereof, for example, G-protein-binding/signal transduction, can be replaced. Finally, the carboxy terminal intracellular domain or

subregion can be replaced. Thus, chimeric receptors can be formed in which one or more of the native domains or subregions has been replaced

5 The isolated 2838 receptor protein can be purified from cells that naturally express it, such as from lymph node, thymus, spleen, testes, colon, and peripheral blood lymphocytes, and from those cells in which it is significantly expressed as shown in Figure 15, such as activated T-helper cells (1 and 2), hypoxic Hep 3B cells, CD3 cells (both CD4 and CD8), activated B cells, Jurkat cells, among others, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods.

10 The isolated 14618 receptor protein can be purified from cells that naturally express it, such as from breast, skeletal muscle, lymph node, spleen and blood peripheral lymphocytes, as well as those tissues in which the gene is significantly expressed as shown in Figures 13 and 14 including, but not limited to, CD34⁺ cells and megakaryocytes, purified from cells that have been altered to express it
15 (recombinant), or synthesized using known protein synthesis methods.

The isolated 15334 receptor protein can be purified from cells that naturally express it, such as from colon, placenta, pancreas, tonsil, lymph node, spleen, peripheral blood cells, thymus, adrenal gland and heart, as well as those tissues shown in Figures 16-19, including K562 cells, erythroblasts, and megakaryocytes, purified
20 from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods.

In one embodiment, the protein is produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the receptor polypeptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein
25 expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally-occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural
30 processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in polypeptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art.

Accordingly, the polypeptides also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for
5 example, polyethylene glycol), or in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence for purification of the mature polypeptide or a pro-protein sequence.

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a
10 heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation,
15 iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well-known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common
20 modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational*
25 *Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter *et al.* (1990) *Meth. Enzymol.* 182: 626-646) and Rattan *et al.* (1992) *Ann. N.Y. Acad. Sci.* 663:48-62).

As is also well known, polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be
30 circular, with or without branching, generally as a result of post-translation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translational natural processes and by synthetic methods.

Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. Blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally-occurring and synthetic polypeptides. For instance, the amino
5 terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

The modifications can be a function of how the protein is made. For recombinant polypeptides, for example, the modifications will be determined by the host cell posttranslational modification capacity and the modification signals in the
10 polypeptide amino acid sequence. Accordingly, when glycosylation is desired, a polypeptide should be expressed in a glycosylating host, generally a eukaryotic cell. Insect cells often carry out the same posttranslational glycosylations as mammalian cells and, for this reason, insect cell expression systems have been developed to efficiently express mammalian proteins having native patterns of glycosylation.
15 Similar considerations apply to other modifications.

The same type of modification may be present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain more than one type of modification.

20 Polypeptide uses

The receptor polypeptides are useful for producing antibodies specific for the 2838, 14618, and 15334 receptor protein, regions, or fragments. Regions having a high antigenicity index score are shown in Figures 2, 6, and 10.

The receptor polypeptides, variants, and fragments (including those which
25 may have been disclosed prior to the present invention) are useful for biological assays related to GPCRs. Such assays involve any of the known GPCR functions or activities or properties useful diagnosis and treatment of GPCR-related conditions.

The receptor polypeptides are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, *i.e.*, cells that normally
30 express the receptor protein, as a biopsy or expanded in cell culture. In one embodiment, however, cell-based assays involve recombinant host cells expressing the receptor protein.

Determining the ability of the test compound to interact with the polypeptide can also comprise determining the ability of the test compound to preferentially bind

to the polypeptide as compared to the ability of the ligand, or a biologically active portion thereof, to bind to the polypeptide

The polypeptides can be used to identify compounds that modulate receptor activity. Such compounds, for example, can increase or decrease affinity or rate of
5 binding to a known ligand, compete with ligand for binding to the receptor, or displace ligand bound to the receptor. 2838, 14618, and 15334 protein and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the receptor. These compounds can be further screened
10 against a functional receptor to determine the effect of the compound on the receptor activity. Compounds can be identified that activate (agonist) or inactivate (antagonist) the receptor to a desired degree. Modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). Examples include purine analogs such as those discussed above.

15 The receptor polypeptides can be used to screen a compound for the ability to stimulate or inhibit interaction between the receptor protein and a target molecule that normally interacts with the receptor protein. The target can be ligand or a component of the signal pathway with which the receptor protein normally interacts (for example, a G-protein or other interactor involved in cAMP or phosphatidylinositol turnover
20 and/or adenylate cyclase, or phospholipase C activation). The assay includes the steps of combining the receptor protein with a candidate compound under conditions that allow the receptor protein or fragment to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the receptor protein and the target,
25 such as any of the associated effects of signal transduction such as G-protein phosphorylation, cyclic AMP or phosphatidylinositol turnover, and adenylate cyclase or phospholipase C activation.

Determining the ability of the protein to bind to a target molecule can also be accomplished using a technology such as real-time Bimolecular Interaction Analysis
30 (BIA). Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore™). Changes in the optical phenomenon surface

plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules

The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including
5 biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide
10 oligomer or small molecule libraries of compounds (Lam, K S (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med.*
15 *Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233. Libraries of compounds may be presented in solution (e.g., Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556),
20 bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390); (Devlin (1990) *Science* 249:404-406); (Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 97:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra*).

25 Candidate compounds include, for example, 1) purine analogs, 2) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam *et al.* (1991) *Nature* 354:82-84; Houghten *et al.* (1991) *Nature* 354:84-86) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 3) phosphopeptides (e.g., members
30 of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang *et al.* (1993) *Cell* 72:767-778), 4) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-binding fragments of

antibodies); and 5) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble full-length receptor or fragment that competes for ligand binding. Other candidate compounds include mutant receptors or
5 appropriate fragments containing mutations that affect receptor function and thus compete for ligand. Accordingly, a fragment that competes for ligand, for example with a higher affinity, or a fragment that binds ligand but does not allow release, is encompassed by the invention.

The invention provides other end points to identify compounds that modulate
10 (stimulate or inhibit) receptor activity. The assays typically involve an assay of events in the signal transduction pathway that indicate receptor activity. Thus, the expression of genes that are up- or down-regulated in response to the receptor protein dependent signal cascade can be assayed. In one embodiment, the regulatory region of such genes can be operably linked to a marker that is easily detectable, such as
15 luciferase. Alternatively, phosphorylation of the receptor protein, or a receptor protein target, could also be measured.

Binding and/or activating compounds can also be screened by using chimeric receptor proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven
20 transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a G-protein-binding region can be used that interacts with a different G-protein than that which is recognized by the native receptor. Accordingly, a different set of signal transduction components is
25 available as an end-point assay for activation. Alternatively, the entire transmembrane portion or subregions (such as transmembrane segments or intracellular or extracellular loops) can be replaced with the entire transmembrane portion or subregions specific to a host cell that is different from the host cell from which the amino terminal extracellular domain and/or the G-protein-binding region
30 are derived. This allows for assays to be performed in other than the specific host cell from which the receptor is derived. Alternatively, the amino terminal extracellular domain (and/or other ligand-binding regions) could be replaced by a domain (and/or other binding region) binding a different ligand, thus, providing an assay for test compounds that interact with the heterologous amino terminal extracellular domain

(or region) but still cause signal transduction. Finally, activation can be detected by a reporter gene containing an easily detectable coding region operably linked to a transcriptional regulatory sequence that is part of the native signal transduction pathway.

5 The receptor polypeptides are also useful in competition binding assays in methods designed to discover compounds that interact with the receptor. Thus, a compound is exposed to a receptor polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble receptor polypeptide is also added to the mixture. If the test compound interacts with the
10 soluble receptor polypeptide, it decreases the amount of complex formed or activity from the receptor target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the receptor. Thus, the soluble polypeptide that competes with the target receptor region is designed to contain peptide sequences corresponding to the region of interest.

15 To perform cell free drug screening assays, it is desirable to immobilize either the receptor protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

 Techniques for immobilizing proteins on matrices can be used in the drug
20 screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase/2838, 14618, and 15334 fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and
25 the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the
30 matrix, separated by SDS-PAGE, and the level of receptor-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with

binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a receptor-binding protein and a candidate compound are incubated in the receptor protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the receptor protein target molecule, or which are reactive with receptor protein and compete with the target molecule; as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Modulators of receptor protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the receptor pathway, by treating cells that express the 2838 protein, such as in lymph node, thymus, spleen, testes, colon, and peripheral blood lymphocytes including, but not limited to, T-helper cells (1 and 2), CD3⁺ (CD4 and CD8) cells, B cells and granulocytes. Modulators of receptor protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the receptor pathway, by treating cells that express the 14618 protein, such as in breast, skeletal muscle, spleen and peripheral blood lymphocytes as well as CD34⁺ cells and megakaryocytes. Modulators of receptor protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the receptor pathway, by treating cells that express the 15334 protein, such as in lymph node, tonsil, pancreas, colon, spleen, peripheral blood cells, thymus, adrenal gland and heart as well as megakaryocytes and erythroblasts. These methods of treatment include the steps of administering the modulators of protein activity in a pharmaceutical composition as described herein, to a subject in need of such treatment.

Figure 13 shows expression of the 14618 receptor in a variety of normal human tissues. The gene is highly expressed in breast and skeletal muscle. Accordingly, expression of the gene in disorders involving these tissues is particularly relevant. Significant expression also occurs in the thyroid, placenta, fetal kidney, fetal heart, and lymph node. Accordingly, expression of the gene is relevant to disorders involving these tissues as well. Furthermore, as shown in Figure 13, lower levels of

expression are seen in a variety of other tissues. Accordingly, expression of the gene is also relevant in disorders involving these tissues.

The 14618 receptor is also expressed in various hematopoietic cells with and without activation. The gene is highly expressed in CD34⁺ bone marrow cells.

5 Accordingly, expression of the gene is relevant in a variety of blood cell progenitors. Expression of this gene is therefore relevant to disorders involving deficiencies in any of the major blood cell types, *i.e.* neutropenia, thrombocytopenia or anemia. The gene is also highly expressed in mobilized peripheral blood cell megakaryocytes (mobilized with G-CSF). Accordingly, expression of this gene is relevant to disorders
10 involving platelet function, such as thrombocytopenia. Significant expression is also seen in mobilized peripheral blood cell leukocytes, mobilized bone marrow CD34⁺ cells, and cord blood CD434⁺ cells. Accordingly, expression of the gene is relevant to function of these cells, and therefore relevant to disorders involving immune function or inflammation. Further, expression of the gene occurs in activated peripheral blood
15 mononuclear cells. Activated B cells differentially express the gene. Accordingly, expression of the gene is relevant to disorders involving immune function and/or inflammation.

The 2838 receptor is expressed in the cells and tissues shown in Figure 15. High levels of expression are shown in lymph node and thymus. Accordingly,
20 expression of the gene is especially relevant to disorders involving these tissues. Extremely high expression is found in CD8 cells and activated B cells. High expression also occurs in activated T-helper cells (1 and 2), CD4 cells and Jurkat cells (a T-cell line). Expression is differential in activated B cells and activated T-helper cells. Expression increases upon activation in both of these cell types. Accordingly,
25 expression of the gene is relevant to disorders involving immune function and inflammation. The gene is also significantly expressed in granulocytes. Accordingly, expression of the gene is relevant to disorders involving these cells.

Figure 16 shows expression of the 15334 receptor in normal human tissues. The gene is highly expressed in lymph node, tonsil, and pancreas. Accordingly,
30 expression of the gene is particularly relevant to disorders involving these tissues. Expression of the gene is also high in colon, testis, placenta, fetal heart, and spleen. Accordingly, expression of the gene is also relevant to disorders involving these tissues. In addition, the figure shows low levels of expression in several other tissues. Accordingly, expression of the gene may be relevant to disorders involving these

tissues. Expression of the 15334 receptor has also been studied in various hematopoietic cells (Figures 17-19). Extremely high expression occurs in primary megakaryocytes and erythroblasts. Accordingly, expression of the gene is relevant to erythrocyte differentiation and megakaryocyte differentiation and thus is relevant to treating anemia and thrombocytopenia. Further, expression of the gene is significantly increased in resting B cells compared to activated B cells. Accordingly, expression of the gene is relevant to B cell immune function. Further, lower levels of expression are found in various other cells of the hematopoietic lineage. See Figure 17. The expression of this gene in hematopoietic cells in a lineage-restricted manner indicates that expression is relevant in regulating the development of the lineage cells, erythrocytes/red blood cells, or megakaryocytes/platelets.

Disorders involving the spleen include, but are not limited to, splenomegaly, including nonspecific acute splenitis, congestive splenomegaly, and splenic infarcts; neoplasms, congenital anomalies, and rupture. Disorders associated with splenomegaly include infections, such as nonspecific splenitis, infectious mononucleosis, tuberculosis, typhoid fever, brucellosis, cytomegalovirus, syphilis, malaria, histoplasmosis, toxoplasmosis, kala-azar, trypanosomiasis, schistosomiasis, leishmaniasis, and echinococcosis; congestive states related to partial hypertension, such as cirrhosis of the liver, portal or splenic vein thrombosis, and cardiac failure; lymphohematogenous disorders, such as Hodgkin disease, non-Hodgkin lymphomas/leukemia, multiple myeloma, myeloproliferative disorders, hemolytic anemias, and thrombocytopenic purpura; immunologic-inflammatory conditions, such as rheumatoid arthritis and systemic lupus erythematosus; storage diseases such as Gaucher disease, Niemann-Pick disease, and mucopolysaccharidoses; and other conditions, such as amyloidosis, primary neoplasms and cysts, and secondary neoplasms.

Disorders involving the lung include, but are not limited to, congenital anomalies; atelectasis; diseases of vascular origin, such as pulmonary congestion and edema, including hemodynamic pulmonary edema and edema caused by microvascular injury, adult respiratory distress syndrome (diffuse alveolar damage), pulmonary embolism, hemorrhage, and infarction, and pulmonary hypertension and vascular sclerosis; chronic obstructive pulmonary disease, such as emphysema, chronic bronchitis, bronchial asthma, and bronchiectasis; diffuse interstitial (infiltrative, restrictive) diseases, such as pneumoconioses, sarcoidosis, idiopathic

pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia (pulmonary infiltration with eosinophilia), *Bronchiolitis obliterans*-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, including Goodpasture syndrome, idiopathic pulmonary hemosiderosis and other hemorrhagic syndromes, pulmonary involvement in collagen vascular disorders, and pulmonary alveolar proteinosis, complications of therapies, such as drug-induced lung disease, radiation-induced lung disease, and lung transplantation, tumors, such as bronchogenic carcinoma, including paraneoplastic syndromes, bronchioloalveolar carcinoma, neuroendocrine tumors, such as bronchial carcinoid, miscellaneous tumors, and metastatic tumors, pathologies of the pleura, including inflammatory pleural effusions, noninflammatory pleural effusions, pneumothorax, and pleural tumors, including solitary fibrous tumors (pleural fibroma) and malignant mesothelioma.

Disorders involving the colon include, but are not limited to, congenital anomalies, such as atresia and stenosis, Meckel diverticulum, congenital aganglionic megacolon-Hirschsprung disease, enterocolitis, such as diarrhea and dysentery, infectious enterocolitis, including viral gastroenteritis, bacterial enterocolitis, necrotizing enterocolitis, antibiotic-associated colitis (pseudomembranous colitis), and collagenous and lymphocytic colitis, miscellaneous intestinal inflammatory disorders, including parasites and protozoa, acquired immunodeficiency syndrome, transplantation, drug-induced intestinal injury, radiation enterocolitis, neutropenic colitis (typhlitis), and diversion colitis, idiopathic inflammatory bowel disease, such as Crohn disease and ulcerative colitis, tumors of the colon, such as non-neoplastic polyps, adenomas, familial syndromes, colorectal carcinogenesis, colorectal carcinoma, and carcinoid tumors.

Disorders involving the liver include, but are not limited to, hepatic injury, jaundice and cholestasis, such as bilirubin and bile formation; hepatic failure and cirrhosis, such as cirrhosis, portal hypertension, including ascites, portosystemic shunts, and splenomegaly; infectious disorders, such as viral hepatitis, including hepatitis A-E infection and infection by other hepatitis viruses, clinicopathologic syndromes, such as the carrier state, asymptomatic infection, acute viral hepatitis, chronic viral hepatitis, and fulminant hepatitis; autoimmune hepatitis, drug- and toxin-induced liver disease, such as alcoholic liver disease; inborn errors of metabolism and pediatric liver disease, such as hemochromatosis, Wilson disease, α -

antitrypsin deficiency, and neonatal hepatitis, intrahepatic biliary tract disease, such as secondary biliary cirrhosis, primary biliary cirrhosis, primary sclerosing cholangitis, and anomalies of the biliary tree; circulatory disorders, such as impaired blood flow into the liver, including hepatic artery compromise and portal vein obstruction and thrombosis, impaired blood flow through the liver, including passive congestion and centrilobular necrosis and peliosis hepatis, hepatic vein outflow obstruction, including hepatic vein thrombosis (Budd-Chiari syndrome) and veno-occlusive disease; hepatic disease associated with pregnancy, such as preeclampsia and eclampsia, acute fatty liver of pregnancy, and intrahepatic cholestasis of pregnancy; hepatic complications of organ or bone marrow transplantation, such as drug toxicity after bone marrow transplantation, graft-versus-host disease and liver rejection, and nonimmunologic damage to liver allografts; tumors and tumorous conditions, such as nodular hyperplasias, adenomas, and malignant tumors, including primary carcinoma of the liver and metastatic tumors.

Disorders involving the uterus and endometrium include, but are not limited to, endometrial histology in the menstrual cycle; functional endometrial disorders, such as anovulatory cycle, inadequate luteal phase, oral contraceptives and induced endometrial changes, and menopausal and postmenopausal changes; inflammations, such as chronic endometritis; adenomyosis; endometriosis; endometrial polyps; endometrial hyperplasia; malignant tumors, such as carcinoma of the endometrium; mixed Müllerian and mesenchymal tumors, such as malignant mixed Müllerian tumors; tumors of the myometrium, including leiomyomas, leiomyosarcomas, and endometrial stromal tumors.

Disorders involving the brain include, but are not limited to, disorders involving neurons, and disorders involving glia, such as astrocytes, oligodendrocytes, ependymal cells, and microglia; cerebral edema, raised intracranial pressure and herniation, and hydrocephalus; malformations and developmental diseases, such as neural tube defects, forebrain anomalies, posterior fossa anomalies, and syringomyelia and hydromyelia; perinatal brain injury; cerebrovascular diseases, such as those related to hypoxia, ischemia, and infarction, including hypotension, hypoperfusion, and low-flow states--global cerebral ischemia and focal cerebral ischemia--infarction from obstruction of local blood supply, intracranial hemorrhage, including intracerebral (intraparenchymal) hemorrhage, subarachnoid hemorrhage and ruptured berry aneurysms, and vascular malformations, hypertensive cerebrovascular disease.

- including lacunar infarcts, slit hemorrhages, and hypertensive encephalopathy.
infections, such as acute meningitis, including acute pyogenic (bacterial) meningitis
and acute aseptic (viral) meningitis, acute focal suppurative infections, including brain
abscess, subdural empyema, and extradural abscess, chronic bacterial
- 5 meningoencephalitis, including tuberculosis and mycobacterioses, neurosyphilis, and
neuroborreliosis (Lyme disease), viral meningoencephalitis, including arthropod-
borne (Arbo) viral encephalitis, *Herpes simplex* virus Type 1, *Herpes simplex* virus
Type 2, *Varicella-zoster* virus (*Herpes zoster*), cytomegalovirus, poliomyelitis, rabies,
and human immunodeficiency virus 1, including HIV-1 meningoencephalitis
- 10 (subacute encephalitis), vacuolar myelopathy, AIDS-associated myopathy, peripheral
neuropathy, and AIDS in children, progressive multifocal leukoencephalopathy,
subacute sclerosing panencephalitis, fungal meningoencephalitis, other infectious
diseases of the nervous system; transmissible spongiform encephalopathies (prion
diseases); demyelinating diseases, including multiple sclerosis, multiple sclerosis
- 15 variants, acute disseminated encephalomyelitis and acute necrotizing hemorrhagic
encephalomyelitis, and other diseases with demyelination; degenerative diseases, such
as degenerative diseases affecting the cerebral cortex, including Alzheimer disease
and Pick disease, degenerative diseases of basal ganglia and brain stem, including
Parkinsonism, idiopathic Parkinson disease (paralysis agitans), progressive
- 20 supranuclear palsy, corticobasal degeneration, multiple system atrophy, including
striatonigral degeneration, Shy-Drager syndrome, and olivopontocerebellar atrophy,
and Huntington disease; spinocerebellar degenerations, including spinocerebellar
ataxias, including Friedreich ataxia, and ataxia-telangiectasia, degenerative diseases
affecting motor neurons, including amyotrophic lateral sclerosis (motor neuron
- 25 disease), bulbospinal atrophy (Kennedy syndrome), and spinal muscular atrophy;
inborn errors of metabolism, such as leukodystrophies, including Krabbe disease,
metachromatic leukodystrophy, adrenoleukodystrophy, Pelizaeus-Merzbacher
disease, and Canavan disease, mitochondrial encephalomyopathies, including Leigh
disease and other mitochondrial encephalomyopathies, toxic and acquired metabolic
- 30 diseases, including vitamin deficiencies such as thiamine (vitamin B₁) deficiency and
vitamin B₁₂ deficiency, neurologic sequelae of metabolic disturbances, including
hypoglycemia, hyperglycemia, and hepatic encephatopathy, toxic disorders, including
carbon monoxide, methanol, ethanol, and radiation, including combined methotrexate
and radiation-induced injury, tumors, such as gliomas, including astrocytoma,

- including fibrillary (diffuse) astrocytoma and glioblastoma multiforme, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and brain stem glioma, oligodendroglioma, and ependymoma and related paraventricular mass lesions, neuronal tumors, poorly differentiated neoplasms, including medulloblastoma, other
- 5 parenchymal tumors, including primary brain lymphoma, germ cell tumors, and pineal parenchymal tumors, meningiomas, metastatic tumors, paraneoplastic syndromes, peripheral nerve sheath tumors, including schwannoma, neurofibroma, and malignant peripheral nerve sheath tumor (malignant schwannoma), and neurocutaneous syndromes (phakomatoses), including neurofibromatosis, including
- 10 Type 1 neurofibromatosis (NF1) and TYPE 2 neurofibromatosis (NF2), tuberous sclerosis, and Von Hippel-Lindau disease

- Disorders involving T-cells include, but are not limited to, cell-mediated hypersensitivity, such as delayed type hypersensitivity and T-cell-mediated cytotoxicity, and transplant rejection; autoimmune diseases, such as systemic lupus
- 15 erythematosus, Sjögren syndrome, systemic sclerosis, inflammatory myopathies, mixed connective tissue disease, and polyarteritis nodosa and other vasculitides; immunologic deficiency syndromes, including but not limited to, primary immunodeficiencies, such as thymic hypoplasia, severe combined immunodeficiency diseases, and AIDS; leukopenia; reactive (inflammatory) proliferations of white cells,
- 20 including but not limited to, leukocytosis, acute nonspecific lymphadenitis, and chronic nonspecific lymphadenitis; neoplastic proliferations of white cells, including but not limited to lymphoid neoplasms, such as precursor T-cell neoplasms, such as acute lymphoblastic leukemia/lymphoma, peripheral T-cell and natural killer cell neoplasms that include peripheral T-cell lymphoma, unspecified, adult T-cell
- 25 leukemia/lymphoma, mycosis fungoides and Sézary syndrome, and Hodgkin disease.

- Diseases of the skin, include but are not limited to, disorders of pigmentation and melanocytes, including but not limited to, vitiligo, freckle, melasma, lentigo, nevocellular nevus, dysplastic nevi, and malignant melanoma; benign epithelial
- 30 tumors, including but not limited to, seborrheic keratoses, acanthosis nigricans, fibroepithelial polyp, epithelial cyst, keratoacanthoma, and adnexal (appendage) tumors; premalignant and malignant epidermal tumors, including but not limited to, actinic keratosis, squamous cell carcinoma, basal cell carcinoma, and merkel cell carcinoma; tumors of the dermis, including but not limited to, benign fibrous histiocytoma, dermatofibrosarcoma protuberans, xanthomas, and dermal vascular

tumors, tumors of cellular immigrants to the skin, including but not limited to, histiocytosis X, mycosis fungoides (cutaneous T-cell lymphoma), and mastocytosis, disorders of epidermal maturation, including but not limited to, ichthyosis, acute inflammatory dermatoses, including but not limited to, urticaria, acute eczematous dermatitis, and erythema multiforme, chronic inflammatory dermatoses, including but not limited to, psoriasis, lichen planus, and lupus erythematosus, blistering (bullous) diseases, including but not limited to, pemphigus, bullous pemphigoid, dermatitis herpetiformis, and noninflammatory blistering diseases epidermolysis bullosa and porphyria, disorders of epidermal appendages, including but not limited to, acne vulgaris, panniculitis, including but not limited to, erythema nodosum and erythema induratum, and infection and infestation, such as verrucae, molluscum contagiosum, impetigo, superficial fungal infections, and arthropod bites, stings, and infestations

In normal bone marrow, the myelocytic series (polymorphoneuclear cells) make up approximately 60% of the cellular elements, and the erythrocytic series, 20-30%. Lymphocytes, monocytes, reticular cells, plasma cells and megakaryocytes together constitute 10-20%. Lymphocytes make up 5-15% of normal adult marrow. In the bone marrow, cell types are add mixed so that precursors of red blood cells (erythroblasts), macrophages (monoblasts), platelets (megakaryocytes), polymorphoneuclear leucocytes (myeloblasts), and lymphocytes (lymphoblasts) can be visible in one microscopic field. In addition, stem cells exist for the different cell lineages, as well as a precursor stem cell for the committed progenitor cells of the different lineages. The various types of cells and stages of each would be known to the person of ordinary skill in the art and are found, for example, on page 42 (Figure 2-8) of *Immunology, Immunopathology and Immunity*, Fifth Edition, Sell *et al.* Simon and Schuster (1996), incorporated by reference for its teaching of cell types found in the bone marrow. According, the invention is directed to disorders arising from these cells. These disorders include but are not limited to the following: diseases involving hematopoietic stem cells, committed lymphoid progenitor cells, lymphoid cells including B and T-cells; committed myeloid progenitors, including monocytes, granulocytes, and megakaryocytes; and committed erythroid progenitors. These include but are not limited to the leukemias, including B-lymphoid leukemias, T-lymphoid leukemias, undifferentiated leukemias; erythroleukemia, megakaryoblastic leukemia, monocytic, [leukemias are encompassed with and without differentiation], chronic and acute lymphoblastic leukemia, chronic and acute lymphocytic leukemia,

- chronic and acute myelogenous leukemia, lymphoma, myelo dysplastic syndrome, chronic and acute myeloid leukemia, myelomonocytic leukemia; chronic and acute myeloblastic leukemia, chronic and acute myelogenous leukemia, chronic and acute promyelocytic leukemia, chronic and acute myelocytic leukemia, hematologic
- 5 malignancies of monocyte-macrophage lineage, such as juvenile chronic myelogenous leukemia; secondary AML, antecedent hematological disorder; refractory anemia; aplastic anemia; reactive cutaneous angioendotheliomatosis; fibrosing disorders involving altered expression in dendritic cells, disorders including systemic sclerosis, E-M syndrome, epidemic toxic oil syndrome, eosinophilic fasciitis
- 10 localized forms of scleroderma, keloid, and fibrosing colonopathy; angiomatoid malignant fibrous histiocytoma; carcinoma, including primary head and neck squamous cell carcinoma; sarcoma, including kaposi's sarcoma, fibroadenoma and phyllodes tumors, including mammary fibroadenoma; stromal tumors; phyllodes tumors, including histiocytoma; erythroblastosis; neurofibromatosis; diseases of the
- 15 vascular endothelium; demyelinating, particularly in old lesions; gliosis, vasogenic edema, vascular disease, Alzheimer's and Parkinson's disease, T-cell lymphomas; B cell lymphomas.

- Disorders involving the heart, include but are not limited to, heart failure, including but not limited to, cardiac hypertrophy, left-sided heart failure, and right-
- 20 sided heart failure; ischemic heart disease, including but not limited to angina pectoris, myocardial infarction, chronic ischemic heart disease, and sudden cardiac death; hypertensive heart disease, including but not limited to, systemic (left-sided) hypertensive heart disease and pulmonary (right-sided) hypertensive heart disease; valvular heart disease, including but not limited to, valvular degeneration caused by
- 25 calcification, such as calcific aortic stenosis, calcification of a congenitally bicuspid aortic valve, and mitral annular calcification, and myxomatous degeneration of the mitral valve (mitral valve prolapse), rheumatic fever and rheumatic heart disease, infective endocarditis, and noninfected vegetations, such as nonbacterial thrombotic endocarditis and endocarditis of systemic lupus erythematosus (Libman-Sacks
- 30 disease), carcinoid heart disease, and complications of artificial valves, myocardial disease, including but not limited to dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and myocarditis; pericardial disease, including but not limited to, pericardial effusion and hemopericardium and pericarditis, including acute pericarditis and healed pericarditis, and rheumatoid heart

disease; neoplastic heart disease, including but not limited to, primary cardiac tumors, such as myxoma, lipoma, papillary fibroelastoma, rhabdomyoma, and sarcoma, and cardiac effects of noncardiac neoplasms, congenital heart disease, including but not limited to, left-to-right shunts--late cyanosis, such as atrial septal defect, ventricular
5 septal defect, patent ductus arteriosus, and atrioventricular septal defect, right-to-left shunts--early cyanosis, such as tetralogy of fallot, transposition of great arteries, truncus arteriosus, tricuspid atresia, and total anomalous pulmonary venous connection, obstructive congenital anomalies, such as coarctation of aorta, pulmonary stenosis and atresia, and aortic stenosis and atresia, and disorders involving cardiac
10 transplantation

Disorders involving blood vessels include, but are not limited to, responses of vascular cell walls to injury, such as endothelial dysfunction and endothelial activation and intimal thickening; vascular diseases including, but not limited to, congenital anomalies, such as arteriovenous fistula, atherosclerosis, and hypertensive
15 vascular disease, such as hypertension; inflammatory disease--the vasculitides, such as giant cell (temporal) arteritis, Takayasu arteritis, polyarteritis nodosa (classic), Kawasaki syndrome (mucocutaneous lymph node syndrome), microscopic polyanglitis (microscopic polyarteritis, hypersensitivity or leukocytoclastic angitis), Wegener granulomatosis, thromboanglitis obliterans (Buerger disease), vasculitis
20 associated with other disorders, and infectious arteritis; Raynaud disease; aneurysms and dissection, such as abdominal aortic aneurysms, syphilitic (luetic) aneurysms, and aortic dissection (dissecting hematoma); disorders of veins and lymphatics, such as varicose veins, thrombophlebitis and phlebothrombosis, obstruction of superior vena cava (superior vena cava syndrome), obstruction of inferior vena cava (inferior vena
25 cava syndrome), and lymphangitis and lymphedema; tumors, including benign tumors and tumor-like conditions, such as hemangioma, lymphangioma, glomus tumor (glomangioma), vascular ectasias, and bacillary angiomatosis, and intermediate-grade (borderline low-grade malignant) tumors, such as Kaposi sarcoma and hemangioendothelioma, and malignant tumors, such as angiosarcoma and
30 hemangiopericytoma, and pathology of therapeutic interventions in vascular disease, such as balloon angioplasty and related techniques and vascular replacement, such as coronary artery bypass graft surgery.

Disorders involving red cells include, but are not limited to, anemias, such as hemolytic anemias, including hereditary spherocytosis, hemolytic disease due to

erythrocyte enzyme defects: glucose-6-phosphate dehydrogenase deficiency, sickle cell disease, thalassemia syndromes, paroxysmal nocturnal hemoglobinuria, immunohemolytic anemia, and hemolytic anemia resulting from trauma to red cells, and anemias of diminished erythropoiesis, including megaloblastic anemias, such as anemias of vitamin B12 deficiency: pernicious anemia, and anemia of folate deficiency, iron deficiency anemia, anemia of chronic disease, aplastic anemia, pure red cell aplasia, and other forms of marrow failure.

Disorders involving the thymus include developmental disorders, such as DiGeorge syndrome with thymic hypoplasia or aplasia, thymic cysts; thymic hypoplasia, which involves the appearance of lymphoid follicles within the thymus, creating thymic follicular hyperplasia; and thymomas, including germ cell tumors, lymphomas, Hodgkin disease, and carcinoids. Thymomas can include benign or encapsulated thymoma, and malignant thymoma Type I (invasive thymoma) or Type II, designated thymic carcinoma.

Disorders involving B cells include, but are not limited to precursor B cell neoplasms, such as lymphoblastic leukemia/lymphoma. Peripheral B cell neoplasms include, but are not limited to, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, diffuse large B cell lymphoma, Burkitt lymphoma, plasma cell neoplasms, multiple myeloma, and related entities, lymphoplasmacytic lymphoma (Waldenström macroglobulinemia), mantle cell lymphoma, marginal zone lymphoma (MALToma), and hairy cell leukemia.

Disorders involving the kidney include, but are not limited to, congenital anomalies including, but not limited to, cystic diseases of the kidney, that include but are not limited to, cystic renal dysplasia, autosomal dominant (adult) polycystic kidney disease, autosomal recessive (childhood) polycystic kidney disease, and cystic diseases of renal medulla, which include, but are not limited to, medullary sponge kidney, and nephronophthisis-uremic medullary cystic disease complex, acquired (dialysis-associated) cystic disease, such as simple cysts; glomerular diseases including pathologies of glomerular injury that include, but are not limited to, in situ immune complex deposition, that includes, but is not limited to, anti-GBM nephritis, Heymann nephritis, and antibodies against planted antigens, circulating immune complex nephritis, antibodies to glomerular cells, cell-mediated immunity in glomerulonephritis, activation of alternative complement pathway, epithelial cell injury, and pathologies involving mediators of glomerular injury including cellular and soluble mediators, acute

- glomerulonephritis, such as acute proliferative (poststreptococcal, postinfectious) glomerulonephritis, including but not limited to, poststreptococcal glomerulonephritis and nonstreptococcal acute glomerulonephritis, rapidly progressive (crescentic) glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis (membranous nephropathy), minimal change disease (lipoid nephrosis), focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, IgA nephropathy (Berger disease), focal proliferative and necrotizing glomerulonephritis (focal glomerulonephritis), hereditary nephritis, including but not limited to, Alport syndrome and thin membrane disease (benign familial hematuria), chronic glomerulonephritis,
- 10 glomerular lesions associated with systemic disease, including but not limited to, systemic lupus erythematosus, Henoch-Schonlein purpura, bacterial endocarditis, diabetic glomerulosclerosis, amyloidosis, fibrillary and immunotactoid glomerulonephritis, and other systemic disorders; diseases affecting tubules and interstitium, including acute tubular necrosis and tubulointerstitial nephritis, including
- 15 but not limited to, pyelonephritis and urinary tract infection, acute pyelonephritis, chronic pyelonephritis and reflux nephropathy, and tubulointerstitial nephritis induced by drugs and toxins, including but not limited to, acute drug-induced interstitial nephritis, analgesic abuse nephropathy, nephropathy associated with nonsteroidal anti-inflammatory drugs, and other tubulointerstitial diseases including, but not limited to,
- 20 urate nephropathy, hypercalcemia and nephrocalcinosis, and multiple myeloma, diseases of blood vessels including benign nephrosclerosis, malignant hypertension and accelerated nephrosclerosis, renal artery stenosis, and thrombotic microangiopathies including, but not limited to, classic (childhood) hemolytic-uremic syndrome, adult hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura, idiopathic
- 25 HUS/TTP, and other vascular disorders including, but not limited to, atherosclerotic ischemic renal disease, atheroembolic renal disease, sickle cell disease nephropathy, diffuse cortical necrosis, and renal infarcts; urinary tract obstruction (obstructive uropathy); urolithiasis (renal calculi, stones); and tumors of the kidney including, but not limited to, benign tumors, such as renal papillary adenoma, renal fibroma or hamartoma
- 30 (renomedullary interstitial cell tumor), angiomyolipoma, and oncocytoma, and malignant tumors, including renal cell carcinoma (hypernephroma, adenocarcinoma of kidney), which includes urothelial carcinomas of renal pelvis

Disorders of the breast include, but are not limited to, disorders of development, inflammations, including but not limited to, acute mastitis, periductal mastitis, periductal

- mastitis (recurrent subareolar abscess, squamous metaplasia of lactiferous ducts), mammary duct ectasia, fat necrosis, granulomatous mastitis, and pathologies associated with silicone breast implants; fibrocystic changes; proliferative breast disease including, but not limited to, epithelial hyperplasia, sclerosing adenosis, and small duct papillomas;
- 5 tumors including, but not limited to, stromal tumors such as fibroadenoma, phyllodes tumor, and sarcomas, and epithelial tumors such as large duct papilloma; carcinoma of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, no special type,
- 10 invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma, and miscellaneous malignant neoplasms.

Disorders in the male breast include, but are not limited to, gynecomastia and carcinoma.

- Disorders involving the testis and epididymis include, but are not limited to,
- 15 congenital anomalies such as cryptorchidism, regressive changes such as atrophy, inflammations such as nonspecific epididymitis and orchitis, granulomatous (autoimmune) orchitis, and specific inflammations including, but not limited to, gonorrhea, mumps, tuberculosis, and syphilis, vascular disturbances including torsion, testicular tumors including germ cell tumors that include, but are not limited to,
- 20 seminoma, spermatocytic seminoma, embryonal carcinoma, yolk sac tumor choriocarcinoma, teratoma, and mixed tumors, tumor of sex cord-gonadal stroma including, but not limited to, leydig (interstitial) cell tumors and sertoli cell tumors (androblastoma), and testicular lymphoma, and miscellaneous lesions of tunica vaginalis.

- Disorders involving the prostate include, but are not limited to, inflammations,
- 25 benign enlargement, for example, nodular hyperplasia (benign prostatic hypertrophy or hyperplasia), and tumors such as carcinoma.

- Disorders involving the thyroid include, but are not limited to, hyperthyroidism; hypothyroidism including, but not limited to, cretinism and myxedema; thyroiditis including, but not limited to, hashimoto thyroiditis, subacute (granulomatous) thyroiditis,
- 30 and subacute lymphocytic (painless) thyroiditis; Graves disease; diffuse and multinodular goiter including, but not limited to, diffuse nontoxic (simple) goiter and multinodular goiter; neoplasms of the thyroid including, but not limited to, adenomas, other benign tumors, and carcinomas, which include, but are not limited to, papillary

carcinoma, follicular carcinoma, medullary carcinoma, and anaplastic carcinoma, and congenital anomalies

Disorders involving the skeletal muscle include tumors such as rhabdomyosarcoma

- 5 Disorders involving the pancreas include those of the exocrine pancreas such as congenital anomalies, including but not limited to, ectopic pancreas, pancreatitis, including but not limited to, acute pancreatitis; cysts, including but not limited to, pseudocysts; tumors, including but not limited to, cystic tumors and carcinoma of the pancreas; and disorders of the endocrine pancreas such as, diabetes mellitus; islet cell
10 tumors, including but not limited to, insulinomas, gastrinomas, and other rare islet cell tumors

- Disorders involving the small intestine include the malabsorption syndromes such as, celiac sprue, tropical sprue (postinfectious sprue), whipple disease, disaccharidase (lactase) deficiency, abetalipoproteinemia, and tumors of the small
15 intestine including adenomas and adenocarcinoma.

- Disorders related to reduced platelet number, thrombocytopenia, include idiopathic thrombocytopenic purpura, including acute idiopathic thrombocytopenic purpura, drug-induced thrombocytopenia, HIV-associated thrombocytopenia, and thrombotic microangiopathies: thrombotic thrombocytopenic purpura and hemolytic-
20 uremic syndrome.

- Disorders involving precursor T-cell neoplasms include precursor T lymphoblastic leukemia/lymphoma. Disorders involving peripheral T-cell and natural killer cell neoplasms include T-cell chronic lymphocytic leukemia, large granular lymphocytic leukemia, mycosis fungoides and Sézary syndrome, peripheral T-cell
25 lymphoma, unspecified, angioimmunoblastic T-cell lymphoma, angiocentric lymphoma (NK/T-cell lymphoma^{4a}), intestinal T-cell lymphoma, adult T-cell leukemia/lymphoma, and anaplastic large cell lymphoma.

- Disorders involving the ovary include, for example, polycystic ovarian disease, Stein-leventhal syndrome, Pseudomyxoma peritonei and stromal
30 hyperthecosis; ovarian tumors such as, tumors of coelomic epithelium, serous tumors, mucinous tumors, endometrioid tumors, clear cell adenocarcinoma, cystadenofibroma, brenner tumor, surface epithelial tumors; germ cell tumors such as mature (benign) teratomas, monodermal teratomas, immature malignant teratomas, dysgerminoma, endodermal sinus tumor, choriocarcinoma; sex cord-stromal tumors

such as, granulosa-theca cell tumors, thecoma-fibromas, androblastomas, hill cell tumors, and gonadoblastoma, and metastatic tumors such as Krukenberg tumors.

Bone-forming cells include the osteoprogenitor cells, osteoblasts, and osteocytes. The disorders of the bone are complex because they may have an impact on the skeleton during any of its stages of development. Hence, the disorders may have variable manifestations and may involve one, multiple or all bones of the body. Such disorders include, congenital malformations, achondroplasia and thanatophoric dwarfism, diseases associated with abnormal matix such as type 1 collagen disease, osteoporois, paget disease, rickets, osteomalacia, high-turnover osteodystrophy, low-turnover of aplastic disease, osteonecrosis, pyogenic osteomyelitis, tuberculous osteomyelitism, osteoma, osteoid osteoma, osteoblastoma, osteosarcoma, osteochondroma, chondromas, chondroblastoma, chondromyxoid fibroma, chondrosarcoma, fibrous cortical defects, fibrous dysplasia, fibrosarcoma, malignant fibrous histiocytooma, ewing saracoma, primitive neuroectodermal tumor, giant cell tumor, and metastatic tumors.

The receptor polypeptides are thus useful for treating a receptor-associated disorder characterized by aberrant expression or activity of a receptor protein, especially as disclosed above. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) expression or activity of the protein. In another embodiment, the method involves administering a protein as therapy to compensate for reduced or aberrant expression or activity of the protein.

Stimulation of protein activity is desirable in situations in which the protein is abnormally downregulated and/or in which increased protein activity is likely to have a beneficial effect. Likewise, inhibition of protein activity is desirable in situations in which the protein is abnormally upregulated and/or in which decreased protein activity is likely to have a beneficial effect. In one example of such a situation, a subject has a disorder characterized by aberrant development or cellular differentiation. In another example of such a situation, the subject has a proliferative disease (e.g., cancer) or a disorder characterized by an aberrant hematopoietic response. In another example of such a situation, it is desirable to achieve tissue regeneration in a subject (e.g., where a subject has undergone brain or spinal cord injury and it is desirable to regenerate neuronal tissue in a regulated manner).

In yet another aspect of the invention, the proteins of the invention can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317, Zervos *et al.* (1993) *Cell* 72:223-232, Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054, Bartel *et al.* (1993) *Biotechniques* 14:920-924, Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO 94/10300), to identify other proteins (captured proteins) which bind to or interact with the proteins of the invention and modulate their activity.

The 2838 receptor polypeptides also are useful to provide a target for diagnosing a disease or predisposition to disease mediated by the receptor protein, especially in hematopoietic cells such as T-helper cells (1 and 2), B cells, and granulocytes. The 14618 receptor polypeptides also are useful to provide a target for diagnosing a disease or predisposition to disease mediated by the receptor protein, especially in breast, skeletal, muscle and lymphnode, as well as CD34⁺ progenitor cells and cells generated from these progenitors, which include erythroid, lymphoid, and megakaryocytic lineages. The 15334 receptor polypeptides also are useful to provide a target for diagnosing a disease or predisposition to disease mediated by the receptor protein, especially in pancreas, spleen, tonsils and lymphnodes, as well as in cells of the megakaryocyte and erythroblast lineages. Accordingly, methods are provided for detecting the presence, or levels of, the receptor protein in a cell, tissue, or organism. The method involves contacting a biological sample with a compound capable of interacting with the receptor protein such that the interaction can be detected.

One agent for detecting receptor protein is an antibody capable of selectively binding to receptor protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The receptor protein also provides a target for diagnosing active disease, or predisposition to disease, in a patient having a variant receptor protein. Thus, receptor protein can be isolated from a biological sample, assayed for the presence of a genetic mutation that results in aberrant receptor protein. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered receptor activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern.

altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein

In vitro techniques for detection of receptor protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. Alternatively, the protein can be detected *in vivo* in a subject by introducing into the subject a labeled anti-receptor antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods which detect the allelic variant of a receptor protein expressed in a subject and methods which detect fragments of a receptor protein in a sample.

The receptor polypeptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum (1997) *Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996), and Linder (1997) *Clin. Chem.* 43(2):254-266. The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the receptor protein in which one or more of the receptor functions in one population is different from those in another population. The polypeptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other ligand-binding regions that are more or less active in ligand binding, and receptor activation. Accordingly, ligand dosage would

necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic polypeptides could be identified.

The receptor polypeptides are also useful for monitoring therapeutic effects during clinical trials and other treatment. Thus, the therapeutic effectiveness of an agent that is designed to increase or decrease gene expression, protein levels or receptor activity can be monitored over the course of treatment using the receptor polypeptides as an end-point target. The monitoring can be, for example, as follows: (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression or activity of a specified protein in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the protein in the post-administration samples; (v) comparing the level of expression or activity of the protein in the pre-administration sample with the protein in the post-administration sample or samples; and (vi) increasing or decreasing the administration of the agent to the subject accordingly.

The receptor polypeptides are also useful for treating a receptor-associated disorder. Accordingly, methods for treatment include the use of soluble receptor or fragments of the receptor protein that compete for ligand binding. These receptors or fragments can have a higher affinity for the ligand so as to provide effective competition.

Antibodies

The invention also provides antibodies that selectively bind to the 2838, 14618, and 15334 receptor proteins and variants and fragments. An antibody is considered to selectively bind, even if it also binds to other proteins that are not substantially homologous with the receptor protein. These other proteins share homology with a fragment or domain of the receptor protein. This conservation in specific regions gives rise to antibodies that bind to both proteins by virtue of the homologous sequence. In this case, it would be understood that antibody binding to the receptor protein is still selective.

To generate antibodies, an isolated receptor polypeptide is used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. Either the full-length protein or antigenic peptide

fragment can be used. Regions having a high antigenicity index are shown in Figures 2, 6, and 10.

Antibodies are preferably prepared from these regions or from discrete fragments in these regions. However, antibodies can be prepared from any region of the peptide as described herein. A preferred fragment produces an antibody that diminishes or completely prevents ligand-binding. Antibodies can be developed against the entire receptor or portions of the receptor, for example, the intracellular carboxy terminal domain, the amino terminal extracellular domain, the entire transmembrane domain or specific segments, any of the intra or extracellular loops, or any portions of the above. Antibodies may also be developed against specific functional sites, such as the site of ligand-binding, the site of G protein coupling, or sites that are phosphorylated, glycosylated, or myristoylated.

An antigenic 2838 fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, a contiguous sequence of at least 12, 14 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, or at least 30 amino acid residues. In one embodiment, fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions. These fragments are not to be construed, however, as encompassing any fragments which may be disclosed prior to the invention.

An 14618 antigenic fragment will typically comprise at least 9 contiguous amino acid residues. The antigenic peptide can comprise, however, a contiguous sequence of at least 12, 14 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, or at least 30 amino acid residues. In one embodiment, fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions. These fragments are not to be construed, however, as encompassing any fragments which may be disclosed prior to the invention.

An antigenic 15334 fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, a contiguous sequence of at least 12, 14 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, or at least 30 amino acid residues. In one embodiment, fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions. These fragments are not to be construed, however, as encompassing any fragments which may be disclosed prior to the invention.

Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (e.g. Fab or F(ab')₂) can be used.

Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

An appropriate immunogenic preparation can be derived from native, recombinantly expressed, protein or chemically synthesized peptides.

Antibody Uses

The antibodies can be used to isolate a receptor protein by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural receptor protein from cells and recombinantly produced receptor protein expressed in host cells.

The antibodies are useful to detect the presence of receptor protein in cells or tissues to determine the pattern of expression of the receptor among various tissues in an organism and over the course of normal development.

The antibodies can be used to detect receptor protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression.

The antibodies can be used to assess abnormal tissue distribution or abnormal expression during development.

Antibody detection of circulating fragments of the full length receptor protein can be used to identify receptor turnover.

Further, the antibodies can be used to assess receptor expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to receptor function. When a disorder is caused by an

inappropriate tissue distribution, developmental expression, or level of expression of the receptor protein, the antibody can be prepared against the normal receptor protein. If a disorder is characterized by a specific mutation in the receptor protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant receptor protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Antibodies can be developed against the whole receptor or portions of the receptor, for example, portions of the amino terminal extracellular domain or extracellular loops.

The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting receptor expression level or the presence of aberrant receptors and aberrant tissue distribution or developmental expression, antibodies directed against the receptor or relevant fragments can be used to monitor therapeutic efficacy.

Antibodies accordingly can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic receptor proteins can be used to identify individuals that require modified treatment modalities.

The antibodies are also useful as diagnostic tools as an immunological marker for aberrant receptor protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Thus, where a specific receptor protein has been correlated with expression in a specific tissue, antibodies that are specific for this receptor protein can be used to identify a tissue type.

The antibodies are also useful in forensic identification. Accordingly, where an individual has been correlated with a specific genetic polymorphism resulting in a specific polymorphic protein, an antibody specific for the polymorphic protein can be used as an aid in identification.

The antibodies are also useful for inhibiting receptor function, for example, blocking ligand binding.

These uses can also be applied in a therapeutic context in which treatment involves inhibiting receptor function. An antibody can be used, for example, to block

ligand binding. Antibodies can be prepared against specific fragments containing sites required for function or against intact receptor associated with a cell.

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995, *Int. Rev. Immunol.* 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., U.S. Patent 5,625,126, U.S. Patent 5,633,425, U.S. Patent 5,569,825, U.S. Patent 5,661,016, and U.S. Patent 5,545,806.

The invention also encompasses kits for using antibodies to detect the presence of a receptor protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting receptor protein in a biological sample, means for determining the amount of receptor protein in the sample, and means for comparing the amount of receptor protein in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect receptor protein.

Polynucleotides

The nucleotide sequence in SEQ ID NO:2 was obtained by sequencing the human full length cDNA.

The nucleotide sequence in SEQ ID NO:4 was obtained by sequencing the human full length cDNA.

The nucleotide sequence in SEQ ID NO:6 was obtained by sequencing the human full length cDNA.

The specifically disclosed cDNAs comprise the coding region and 5' and 3' untranslated sequences (SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6).

The human 2838 receptor cDNA is approximately 1617 nucleotides in length and encodes a full length protein that is approximately 319 amino acid residues in length. The nucleic acid is expressed in spleen, testes, colon, and peripheral blood lymphocytes as well as those tissues shown in Figure 15. Structural analysis of the amino acid sequence of SEQ ID NO:1 is provided in Figure 3, a hydropathy plot. The figure shows the putative structure of the seven transmembrane segments, the amino terminal extracellular domain and the carboxy terminal intracellular domain.

The human 14618 receptor cDNA is approximately 1358 nucleotides in length and encodes a full length protein that is approximately 337 amino acid residues in length. The nucleic acid is expressed in spleen, peripheral blood lymphocytes, breast, skeletal muscle, and other tissues shown in Figure 13, as well as various hematopoietic cells shown in Figure 14, especially megakaryocytes and CD34⁺ cells. Structural analysis of the amino acid sequence of SEQ ID NO:3 is provided in Figure 7, a hydropathy plot. The figure shows the putative structure of the seven transmembrane segments, the amino terminal extracellular domain and the carboxy terminal intracellular domain.

The human 153340 receptor cDNA is approximately 2559 nucleotides in length and encodes a full length protein that is approximately 372 amino acid residues in length. The nucleic acid is expressed in lymphnode, tonsils, pancreas, colon, spleen, peripheral blood cells, thymus, adrenal gland and heart as well as cells of the megakaryocytic and erythroid lineages as shown in Figures 17-19. Structural analysis of the amino acid sequence of SEQ ID NO:5 is provided in Figure 11, a hydropathy plot. The figure shows the putative structure of the seven transmembrane segments, the amino terminal extracellular domain and the carboxy terminal intracellular domain.

As used herein, the term "transmembrane segment" refers to a structural amino acid motif which includes a hydrophobic helix that spans the plasma membrane. The entire transmembrane domain of 2838 spans from about amino acid 25 to about amino acid 292. The entire transmembrane domain of 14618 spans from about amino acid 29 to about amino acid 297. The entire transmembrane domain of 15334 spans from about amino acid 26 to about amino acid 299. Seven segments span the membrane and there are three intracellular and three extracellular loops in this domain.

The invention provides isolated polynucleotides encoding a 2838 receptor protein. The term "2838 polynucleotide" or "2838 nucleic acid" refers to the sequence shown in SEQ ID NO:2.

The invention provides isolated polynucleotides encoding a 14618 receptor protein. The term "14618 polynucleotide" or "14618 nucleic acid" refers to the sequence shown in SEQ ID NO:4.

The invention provides isolated polynucleotides encoding a 15334 receptor protein. The term "15334 polynucleotide" or "15334 nucleic acid" refers to the sequence shown in SEQ ID NO:6.

The term "receptor polynucleotide" or "receptor nucleic acid" further includes variants and fragments of the 2838, 14618, and 15334 polynucleotides

An "isolated" receptor nucleic acid is one that is separated from other nucleic acid present in the natural source of the receptor nucleic acid. Preferably, an
5 "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB. The important point is that the nucleic acid is isolated from flanking sequences such that it can be subjected
10 to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the receptor nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a cDNA or RNA molecule, can be substantially free of other cellular material, or culture medium when
15 produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include
20 recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

25 In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstances, the material may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC. Preferably, an isolated nucleic acid comprises at least about 50, 80 or 90 % (on a
30 molar basis) of all macromolecular species present.

The receptor polynucleotides can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor

to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

5 The receptor polynucleotides include, but are not limited to, the sequence encoding the mature polypeptide alone, the sequence encoding the mature polypeptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature polypeptide, with or without the additional coding sequences, plus additional non-coding sequences, for
10 example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the polynucleotide may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

15 Receptor polynucleotides can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense
20 strand).

One receptor nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:2, corresponding to human 2838 cDNA.

One receptor nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:4, corresponding to human 14618 cDNA.

25 One receptor nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:6, corresponding to human 15334 cDNA.

In one embodiment, the receptor nucleic acid comprises only the coding region.

30 The invention further provides variant receptor polynucleotides, and fragments thereof, that differ from the nucleotide sequence shown in SEQ ID NO:2 due to degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequence shown in SEQ ID NO:2.

The invention further provides variant receptor polynucleotides, and fragments thereof, that differ from the nucleotide sequence shown in SEQ ID NO:4 due to

degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequence shown in SEQ ID NO 4

The invention further provides variant receptor polynucleotides, and fragments thereof, that differ from the nucleotide sequence shown in SEQ ID NO 6 due to
5 degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequence shown in SEQ ID NO 6

The invention also provides receptor nucleic acid molecules encoding the variant polypeptides described herein. Such polynucleotides may be naturally occurring, such as allelic variants (same locus), homologs (different locus), and
10 orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions.

15 Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

Typically, variants have a substantial identity with a nucleic acid molecule selected from the group consisting of SEQ ID NOS: 2, 4, and 6 and its complements.

20 Orthologs, homologs, and allelic variants can be identified using methods well known in the art. 2838 variants comprise a nucleotide sequence encoding a receptor that is 40-45%, 45-50%, 50-55%, 55-60%, at least about 65%, typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more homologous to the nucleotide sequence shown in SEQ ID NO 2 or a
25 fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions, to the nucleotide sequence shown in SEQ ID NO 2 or a fragment of the sequence.

14618 variants comprise a nucleotide sequence encoding a receptor that is 40-45%, 45-50%, 50-55%, 55-60%, at least about 65%, typically at least about 70-75%,
30 more typically at least about 80-85%, and most typically at least about 90-95% or more homologous to the nucleotide sequence shown in SEQ ID NO 4 or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions, to the nucleotide sequence shown in SEQ ID NO 4 or a fragment of the sequence

15334 variants comprise a nucleotide sequence encoding a receptor that is 45-50%, 50-55%, 55-60%, at least about 65%, typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more homologous to the nucleotide sequence shown in SEQ ID NO:6 or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions, to the nucleotide sequence shown in SEQ ID NO:6 or a fragment of the sequence

It is understood that stringent hybridization does not indicate substantial homology where it is due to general homology, such as poly A sequences, or sequences common to all or most proteins, all GPCRs, or all family I GPCRs or even all purinoceptors. Moreover, it is understood that variants do not include any of the nucleic acid sequences that may have been disclosed prior to the invention.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a receptor polypeptide at least 50-55%, 55% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95% or more identical to each other remain hybridized to one another. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6, incorporated by reference. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. In another non-limiting example, nucleic acid molecules are allowed to hybridize in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more low stringency washes in 0.2X SSC/0.1% SDS at room temperature, or by one or more moderate stringency washes in 0.2X SSC/0.1% SDS at 42°C, or washed in 0.2X SSC/0.1% SDS at 65°C for high stringency. In one embodiment, an isolated receptor nucleic acid molecule that hybridizes under stringent conditions to the sequence of SEQ ID NOS: 2, 4, and 6 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein)

As understood by those of ordinary skill, the exact conditions can be determined empirically and depend on ionic strength, temperature and the concentration of destabilizing agents such as formamide or denaturing agents such as SDS. Other factors considered in determining the desired hybridization conditions include the length of the nucleic acid sequences, base composition, percent mismatch between the hybridizing sequences and the frequency of occurrence of subsets of the sequences within other non-identical sequences. Thus, equivalent conditions can be determined by varying one or more of these parameters while maintaining a similar degree of identity or similarity between the two nucleic acid molecules.

The present invention also provides isolated nucleic acids that contain a single or double stranded fragment or portion that hybridizes under stringent conditions to a nucleotide sequence selected from the group consisting of SEQ ID NOS: 2, 4, and 6 and the complements of SEQ ID NOS: 2, 4, and 6. In one embodiment, the nucleic acid consists of a portion of a nucleotide sequence selected from the group consisting of SEQ ID NOS: 2, 4, and 6 and the complements. The nucleic acid fragments of the invention are at least about 15, preferably at least about 18, 20, 23 or 25 nucleotides, and can be 30, 40, 50, 100, 200 or more nucleotides in length. Longer fragments, for example, 30 or more nucleotides in length, which encode antigenic proteins or polypeptides described herein are useful.

Furthermore, the invention provides polynucleotides that comprise a fragment of the full length receptor polynucleotides. The fragment can be single or double stranded and can comprise DNA or RNA. The fragment can be derived from either the coding or the non-coding sequence.

In one embodiment, an isolated 2838 receptor nucleic acid from nucleotide 1 to around nucleotide 990 is at least 16 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2. In another embodiment, the nucleic acid from around nucleotide 1487-1617 is at least 20 nucleotides. In other embodiments, the nucleic acid is at least 40, 50, 100, 250 or 500 nucleotides in length or greater.

In another embodiment, an isolated 14168 receptor nucleic acid from around nucleotide 1 to around nucleotide 911 is at least 8 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:4. In other embodiments, the nucleic acid is at least 40, 50, 100, 250, or 500 nucleotides in length or greater.

In another embodiment, an isolated 15334 receptor nucleic acid from nucleotide 1 to around nucleotide 1355 is at least 18 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:6. In another embodiment, the nucleic acid from
5 around nucleotide 868 to around 1355 is at least 11 nucleotides. In other embodiments, the nucleic acid is at least 40, 50, 100, 250, or 500 nucleotides in length or greater.

In another embodiment, an isolated 2838 receptor nucleic acid encodes the entire coding region from amino acid 1 to amino acid 319. In another embodiment,
10 the isolated 2838 receptor nucleic acid encodes a sequence corresponding to the mature protein from about amino acid 6 to about amino acid 319. In another embodiment, an isolated 14618 receptor nucleic acid encodes the entire coding region from amino acid 1 to amino acid 337. In another embodiment, the isolated 14618 receptor nucleic acid encodes a sequence corresponding to the mature protein from
15 about amino acid 6 to about amino acid 337. In another embodiment, an isolated 15334 receptor nucleic acid encodes the entire coding region from amino acid 1 to amino acid 372. In another embodiment, the isolated 15334 receptor nucleic acid encodes a sequence corresponding to the mature protein from about amino acid 6 to about amino acid 372.

20 Other fragments of all three receptors include nucleotide sequences encoding the amino acid fragments described herein. Further, fragments can include subfragments of the specific domains or sites described herein. Fragments also include nucleic acid sequences corresponding to specific amino acid sequences described above or fragments thereof. Nucleic acid fragments, according to the
25 present invention, are not to be construed as encompassing those fragments that may have been disclosed prior to the invention.

However, it is understood that a receptor fragment includes any nucleic acid sequence that does not include the entire gene.

2838 receptor nucleic acid fragments further include sequences corresponding
30 to the domains described herein, subregions also described, and specific functional sites. 2838 receptor nucleic acid fragments include nucleic acid molecules encoding a polypeptide comprising the amino terminal extracellular domain including amino acid residues from 1 to about 24, a polypeptide comprising the region spanning the transmembrane domain (amino acid residues from about 25 to about 292), a

polypeptide comprising the carboxy terminal intracellular domain (amino acid residues from about 293 to about 319), and a polypeptide encoding the G-protein receptor signature (118-120 or surrounding amino acid residues from about 107 to about 123), nucleic acid molecules encoding any of the seven transmembrane
5 segments, extracellular or intracellular loops, glycosylation sites, phosphorylation sites, myristoylation sites, and amidation site

14618 receptor nucleic acid fragments include nucleic acid molecules encoding a polypeptide comprising the amino terminal extracellular domain including amino acid residues from 1 to about 28, a polypeptide comprising the region spanning
10 the transmembrane domain (amino acid residues from about 29 to about 297), a polypeptide comprising the carboxy terminal intracellular domain (amino acid residues from about 298 to about 337), and a polypeptide encoding the G-protein receptor signature (120-122 or surrounding amino acid residues from about 110 to about 132), nucleic acid molecules encoding any of the seven transmembrane
15 segments, extracellular or intracellular loops, glycosylation sites and phosphorylation sites.

15334 receptor nucleic acid fragments include nucleic acid molecules encoding a polypeptide comprising the amino terminal extracellular domain including amino acid residues from 1 to about 25, a polypeptide comprising the region spanning
20 the transmembrane domain (amino acid residues from about 26 to about 299), a polypeptide comprising the carboxy terminal intracellular domain (amino acid residues from about 300 to about 372), and a polypeptide encoding the G-protein receptor signature (118-120 or surrounding amino acid residues from about 110 to about 130), nucleic acid molecules encoding any of the seven transmembrane
25 segments, extracellular or intracellular loops, glycosylation sites, protein kinase C, cAMP, cGMP, and casein kinase II phosphorylation sites, and myristoylation sites.

Where the location of the domains have been predicted by computer analysis, one of ordinary skill would appreciate that the amino acid residues constituting these domains can vary depending on the criteria used to define the domains

30 Receptor nucleic acid fragments also include combinations of the domains, segments, loops, and other functional sites described above. Thus, for example, a receptor nucleic acid could include sequences corresponding to the amino terminal extracellular domain and one transmembrane segment. A person of ordinary skill in the art would be aware of the many permutations that are possible.

Where the location of the domains or sites have been predicted by computer analysis, one of ordinary skill would appreciate that the amino acid residues constituting these domains can vary depending on the criteria used to define the domains.

The invention also provides receptor nucleic acid fragments that encode epitope bearing regions of the receptor proteins described herein

The isolated receptor polynucleotide sequences, and especially fragments, are useful as DNA probes and primers.

For example, the coding region of a receptor gene can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of receptor genes.

A probe/primer typically comprises substantially purified oligonucleotide. The 2838 oligonucleotide typically comprises a region of nucleotide sequence from 1-990 and from 1487-1617 that hybridizes under stringent conditions to at least about 16 and 20, respectively, typically about 25, more typically about 40, 50 or 75 consecutive nucleotides of SEQ ID NO:2 sense or anti-sense strand or other receptor polynucleotides. The 14618 oligonucleotide typically comprises a region of nucleotide sequence from 1-911 that hybridizes under stringent conditions to at least about 9, 12, typically about 25, more typically about 40, 50 or 75 consecutive nucleotides of SEQ ID NO:4 sense or anti-sense strand or other receptor polynucleotides. The 15334 oligonucleotide typically comprises a region of nucleotide sequence from 868-1355 that hybridizes under stringent conditions to at least about 11, 12, typically about 25, more typically about 40, 50 or 75 consecutive nucleotides of SEQ ID NO:6 sense or anti-sense strand or other receptor polynucleotides. The 15334 oligonucleotide also typically comprises a region of nucleotide sequence from nucleotide 1-1355 that hybridizes under stringent conditions to at least about 18, typically about 25, more typically about 40, 50, or 75 consecutive nucleotides of SEQ ID NO:6 sense or anti-sense strand or other receptor polynucleotides.

Polynucleotide Uses

The nucleic acid sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example,

identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul *et al.* (1990). *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences
5 homologous to the nucleic acid molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

10 The nucleic acid fragments of the invention provide probes or primers in assays such as those described below. "Probes" are oligonucleotides that hybridize in a base-specific manner to a complementary strand of nucleic acid. Such probes include polypeptide nucleic acids, as described in Nielsen *et al.* (1991) *Science* 254:1497-1500. Typically, a probe comprises a region of nucleotide sequence that
15 hybridizes under highly stringent conditions to at least about 15, typically about 20-25, and more typically about 40, 50 or 75 consecutive nucleotides of a nucleic acid selected from the group consisting of SEQ ID NOS: 2, 4, and 6 and the complements thereof. More typically, the probe further comprises a label, e.g., radioisotope, fluorescent compound, enzyme, or enzyme co-factor.

20 As used herein, the term "primer" refers to a single-stranded oligonucleotide which acts as a point of initiation of template-directed DNA synthesis using well-known methods (e.g., PCR, LCR) including, but not limited to those described herein. The appropriate length of the primer depends on the particular use, but typically ranges from about 15 to 30 nucleotides. The term "primer site" refers to the area of
25 the target DNA to which a primer hybridizes. The term "primer pair" refers to a set of primers including a 5' (upstream) primer that hybridizes with the 5' end of the nucleic acid sequence to be amplified and a 3' (downstream) primer that hybridizes with the complement of the sequence to be amplified.

30 The receptor polynucleotides are useful for probes, primers, and in biological assays.

Where the polynucleotides are used to assess GPCR properties or functions, such as in the assays described herein, all or less than all of the entire cDNA can be useful. In this case, even fragments that may have been known prior to the invention are encompassed. Thus, for example, assays specifically directed to GPCR functions,

such as assessing agonist or antagonist activity, encompass the use of known fragments. Further, diagnostic methods for assessing receptor function can also be practiced with any fragment, including those fragments that may have been known prior to the invention. Similarly, in methods involving treatment of receptor dysfunction, all fragments are encompassed including those which may have been known in the art.

The 2838 receptor polynucleotides are useful as a hybridization probe for cDNA and genomic DNA to isolate a full-length cDNA and genomic clones encoding the polypeptide described in SEQ ID NO:1 and to isolate cDNA and genomic clones that correspond to variants producing the same polypeptide shown in SEQ ID NO:1 or the other variants described herein. Variants can be isolated from the same tissue and organism from which the polypeptide shown in SEQ ID NO:1 was isolated, different tissues from the same organism, or from different organisms.

The 14618 receptor polynucleotides are useful as a hybridization probe for cDNA and genomic DNA to isolate a full-length cDNA and genomic clones encoding the polypeptide described in SEQ ID NO:3 and to isolate cDNA and genomic clones that correspond to variants producing the same polypeptide shown in SEQ ID NO:3 or the other variants described herein. Variants can be isolated from the same tissue and organism from which the polypeptide shown in SEQ ID NO:3 was isolated, different tissues from the same organism, or from different organisms.

The 15334 receptor polynucleotides are useful as a hybridization probe for cDNA and genomic DNA to isolate a full-length cDNA and genomic clones encoding the polypeptide described in SEQ ID NO:5 and to isolate cDNA and genomic clones that correspond to variants producing the same polypeptide shown in SEQ ID NO:5 or the other variants described herein. Variants can be isolated from the same tissue and organism from which the polypeptide shown in SEQ ID NO:5 was isolated, different tissues from the same organism, or from different organisms.

This method is useful for isolating genes and cDNA that are developmentally-controlled and therefore may be expressed in the same tissue or different tissues at different points in the development of an organism.

The probe can correspond to any sequence along the entire length of the gene encoding the receptor. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. Probes, however, are not to be construed as corresponding to any sequences that may be known prior to the invention.

The 2838 nucleic acid probe can be, for example, the full-length cDNA of SEQ ID NO. 1, or a fragment thereof, such as an oligonucleotide of at least 11, 16, 18, 20, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to mRNA or DNA. The 14618 nucleic acid probe can be, for example, the full-length cDNA of SEQ ID NO. 3, or a fragment thereof, such as an oligonucleotide of at least 8, 12, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to mRNA or DNA. The 15334 nucleic acid probe can be, for example, the full-length cDNA of SEQ ID NO. 5, or a fragment thereof, such as an oligonucleotide of at least 11, 12, 15, 18, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to mRNA or DNA.

Fragments of the polynucleotides described herein are also useful to synthesize larger fragments or full-length polynucleotides described herein. For example, a fragment can be hybridized to any portion of an mRNA and a larger or full-length cDNA can be produced.

The fragments are also useful to synthesize antisense molecules of desired length and sequence.

Antisense nucleic acids of the invention can be designed using the nucleotide sequences of SEQ ID NOS: 2, 4, and 6 constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxymethylaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-

N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest.

Additionally, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4:5). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup *et al.* (1996), *supra*; Perry-O'Keefe *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:14670. PNAs can be further modified, e.g., to enhance their stability, specificity or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), *supra*, Finn *et al.* (1996) *Nucleic Acids Res.* 24(17):3357-63, Mag *et al.* (1989) *Nucleic Acids Res.* 17:5973, and Peterser *et al.* (1975) *Bioorganic Med. Chem. Lett.* 5:1119.

The nucleic acid molecules and fragments of the invention can also include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556, Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. WO 88/0918) or the blood brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol *et al.*

(1988) *Bio-Techniques* 6:958-976) or intercalating agents (see, e.g., Zon (1988) *Pharm Res.* 5:539-549)

The receptor polynucleotides are also useful as primers for PCR to amplify any given region of a receptor polynucleotide

- 5 The receptor polynucleotides are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the receptor polypeptides. Vectors also include insertion vectors, used to integrate into another polynucleotide sequence, such as into the cellular genome, to alter *in situ* expression of receptor genes and gene products. For example, an endogenous
- 10 receptor coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The receptor polynucleotides are also useful for expressing antigenic peptides. Peptide regions having a high antigenicity index are shown in Figures 2, 6, and 10.

- 15 The receptor polynucleotides are also useful as probes for determining the chromosomal positions of the receptor polynucleotides by means of *in situ* hybridization methods, such as FISH (for a review of this technique, see Verma *et al.* (1988) *Human Chromosomes: A Manual of Basic Techniques* (Pergamon Press, New York), and PCR mapping of somatic cell hybrids. The mapping of the sequences to chromosomes is an important first step in correlating these sequences with genes
- 20 associated with disease.

- Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding
- 25 sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping

- Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, *Mendelian Inheritance*
- 30 *in Man*, available on-line through Johns Hopkins University Welch Medical Library). The relationship between a gene and a disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland *et al.* (1987) *Nature* 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with a specified gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

The receptor polynucleotide probes are also useful to determine patterns of the presence of the gene encoding the receptors and their variants with respect to tissue distribution, for example, whether gene duplication has occurred and whether the duplication occurs in all or only a subset of tissues. The genes can be naturally occurring or can have been introduced into a cell, tissue, or organism exogenously.

The receptor polynucleotides are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from genes encoding the polynucleotides described herein.

The receptor polynucleotides are also useful for constructing host cells expressing a part, or all, of the receptor polynucleotides and polypeptides.

The receptor polynucleotides are also useful for constructing transgenic animals expressing all, or a part, of the receptor polynucleotides and polypeptides.

The receptor polynucleotides are also useful for making vectors that express part, or all, of the receptor polypeptides.

The receptor polynucleotides are also useful as hybridization probes for determining the level of receptor nucleic acid expression. Accordingly, the probes can be used to detect the presence of, or to determine levels of, receptor nucleic acid in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the polypeptides described herein can be used to assess gene copy number in a given cell, tissue, or organism. This is particularly relevant in cases in which there has been an amplification of the receptor genes.

Alternatively, the probe can be used in an *in situ* hybridization context to assess the position of extra copies of the receptor genes, as on extrachromosomal

elements or as integrated into chromosomes in which the receptor gene is not normally found, for example as a homogeneously staining region

These uses are relevant for diagnosis of disorders involving an increase or decrease in receptor expression relative to normal results, such as a proliferative disorder, a differentiative or developmental disorder, or a hematopoietic disorder

Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant expression or activity of receptor nucleic acid, in which a test sample is obtained from a subject and nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of the nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant expression or activity of the nucleic acid.

One aspect of the invention relates to diagnostic assays for determining nucleic acid expression as well as activity in the context of a biological sample (e.g., blood, serum, cells, tissue) to determine whether an individual has a disease or disorder, or is at risk of developing a disease or disorder, associated with aberrant nucleic acid expression or activity. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with expression or activity of the nucleic acid molecules.

In vitro techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA includes Southern hybridizations and *in situ* hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a receptor protein, such as by measuring a level of a receptor-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a receptor gene has been mutated.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate receptor nucleic acid expression (e.g., antisense, polypeptides, peptidomimetics, small molecules or other drugs). A cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of receptor mRNA in the presence of the candidate compound is compared to the level of expression of receptor mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder

characterized by aberrant nucleic acid expression. The modulator can bind to the nucleic acid or indirectly modulate expression, such as by interacting with other cellular components that affect nucleic acid expression.

Modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject) in patients or in transgenic animals.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the receptor gene. The method typically includes assaying the ability of the compound to modulate the expression of the receptor nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired receptor nucleic acid expression.

The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the receptor nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

Alternatively, candidate compounds can be assayed *in vivo* in patients or in transgenic animals.

The assay for receptor nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway (such as cyclic AMP or phosphatidylinositol turnover). Further, the expression of genes that are up- or down-regulated in response to the receptor protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of receptor gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of receptor mRNA in the presence of the candidate compound is compared to the level of expression of receptor mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

Accordingly, the invention provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate receptor nucleic acid expression. Modulation includes both up-regulation (*i.e.* activation or agonization) or down-regulation (suppression or antagonization) or effects on nucleic acid activity (e.g. when nucleic acid is mutated or improperly modified). Treatment is of disorders characterized by aberrant expression or activity of the nucleic acid.

Alternatively, a modulator for receptor nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the receptor nucleic acid expression.

The receptor polynucleotides are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the receptor gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

Monitoring can be, for example, as follows: (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a specified mRNA or genomic DNA of the invention in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the mRNA or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the mRNA or genomic DNA in the pre-administration sample with the mRNA or genomic DNA in the post-administration sample or samples; and (vi) increasing or decreasing the administration of the agent to the subject accordingly.

The receptor polynucleotides are also useful in diagnostic assays for qualitative changes in receptor nucleic acid, and particularly in qualitative changes that lead to pathology. The polynucleotides can be used to detect mutations in receptor genes and gene expression products such as mRNA. The polynucleotides

can be used as hybridization probes to detect naturally-occurring genetic mutations in the receptor gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the receptor gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a receptor protein.

Mutations in the receptor gene can be detected at the nucleic acid level by a variety of techniques. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way.

In certain embodiments, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, (1988) *Science* 241:1077-1080; and Nakazawa *et al.*, (1994) *PNAS* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.* (1995) *Nucleic Acids Res.* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include self sustained sequence replication (Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional

amplification system (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.* (1988) *Bio Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well-known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers

Alternatively, mutations in a receptor gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis

Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site

Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method

Furthermore, sequence differences between a mutant receptor gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.* (1996) *Adv. Chromatogr.* 36:127-162; and Griffin *et al.* (1993) *Appl. Biochem. Biotechnol.* 38:147-159)

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers *et al.* (1985) *Science* 230:1242; Cotton *et al.* (1988) *PNAS* 85:4397; Saleeba *et al.* (1992) *Meth. Enzymol.* 217:286-295), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.* (1989) *PNAS* 86:2766; Cotton *et al.* (1993) *Mutat. Res.* 285:125-144, and Hayashi *et al.* (1992) *Genet. Anal. Tech. Appl.* 9:73-79), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers *et al.* (1985) *Nature* 313:495). The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex

molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends (Genet.* 7:5). Examples of other techniques for detecting point mutations include, selective oligonucleotide hybridization, selective amplification, and selective primer extension.

5 In other embodiments, genetic mutations can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotide probes (Cronin *et al.* (1996) *Human Mutation* 7:244-255; Kozal *et al.* (1996) *Nature Medicine* 2:753-759). For example, genetic mutations can be identified in two dimensional arrays containing
10 light-generated DNA probes as described in Cronin *et al. supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the
15 characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

 The receptor polynucleotides are also useful for testing an individual for a
20 genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the polynucleotides can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). In the present case, for example, a mutation in the receptor gene that results in altered affinity for ligand could result in
25 an excessive or decreased drug effect with standard concentrations of ligand that activates the receptor. Accordingly, the receptor polynucleotides described herein can be used to assess the mutation content of the receptor gene in an individual in order to select an appropriate compound or dosage regimen for treatment.

 Thus polynucleotides displaying genetic variations that affect treatment
30 provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The methods can involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting mRNA, or genomic DNA, such that the presence of mRNA or genomic DNA is detected in the biological sample, and comparing the presence of mRNA or genomic DNA in the control sample with the presence of mRNA or genomic DNA in the test sample

The receptor polynucleotides are also useful for chromosome identification when the sequence is identified with an individual chromosome and to a particular location on the chromosome. First, the DNA sequence is matched to the chromosome by *in situ* or other chromosome-specific hybridization. Sequences can also be correlated to specific chromosomes by preparing PCR primers that can be used for PCR screening of somatic cell hybrids containing individual chromosomes from the desired species. Only hybrids containing the chromosome containing the gene homologous to the primer will yield an amplified fragment. Sublocalization can be achieved using chromosomal fragments. Other strategies include prescreening with labeled flow-sorted chromosomes and preselection by hybridization to chromosome-specific libraries. Further mapping strategies include fluorescence *in situ* hybridization which allows hybridization with probes shorter than those traditionally used. Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on the chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

The receptor polynucleotides can also be used to identify individuals from small biological samples. This can be done for example using restriction fragment-length polymorphism (RFLP) to identify an individual. Thus, the polynucleotides described herein are useful as DNA markers for RFLP (See U.S. Patent No. 5,272,057).

Furthermore, the receptor sequence can be used to provide an alternative technique which determines the actual DNA sequence of selected fragments in the genome of an individual. Thus, the receptor sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify DNA from an individual for subsequent sequencing

Panels of corresponding DNA sequences from individuals prepared in this manner can provide unique individual identifications, as each individual will have a unique set of such DNA sequences. It is estimated that allelic variation in humans occurs with a frequency of about once per each 500 bases. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. The receptor sequences can be used to obtain such identification sequences from individuals and from tissue. The sequences represent unique fragments of the human genome. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes.

If a panel of reagents from the sequences is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

The receptor polynucleotides can also be used in forensic identification procedures. PCR technology can be used to amplify DNA sequences taken from very small biological samples, such as a single hair follicle, body fluids (e.g. blood, saliva, or semen). The amplified sequence can then be compared to a standard allowing identification of the origin of the sample.

The receptor polynucleotides can thus be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (*i.e.* another DNA sequence that is unique to a particular individual). As described above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to the noncoding region are particularly useful since greater polymorphism occurs in the noncoding regions, making it easier to differentiate individuals using this technique. Fragments are at least 12 bases.

The receptor polynucleotides can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue. This is useful in cases in

which a forensic pathologist is presented with a tissue of unknown origin. Panels of receptor probes can be used to identify tissue by species and/or by organ type.

In a similar fashion, these primers and probes can be used to screen tissue culture for contamination (*i.e.* screen for the presence of a mixture of different types of cells in a culture).

Alternatively, the receptor polynucleotides can be used directly to block transcription or translation of receptor gene sequences by means of antisense or ribozyme constructs. Thus, in a disorder characterized by abnormally high or undesirable receptor gene expression, nucleic acids can be directly used for treatment.

The receptor polynucleotides are thus useful as antisense constructs to control receptor gene expression in cells, tissues, and organisms. A DNA antisense polynucleotide is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of receptor protein. An antisense RNA or DNA polynucleotide would hybridize to the mRNA and thus block translation of mRNA into receptor protein.

Examples of antisense molecules useful to inhibit nucleic acid expression include antisense molecules complementary to a fragment of the 5' untranslated region of SEQ ID NOS:2, 4, or 6 which also includes the start codon and antisense molecules which are complementary to a fragment of the 3' untranslated region of SEQ ID NOS:2, 4, or 6.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of receptor nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired receptor nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the receptor protein, such as ligand binding.

The receptor polynucleotides also provide vectors for gene therapy in patients containing cells that are aberrant in receptor gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired receptor protein to treat the individual.

The invention also encompasses kits for detecting the presence of a receptor nucleic acid in a biological sample. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting receptor nucleic acid in a biological sample; means for determining the amount of receptor nucleic acid in the sample; and means for comparing the amount of receptor nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect receptor mRNA or DNA.

10 Computer Readable Means

The nucleotide or amino acid sequences of the invention are also provided in a variety of mediums to facilitate use thereof. As used herein, "provided" refers to a manufacture, other than an isolated nucleic acid or amino acid molecule, which contains a nucleotide or amino acid sequence of the present invention. Such a manufacture provides the nucleotide or amino acid sequences, or a subset thereof (e.g., a subset of open reading frames (ORFs)) in a form which allows a skilled artisan to examine the manufacture using means not directly applicable to examining the nucleotide or amino acid sequences, or a subset thereof, as they exist in nature or in purified form.

20 In one application of this embodiment, a nucleotide or amino acid sequence of the present invention can be recorded on computer readable media. As used herein, "computer readable media" refers to any medium that can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. The skilled artisan will readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising computer readable medium having recorded thereon a nucleotide or amino acid sequence of the present invention.

30 As used herein, "recorded" refers to a process for storing information on computer readable medium. The skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising the nucleotide or amino acid sequence information of the present invention.

A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide or amino acid sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition,
5 a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as
10 DB2, Sybase, Oracle, or the like. The skilled artisan can readily adapt any number of dataprocessor structuring formats (e.g., text file or database) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present invention.

By providing the nucleotide or amino acid sequences of the invention in
15 computer readable form, the skilled artisan can routinely access the sequence information for a variety of purposes. For example, one skilled in the art can use the nucleotide or amino acid sequences of the invention in computer readable form to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or
20 regions of the sequences of the invention which match a particular target sequence or target motif.

As used herein, a "target sequence" can be any DNA or amino acid sequence of six or more nucleotides or two or more amino acids. A skilled artisan can readily recognize that the longer a target sequence is, the less likely a target sequence will be
25 present as a random occurrence in the database. The most preferred sequence length of a target sequence is from about 10 to 100 amino acids or from about 30 to 300 nucleotide residues. However, it is well recognized that commercially important fragments, such as sequence fragments involved in gene expression and protein processing, may be of shorter length.

30 As used herein, "a target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration which is formed upon the folding of the target motif. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences

Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences)

Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium for analysis and comparison to other sequences. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. Examples of such software includes, but is not limited to, MacPattern (EMBL), BLASTN and BLASTX (NCBIA).

For example, software which implements the BLAST (Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-410) and BLAZE (Brutlag *et al.* (1993) *Comp. Chem.* 17:203-207) search algorithms on a Sybase system can be used to identify open reading frames (ORFs) of the sequences of the invention which contain homology to ORFs or proteins from other libraries. Such ORFs are protein encoding fragments and are useful in producing commercially important proteins such as enzymes used in various reactions and in the production of commercially useful metabolites.

Vectors/host cells

The invention also provides vectors containing the receptor polynucleotides. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, that can transport the receptor polynucleotides. When the vector is a nucleic acid molecule, the receptor polynucleotides are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the receptor polynucleotides. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the receptor polynucleotides when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the receptor polynucleotides. The vectors can function in procaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the receptor polynucleotides such that transcription of the

polynucleotides is allowed in a host cell. The polynucleotides can be introduced into the host cell with a separate polynucleotide capable of affecting transcription. Thus, the second polynucleotide may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the receptor polynucleotides from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself.

It is understood, however, that in some embodiments, transcription and/or translation of the receptor polynucleotides can occur in a cell-free system.

The regulatory sequence to which the polynucleotides described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook *et al. Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

A variety of expression vectors can be used to express a receptor polynucleotide. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses.

Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989)

The regulatory sequence may provide constitutive expression in one or more host cells (*i.e.* tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The receptor polynucleotides can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate polynucleotide can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the polypeptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the receptor polypeptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired polypeptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith *et al.* (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST).

maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.* (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.* (1990) *Gene Expression Technology: Methods in Enzymology* 185:60-89).

5 Recombinant protein expression can be maximized in a host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein (Gottesman *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the polynucleotide of interest can be
10 altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.* (1992) *Nucleic Acids Res.* 20:2111-2118)

 The receptor polynucleotides can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYepSec1 (Baldari, *et al.* (1987) *EMBO J.* 6:229-234), pMFa (Kurjan *et al.*
15 (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.* (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA)

 The receptor polynucleotides can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf9 cells) include the pAc series
20 (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow *et al.* (1989) *Virology* 170:31-39).

 In certain embodiments of the invention, the polynucleotides described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed (1987) *Nature* 329:840) and
25 pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195)

 The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the receptor polynucleotides. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression
30 of the polynucleotides described herein. These are found for example in Sambrook, *et al. T. Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989

 The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked

to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the polynucleotide sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression)

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the receptor polynucleotides can be introduced either alone or with other polynucleotides that are not related to the receptor polynucleotides such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the receptor polynucleotide vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the polynucleotides described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance

genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian
5 cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the polypeptide is desired, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the receptor
10 polypeptides or heterologous to these polypeptides.

Where the polypeptide is not secreted into the medium, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The polypeptide can then be recovered and purified by well-known purification methods including
15 ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant
20 production of the polypeptides described herein, the polypeptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the polypeptides may include an initial modified methionine in some cases as a result of a host-mediated process.

25 Uses of vectors and host cells

It is understood that "host cells" and "recombinant host cells" refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to
30 the parent cell, but are still included within the scope of the term as used herein.

The host cells expressing the polypeptides described herein, and particularly recombinant host cells, have a variety of uses. First, the cells are useful for producing receptor proteins or polypeptides that can be further purified to produce desired

amounts of receptor protein or fragments. Thus, host cells containing expression vectors are useful for polypeptide production

Host cells are also useful for conducting cell-based assays involving the receptor or receptor fragments. Thus, a recombinant host cell expressing a native
5 receptor is useful to assay for compounds that stimulate or inhibit receptor function. This includes ligand binding, gene expression at the level of transcription or translation, G-protein interaction, and components of the signal transduction pathway

Host cells are also useful for identifying receptor mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology,
10 host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant receptor (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native receptor.

Recombinant host cells are also useful for expressing the chimeric polypeptides described herein to assess compounds that activate or suppress activation
15 by means of a heterologous amino terminal extracellular domain (or other binding region). Alternatively, a heterologous region spanning the entire transmembrane domain (or parts thereof) can be used to assess the effect of a desired amino terminal extracellular domain (or other binding region) on any given host cell. In this embodiment, a region spanning the entire transmembrane domain (or parts thereof)
20 compatible with the specific host cell is used to make the chimeric vector. Alternatively, a heterologous carboxy terminal intracellular, e.g., signal transduction, domain can be introduced into the host cell.

Further, mutant receptors can be designed in which one or more of the various functions is engineered to be increased or decreased (e.g., ligand binding or G-protein
25 binding) and used to augment or replace receptor proteins in an individual. Thus, host cells can provide a therapeutic benefit by replacing an aberrant receptor or providing an aberrant receptor that provides a therapeutic result. In one embodiment, the cells provide receptors that are abnormally active.

In another embodiment, the cells provide receptors that are abnormally
30 inactive. These receptors can compete with endogenous receptors in the individual

In another embodiment, cells expressing receptors that cannot be activated, are introduced into an individual in order to compete with endogenous receptors for ligand. For example, in the case in which excessive ligand is part of a treatment modality, it may be necessary to inactivate this ligand at a specific point in treatment

Providing cells that compete for the ligand, but which cannot be affected by receptor activation would be beneficial

Homologously recombinant host cells can also be produced that allow the *in situ* alteration of endogenous receptor polynucleotide sequences in a host cell genome. The host cell includes, but is not limited to, a stable cell line, cell *in vivo*, or cloned microorganism. This technology is more fully described in WO 93/09222, WO 91/12650, WO 91/06667, U.S. 5,272,071, and U.S. 5,641,670. Briefly, specific polynucleotide sequences corresponding to the receptor polynucleotides or sequences proximal or distal to a receptor gene are allowed to integrate into a host cell genome by homologous recombination where expression of the gene can be affected. In one embodiment, regulatory sequences are introduced that either increase or decrease expression of an endogenous sequence. Accordingly, a receptor protein can be produced in a cell not normally producing it. Alternatively, increased expression of receptor protein can be effected in a cell normally producing the protein at a specific level. Further, expression can be decreased or eliminated by introducing a specific regulatory sequence. The regulatory sequence can be heterologous to the receptor protein sequence or can be a homologous sequence with a desired mutation that affects expression. Alternatively, the entire gene can be deleted. The regulatory sequence can be specific to the host cell or capable of functioning in more than one cell type. Still further, specific mutations can be introduced into any desired region of the gene to produce mutant receptor proteins. Such mutations could be introduced, for example, into the specific functional regions such as the ligand-binding site.

In one embodiment, the host cell can be a fertilized oocyte or embryonic stem cell that can be used to produce a transgenic animal containing the altered receptor gene. Alternatively, the host cell can be a stem cell or other early tissue precursor that gives rise to a specific subset of cells and can be used to produce transgenic tissues in an animal. See also Thomas *et al.* (1987) *Cell* 51:503 for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous receptor gene is selected (see e.g., Li *et al.* (1992) *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. (IRL, Oxford, 1987) pp 113-152). A chimeric embryo can then be implanted into

a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for
5 constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos. WO 90/11354, WO 91/01140, and WO 93/04169.

The genetically engineered host cells can be used to produce non-human
10 transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These
15 animals are useful for studying the function of a receptor protein and identifying and evaluating modulators of receptor protein activity.

Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

In one embodiment, a host cell is a fertilized oocyte or an embryonic stem cell
20 into which receptor polynucleotide sequences have been introduced.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the receptor nucleotide sequences can be introduced as a transgene into the genome of a
25 non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the receptor protein to
30 particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.* U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan

Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso *et al.* (1992) *PNAS* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman *et al.* (1991) *Science* 251:1351-1355). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut *et al.* (1997) *Nature* 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the polypeptides described herein are useful to conduct the assays described herein in an *in vivo* context. Accordingly, the various physiological factors that are present *in vivo* and that could effect ligand binding, receptor activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* receptor function, including ligand interaction, the effect of specific mutant receptors on receptor function and ligand interaction, and the effect of chimeric receptors. It is also possible to assess the effect of null mutations, that is mutations that substantially or completely eliminate one or more receptor functions.

In general, methods for producing transgenic animals include introducing a nucleic acid sequence according to the present invention, the nucleic acid sequence capable of expressing the receptor protein in a transgenic animal, into a cell in culture or *in vivo*. When introduced *in vivo*, the nucleic acid is introduced into an intact organism such that one or more cell types and, accordingly, one or more tissue types, express the nucleic acid encoding the receptor protein. Alternatively, the nucleic acid can be introduced into virtually all cells in an organism by transfecting a cell in culture, such as an embryonic stem cell, as described herein for the production of transgenic animals, and this cell can be used to produce an entire transgenic organism. As described, in a further embodiment, the host cell can be a fertilized oocyte. Such cells are then allowed to develop in a female foster animal to produce the transgenic organism.

Pharmaceutical compositions

The receptor nucleic acid molecules, protein (particularly fragments such as the amino terminal extracellular domain), modulators of the protein, and antibodies (also referred to herein as "active compounds") can be incorporated into pharmaceutical compositions suitable for administration to a subject, e.g., a human. Such compositions typically comprise the nucleic acid molecule, protein, modulator, or antibody and a pharmaceutically acceptable carrier.

As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for

pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions. A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as

mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a receptor protein or anti-receptor antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.

10 In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For oral administration, the agent can be contained in enteric forms to survive the stomach or further coated or mixed to be released in a particular region of the GI tract by known methods. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules.

20 Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or

25 orange flavoring.

30

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. 5,328,470) or by stereotactic injection (see e.g., Chen *et al.* (1994) *PNAS* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

As defined herein, a therapeutically effective amount of protein or polypeptide (i.e., an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.

The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments. In a preferred example, a subject is treated with antibody, protein, or polypeptide in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of antibody, protein, or polypeptide used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic assays as described herein.

The present invention encompasses agents which modulate expression or activity. An agent may, for example, be a small molecule. For example, such small molecules include, but are not limited to, peptides, peptidomimetics, amino acids.

amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds

It is understood that appropriate doses of small molecule agents depends upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of the small molecule will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the small molecule to have upon the nucleic acid or polypeptide of the invention. Exemplary doses include milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is furthermore understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. Such appropriate doses may be determined using the assays described herein. When one or more of these small molecules is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated

This invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments

are provided so that this disclosure will fully convey the invention to those skilled in the art. Many modifications and other embodiments of the invention will come to mind in one skilled in the art to which this invention pertains having the benefit of the teachings presented in the foregoing description. Although specific terms are

5 employed, they are used as in the art unless otherwise indicated.

THAT WHICH IS CLAIMED

1 An isolated polypeptide having an amino acid sequence selected from the group consisting of

5 (a) The amino acid sequence shown in SEQ ID NO 1, the amino acid sequence shown in SEQ ID NO 3, and the amino acid sequence shown in SEQ ID NO 5;

(b) The amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO 1, the amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO 3, and the amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO 5.

10 (c) The amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO 1, wherein the sequence variant is encoded by a nucleic acid molecule hybridizing to the nucleic acid molecule shown in SEQ ID NO 2 under stringent conditions, the amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO 3, wherein the sequence variant is encoded by a nucleic acid molecule hybridizing to the nucleic acid molecule shown in SEQ ID NO 4 under stringent conditions, and the amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO 5, wherein the sequence variant is encoded by a nucleic acid molecule hybridizing to the nucleic acid molecule shown in SEQ ID NO 6 under stringent conditions;

20 (d) A fragment of the amino acid sequence shown in SEQ ID NO 1, wherein the fragment comprises at least 8 contiguous amino acids from 1-264, a fragment of the amino acid sequence shown in SEQ ID NO 3, wherein the fragment comprises at least 9 contiguous amino acids from 1-244, and a fragment of the amino acid sequence shown in SEQ ID NO 5, wherein the fragment comprises at least 8 contiguous amino acids;

25 (e) The amino acid sequence of the mature receptor polypeptide from about amino acid 6 to about amino acid 319, shown in SEQ ID NO 1, the amino acid sequence of the mature receptor polypeptide from about amino acid 6 to about amino acid 337, shown in SEQ ID NO 3, and the amino acid sequence of the mature receptor polypeptide from about amino acid 6 to about amino acid 372, shown in SEQ ID NO 5,

30 (f) The amino acid sequence of the polypeptide shown in SEQ ID NO 1, from about amino acid 1 to about amino acid 24, the amino acid sequence of the polypeptide shown in SEQ ID NO 3, from about amino acid 1 to about amino acid 28.

and the amino acid sequence of the polypeptide shown in SEQ ID NO 5, from about amino acid 1 to about amino acid 25,

(g) The amino acid sequence of an epitope bearing region of any one of the polypeptides of (a)-(f).

5

2 An isolated antibody that selectively binds to a polypeptide of claim 1, (a)-(g).

3. An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:

10 (a) The nucleotide sequence shown in SEQ ID NO 2, the nucleotide sequence shown in SEQ ID NO 4, and the nucleotide sequence shown in SEQ ID NO 6;

(b) A nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO 1, a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO 3, and a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO 5;

15 (c) A nucleotide sequence complementary to any of the nucleotide sequences in (a) or (b).

20 4. An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:

(a) A nucleotide sequence encoding an amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO 1 that hybridizes to the nucleotide sequence shown in SEQ ID NO 2 under stringent conditions, a nucleotide sequence encoding an amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO 3 that hybridizes to the nucleotide sequence shown in SEQ ID NO 4 under stringent conditions, and a nucleotide sequence encoding an amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO 5 that hybridizes to the nucleotide sequence shown in SEQ ID NO 6 under stringent conditions;

30

(b) A nucleotide sequence complementary to the nucleotide sequences in (a).

5 An isolated nucleic acid molecule a polynucleotide having a nucleotide sequence selected from the group consisting of

 (a) A nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO 1, wherein the fragment comprises at least 8 contiguous amino acids from 1-264, a nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO 3, wherein the fragment comprises at least 9 contiguous amino acids from 1-244, and a nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO 5, wherein the fragment comprises at least 8 contiguous amino acids;

10 (b) A nucleotide sequence complementary to the nucleotide sequences in (a)

6 A nucleic acid vector comprising the nucleic acid sequences in any of claims 3-5.

15 7. A host cell containing the vector of claim 6

8 A method for producing any of the polypeptides in claim 1 comprising introducing a nucleotide sequence encoding any of the polypeptide sequences in (a)-(f) into a host cell, and culturing the host cell under conditions in which the proteins are expressed from the nucleic acid.

20 9. A method for detecting the presence of any of the polypeptides in claim 1 in a sample, said method comprising contacting said sample with an agent that specifically allows detection of the presence of the polypeptide in the sample and then detecting the presence of the polypeptide.

25 10 The method of claim 9, wherein said agent is capable of selective physical association with said polypeptide.

30 11 The method of claim 10, wherein said agent binds to said polypeptide

12 The method of claim 11, wherein said agent is an antibody

13 The method of claim 11, wherein said agent is a ligand

14 A kit comprising reagents used for the method of claim 9, wherein the
reagents comprise an agent that specifically binds to said polypeptide

5

15 A method for detecting the presence of any of the nucleic acid
sequences in any of claims 3-5 in a sample, the method comprising contacting the
sample with an oligonucleotide that hybridizes to the nucleic acid sequences under
stringent conditions and determining whether the oligonucleotide binds to the nucleic
10 acid sequence in the sample.

16 The method of claim 15, wherein the nucleic acid, whose presence is
detected, is mRNA.

15 17 A kit comprising reagents used for the method of claim 15, wherein the
reagents comprise a compound that hybridizes under stringent conditions to any of the
nucleic acid molecules.

18 A method for identifying an agent that interacts with any of the
20 polypeptides in claim 1, said method comprising contacting said agent with a cell
capable of allowing an interaction between said polypeptide and said agent such that
said polypeptide can interact with said agent and measuring the interaction

19 A method of screening a cell to identify an agent that interacts with
25 any of the polypeptides in claim 1, said method comprising contacting said agent with
a cell capable of allowing an interaction between said polypeptide and said agent such
that said polypeptide can interact with said agent and measuring the interaction.

20 A method for identifying an agent that modulates the level or activity
30 of any of the polypeptides of claim 1 in a cell, said method comprising contacting said
agent with a cell capable of expressing said polypeptide such that said polypeptide
level or activity can be modulated in said cell by said agent and measuring said
polypeptide level or activity

21 A method of screening a cell to identify an agent that modulates the level or activity of any of the polypeptides of claim 1 in a cell, said method comprising contacting said agent with a cell capable of expressing said polypeptide such that said polypeptide level or activity can be modulated in said cell by said agent
5 and measuring said polypeptide level or activity

22 The method of either of claims 19 or 20 wherein said interaction is binding

10 23 The method of claim 22, wherein a fragment of the polypeptide is contacted.

24 A method for modulating the activity of any of the polypeptides in claim 1, the method comprising contacting any of the polypeptides of claim 1 with an
15 agent under conditions that allow the agent to modulate the activity of the polypeptide.

25 A method for identifying an agent that interacts with any of the nucleic acid molecules of claims 3-5, said method comprising contacting said agent with a
20 cell capable of allowing an interaction between said nucleic acid molecule and said agent such that said nucleic acid molecule can interact with said agent and measuring the interaction.

26 A method of screening a cell to identify an agent that interacts with
25 any of the nucleic acid molecules of claims 3-5, said method comprising contacting said agent with a cell capable of allowing an interaction between said nucleic acid molecule and said agent such that said nucleic acid molecule can interact with said agent and measuring the interaction.

30 27 A method for identifying an agent that modulates the level or activity of any of the nucleic acid molecules of claims 3-5 in a cell, said method comprising contacting said agent with a cell capable of expressing said nucleic acid molecule such that said nucleic acid molecule level or activity can be modulated in said cell by said agent and measuring said nucleic acid molecule level or activity

28 A method of screening a cell to identify an agent that modulates the level or activity of any of the nucleic acid molecules of claims 3-5 in a cell, said method comprising contacting said agent with a cell capable of expressing said
5 nucleic acid molecule such that said nucleic acid molecule level or activity can be modulated in said cell by said agent and measuring said nucleic acid molecule level or activity.

29 The method of either of claims 25 or 26 wherein said interaction is
10 binding

30 A method for modulating the activity of any of the nucleic acid molecules in claim 3-5, the method comprising contacting any of the nucleic acid molecules of claim 1 with an agent under conditions that allow the agent to modulate
15 the activity of the nucleic acid molecule.

31 A pharmaceutical composition containing any of the polypeptides in claim 1 in a pharmaceutically acceptable carrier.

20 32 A pharmaceutical composition containing any of the nucleic acid molecules of claims 3-5 in a pharmaceutically acceptable carrier.

25 33 A non-human transgenic animal wherein one or more of the cells of said animal contains any of the nucleic acid sequences of claims 3-5.

34 A non-human transgenic animal wherein one or more of cells of said animal contains any of the nucleic acid sequences of claims 3-5 wherein said cell expresses any of the polypeptides of claim 1

30 35 A method for producing a transgenic animal according to claims 32 and 33, said method comprising introducing any of the nucleic acid sequences of claim 1 into a cell, wherein said cell is present in said animal or gives rise to said animal.

36 An agent identified using any of the methods of claims 19-22 or 25-28

37 A method of treating a disorder in a subject comprising administering the pharmaceutical compositions of either of claims 31 or 32.

5

38 A method of treating a disorder in a subject by modulating the level or expression of any of the polypeptides of claim 1 in said subject

39 A method of treating a disorder in a subject by modulating the level or
10 activity of any of the nucleic acid molecules of claims 3-5 in said subject

40 The method of either of claims 9 or 15 wherein said detecting is in a cell derived from a subject having a disorder involving said cell.

15 41 The method of either of claims 24 or 30 wherein said modulation is in a subject having a disorder involving said cell

42 The method of claim 39 wherein said disorder is anemia, neutropenia or thrombocytopenia.

20

43 The method of claim 41 wherein said disorder is anemia, neutropenia or thrombocytopenia.

Protein Family/Domain HMM Matches for flh2838

>PF00001|7tm_1 7 transmembrane receptor (rhodopsin family)

Score: 154.54 Seq: 37 288 Model: 1 269

*GNI LVIWvIcRyRRMR....TPMNYFIvNLAVADLLFslftMPFWMvYy
 N+L I ++ + R +++++NLAV DLL+ +++++PF MV

flh2838 37 LNLLAIHGfSTFLKNRWPDYAATSIYMINLAVFDLLL-VLSLPFKMVLS 84

vMqgRWpFGdfMcrIWmYFDYMNMYASIFfLTcISIDRYLWAICHPMrYm
 PF++ +C ++ +++++MY S+F++++IS+DR+L AI +P+

flh2838 85 QV-Q-SPFPS-LCTLVECLYFVSMYGSVFTICFISMDRFL-AIRYPLLVS 130

RWMTpRHRAWvMIiiiWvMSfLISMPPFLMFrWstYrDeneWNmTWCMiY
 +++PR + + +++ IWV+ S+P+ + F + E + M C+

flh2838 131 HLRSPR-KIFGICCTIWVLVWTGSIPI-YSF-HGKV--EKY--M--CFH- 170

DWPewMWrwYvILmtiimgFYIPMiIMlFCYwRIYRIaRlWMRMlpswQr
 + ++W + V + + ++GF++PM IM FC +R I ++ + ++ Q

flh2838 171 NMSDDTWSAKVFFPLEVFGFLLPMGIMGFCCSRS--I-HILLGRRDHTQD 217

RRrmSmRrERRivKMliiIMvVFIIcWlPYFIvmfMDTLM.MwwFCefC.
 + + ++ + +++ + VF++++LP ++ +F++ L + + E C

flh2838 218 WVQQ-----KACIYSIAASLAVFVVSFLPVHLGFFLQFLVRNSFIWE-CR 261

IwrrlWm.Y.IfeWLaYvNCpCiNPIIY*
 + +++ + + +++++ VNC C++ + Y

flh2838 262 AKQSISFFLQLSMCFNVNC-CLDVFCY 288

FIGURE 1





FIGURE 2

Analysis of flh2838 (320 aa)



>flh2838
MSQQNTSGDCLFDGVNELMKTLQFAVHIPTFVLGLLLNLAIHGFSTFLKNRWPDYAATS
IYMINLAVFDLLLVLSPFKMVLVSQVQSPFPSLCTLVECLYFVSMYGSVFTICFISMDRF
LAIRYPLLVSRLSPRKIFGICCTIWVLVWTGSIPIYSFHGKVEKYMCFHNMSDDTWSAK
VFFPLEVFGFLLPMGIMGFCCSRSIHILLGRRDHTQDWVQQKACIYSIAASLAVFVVSFL
PVHLGFFLQFLVRNSFIVECRAKQSSISFFLQLSMCFSNVNCCLDVFCYYFVIKEFRMNIR
AHRPSRVQLVLQDTTISRG*

FIGURE 3

Prosite Pattern Matches for flh2838

>PS00001|PDOC00001|ASN_GLYCOSYLATION N-glycosylation site.

Query: 5 NTSG 8

Query: 171 NMSD 174

>PS00005|PDOC00005|PKC_PHOSPHO_SITE Protein kinase C phosphorylation site.

Query: 134 SPR 136

Query: 178 SAK 180

>PS00006|PDOC00006|CK2_PHOSPHO_SITE Casein kinase II phosphorylation site.

Query: 6 TSGD 9

Query: 95 TLVE 98

>PS00008|PDOC00008|MYRISTYL N-myristoylation site.

Query: 34 GLLLNL 39

Query: 107 GSVFTI 112

Query: 140 GICCTI 145

>PS00009|PDOC00009|AMIDATION Amidation site.

Query: 209 LGRR 212

>PS00227|PDOC00210|G_PROTEIN_RECEPTOR G-protein coupled receptors signature.

Query: 107 GSVFTICFISMDRFLAI 123

>PS00339|PDOC00363|AA_TRNA_LIGASE_II_2 Aminoacyl-transfer RNA synthetases class-II sign

Query: 114 FISMDRFLAI 123

FIGURE 4

Protein Family/Domain HMM Matches for flh14618

>PF00001|7tm_1 7 transmembrane receptor (rhodopsin family)

| | | | |
|---------------|-------------|--|-----|
| Score: 230.98 | Seq: 40 295 | Model: 1 269 | |
| | | *GNI LVIWvIcRyRRMRTPMNYFIvNLAvADLLFs1ftMPFWmvYyvMqg | |
| flh14618 | 40 | GN++V++V++++ + ++ + ++++NLAVADLL + T+P+ VYV+ G | 87 |
| | | GNGFVLYVLIKTYHKSAFQVYMINLAVADLLC-VCTLPLRVVYVHKG | |
| | | RWpFGdfmCrIWmYFDYMMNYASIFfLTcISIDRYLWAICHPMrYmRWMT | |
| flh14618 | 88 | W+FGDF+CR+++Y Y+N+Y SIFF+T++S+ R +AI+ P++ ++ T | 136 |
| | | IWLFGDFLCRLSTYALYVNLVYCSIFFMTAMSFERC-IAIVFPVQININLVT | |
| | | pRHRawmIiiiIWvMSFliSMPPFLMFrWstyrDeneWNmTWcmIyDWPe | |
| flh14618 | 137 | + +A+++++IW++ +L S P F ++ +DE + T C++ ++ | 179 |
| | | QK-KARFVCVGIWIFVILTSSP-F-LM-AKPQKDEKN--NTKCFE-PPQD | |
| | | ...wMWrWYvILmtiimgFYIPMiIMlFCYwRIYRIaRlWMMIpswQrR | |
| flh14618 | 180 | +++ +++ +++++ GF+IP+ I+++CY++I I L++++ S+++ | 223 |
| | | NQTKNHVLVLHYVSLVGGFIIPFVIIIVCYTMI--I--LTLLK-KSMKK- | |
| | | RrmSmRrERRivKMliiIMvFIIICWlPYFivmfMDTLMMwvF..... | |
| flh14618 | 224 | + ++++++ M++++ +F+++++PY+I + +++++ | 265 |
| | | ---NLSSHKKAIGMIMVVTAAFLVSFMPYHIQRT-----IHLHFLHNETK | |
| | | .CefCIwrrlWmY.IfewLaYvNCpCiNPIIY* | |
| flh14618 | 266 | C+ +++R++ I++ LA +NC C++P++Y | 295 |
| | | PCD-SVLRMQKSVVITLSLAASNC-CFDPLLY | |

FIGURE 5





FIGURE 6

Analysis of flh14618 (338 aa)



```
>flh14618
MDETGNLTVSSATCHDTIDDFRNQVYSTLYSMISVVGFFGNGFVLYVLIKTYHKKSAFQV
YMINLAVADLLCVCTLPLRVVYVHKGIWLFQDFLCRLSTYALYVNLCSIFFMTAMSFF
RCIAIVFPVQININLVTQKKARFVCVGWIFVILTSSPFLMAKPQKDEKNNTKCFEPPQDN
QTKNHVLLVHYVSLVGGFIIIPFVIIIVCYTMIILTLKKSMKKNLSSHKKAIGMIMVVT
AFLVSFMPYHIQRTIHLHFLHNETKPCDSVLRMQKSVVITLSLAASNCCFDPLLYFFSGG
NFRKRLSTFRKHSLSVTVPRKKASLPEKGEEICKV*
```

FIGURE 7

Prosite Pattern Matches for flh14618

>PS00001|PDOC00001|ASN_GLYCOSYLATION N-glycosylation site.

| | | |
|------------|------|-----|
| Query: 6 | NLTV | 9 |
| Query: 169 | NNTK | 172 |
| Query: 180 | NQTK | 183 |
| Query: 224 | NLSS | 227 |
| Query: 262 | NETK | 265 |

>PS00004|PDOC00004|CAMP_PHOSPHO_SITE cAMP- and cGMP-dependent protein kinase phosphorylation site.

| | | |
|------------|------|-----|
| Query: 304 | KRLS | 307 |
| Query: 310 | RKHS | 313 |
| Query: 323 | KKAS | 326 |

>PS00005|PDOC00005|PKC_PHOSPHO_SITE Protein kinase C phosphorylation site.

| | | |
|------------|-----|-----|
| Query: 136 | TQK | 138 |
| Query: 220 | SMK | 222 |
| Query: 227 | SHK | 229 |
| Query: 308 | TFR | 310 |

>PS00006|PDOC00006|CK2_PHOSPHO_SITE Casein kinase II phosphorylation site.

| | | |
|------------|------|-----|
| Query: 13 | TCHD | 16 |
| Query: 17 | TIDD | 20 |
| Query: 326 | SLPE | 329 |

>PS00342|PDOC00299|MICROBODIES_CTER Microbodies C-terminal targeting signal.

| | | |
|------------|------|-----|
| Query: 335 | CKV* | 338 |
|------------|------|-----|

FIGURE 8

>PF00001|PF00001 7 transmembrane receptor (rhodopsin family)

Score: 217.21 Seq: 39 297 Model: 1 259
 *RRRIIVWVLCRRRRRTPTNNYTCNLGADLLFELFMBFWVWYVWGG
 N 1. +WV++R R +++ +++++NLA +DILF ++++P+ + YY++ +
 15334orfaa 39 LNALALWVFLRALRVHVVSVVMCNLAASDLLF-TLSLPVRLSYAL-H 85
 RWpFGdfmCrIWmYFDYMNMYASIFFLTcISIDRYLWAICHPMrYmRWMT
 +WPF+D++C +++++ MNNY S FL++I +DRY AI+HP+R + +++
 15334orfaa 86 HWPFPDLLCQTGAIFQMNNYSGCIFLMLINVDY-AAIVHPLRLRLHRR 134
 PRHRAWmIiIiWvMSFLISMPPFLMFr.WstyrDencWNmTWCmIyDWP
 PR +A++++++W++ +++++P + ++R ++R+++ + + C++++
 15334orfaa 135 PR-VARLLCLGVWALILVFAVPAARVHRPS-RCRYRDLEVR-LCFESFSD 181
 e...WMWrwYvILmciimgFYIPmiIMlFCYwRIYRIARlWMMRlpswQr
 E + +V+L +GF++P+ +++ +R+++++ + + +
 15334orfaa 182 ELWKGRLLPLVLLAEA-LGFLPLAAVVYSSGRVFWTLARPDATQ---SQ 227
 RRrmSmRxERRivKmlIiIMvVFICWlPYFIvmfMDTL....M.MwwFC
 R+R++V+ L++ +V+F++C+ PY+ ++ ++ L + ++
 15334orfaa 228 -----RRRKTVRLLLANLVIFLLCFVPYNSTLAVYGLLR\$KLVAASVP 270
 efCIwXrlWmYIfEWLaYvNCpCiNPIIY*
 + R + M + ++LA +NC +++P++Y
 15334orfaa 271 ARDRVrgVLM-VMVLLAGANC-VLDPLVY 297

>PF00010|PF00010 Helix-loop-helix DNA-binding domain

Score: 0.33 Seq: 157 177 Model: 1 21
 RRRnHNMRRERQRRNDVNEaFE
 +R+ +R R R +V++ FE
 15334orfaa 157 ARVHRPSRCRYRDLEVRLCFE 177

FIGURE 9





FIGURE 10

Analysis of sequence28390 (372 aa)



>sequence28390

MLANSSSTNSSVLPCPDYRPTHRLHLVVYSLVLAAGLPLNALALWVFLRALRVHSVSVY
 MCNLAASDLLFTLSLPVRLSYALHHWPFDPDLLCQTGAFQMNMYGSCIFLMLINVDY
 AAIVHPLRLRLRRPRVARLLCLGVWALILVFAVPAARVHRPSRCRYRDLEVRLCFESFS
 DELWKGRLPLVLLAEALGFLPLAAVVYSSGRVFWTLARPDATQSQRERKTVRLLLANL
 VIFLLCFVPYNSTLAVYGLLRSLVAASVPARDRVRGVLMVMVLLAGANCVLDPLVYYS
 AEGFRNTLRGLGTPHRARTSATNGTRAALAQSERSAVTTDATRPDAASQGLLRPSDSHSL
 SSPTQCPQDSAL

FIGURE 11

Prosite Pattern Matches for sequence28390

Prosite version: Release 12.2 of February 1995

>PS00001|PDOC00001|ASN_GLYCOSYLATION N-glycosylation site.

| | | | |
|--------|-----|------|-----|
| Query: | 4 | NSSS | 7 |
| Query: | 9 | NSSV | 12 |
| Query: | 251 | NSTL | 254 |
| Query: | 323 | NGTR | 326 |

>PS00004|PDOC00004|CAMP_PHOSPHO_SITE cAMP- and cGMP-dependent protein kinase phosphorylation site.

| | | | |
|--------|-----|------|-----|
| Query: | 229 | RRKT | 232 |
|--------|-----|------|-----|

>PS00005|PDOC00005|PKC_PHOSPHO_SITE Protein kinase C phosphorylation site.

| | | | |
|--------|-----|-----|-----|
| Query: | 21 | THR | 23 |
| Query: | 211 | SGR | 213 |
| Query: | 226 | SQR | 228 |
| Query: | 232 | TVR | 234 |
| Query: | 307 | TLR | 309 |
| Query: | 332 | SER | 334 |

>PS00006|PDOC00006|CK2_PHOSPHO_SITE Casein kinase II phosphorylation site.

| | | | |
|--------|-----|------|-----|
| Query: | 178 | SFSD | 181 |
| Query: | 342 | TRPD | 345 |

>PS00008|PDOC00008|MYRISTYL N-myristoylation site.

| | | | |
|--------|-----|--------|-----|
| Query: | 36 | GLPLNA | 41 |
| Query: | 258 | GLLRSK | 263 |
| Query: | 324 | GTRAAL | 329 |

>PS00217|PDOC00210|G_PROTEIN_RECEPTOR G-protein coupled receptors signature.

| | | | |
|--------|-----|-------------------|-----|
| Query: | 107 | GSCIFLMLINVDRYAAI | 123 |
|--------|-----|-------------------|-----|

FIGURE 12

Gene 14618 Expression in Normal Human Tissues




FIGURE 13

14618 Expression




FIGURE 14

2838 Expression




FIGURE 15

Gene 15334 Expression in Normal Human Tissues




FIGURE 16

hu15334 Expression



15334 Expression




FIGURE 19

SEQUENCE LISTING

<110> Glucksmann, Maria A.

<120> Novel G-Protein Coupled Receptors

<130> 5803-11-1

<140>

<141>

<160> 7

<170> PatentIn Ver. 2.1

<210> 1

<211> 319

<212> PRT

<213> Homo sapiens

<400> 1

Met Ser Gln Gln Asn Thr Ser Gly Asp Cys Leu Phe Asp Gly Val Asn
 1 5 10 15

Glu Leu Met Lys Thr Leu Gln Phe Ala Val His Ile Pro Thr Phe Val
 20 25 30

Leu Gly Leu Leu Asn Leu Leu Ala Ile His Gly Phe Ser Thr Phe
 35 40 45

Leu Lys Asn Arg Trp Pro Asp Tyr Ala Ala Thr Ser Ile Tyr Met Ile
 50 55 60

Asn Leu Ala Val Phe Asp Leu Leu Leu Val Leu Ser Leu Pro Phe Lys
 65 70 75 80

Met Val Leu Ser Gln Val Gln Ser Pro Phe Pro Ser Leu Cys Thr Leu
 85 90 95

Val Glu Cys Leu Tyr Phe Val Ser Met Tyr Gly Ser Val Phe Thr Ile
 100 105 110

Cys Phe Ile Ser Met Asp Arg Phe Leu Ala Ile Arg Tyr Pro Leu Leu
 115 120 125

Val Ser His Leu Arg Ser Pro Arg Lys Ile Phe Gly Ile Cys Cys Thr
 130 135 140

Ile Trp Val Leu Val Trp Thr Gly Ser Ile Pro Ile Tyr Ser Phe His
145 150 155 160

Gly Lys Val Glu Lys Tyr Met Cys Phe His Asn Met Ser Asp Asp Thr
165 170 175

Trp Ser Ala Lys Val Phe Phe Pro Leu Glu Val Phe Gly Phe Leu Leu
180 185 190

Pro Met Gly Ile Met Gly Phe Cys Cys Ser Arg Ser Ile His Ile Leu
195 200 205

Leu Gly Arg Arg Asp His Thr Gln Asp Trp Val Gln Gln Lys Ala Cys
210 215 220

Ile Tyr Ser Ile Ala Ala Ser Leu Ala Val Phe Val Val Ser Phe Leu
225 230 235 240

Pro Val His Leu Gly Phe Phe Leu Gln Phe Leu Val Arg Asn Ser Phe
245 250 255

Ile Val Glu Cys Arg Ala Lys Gln Ser Ile Ser Phe Phe Leu Gln Leu
260 265 270

Ser Met Cys Phe Ser Asn Val Asn Cys Cys Leu Asp Val Phe Cys Tyr
275 280 285

Tyr Phe Val Ile Lys Glu Phe Arg Met Asn Ile Arg Ala His Arg Pro
290 295 300

Ser Arg Val Gln Leu Val Leu Gln Asp Thr Thr Ile Ser Arg Gly
305 310 315

<210> 2

<211> 1617

<212> DNA

<213> Homo sapiens

<400> 2

aggtacagcc tttggccatt agagaactaa ggcaggaacc tccaaacctga ccttgctctt 60
gtggactgca gttgtgattc aatgggcatg aattgctgtg tgatgctggg aagggtgtttg 120
tgattcttga caaagtcatt tgaatccatc acttcaagag agtgaaagga gccccgtctg 180
atctgttggt gttgtaggaa gaaacatgag tcagcaaaaac accagtgggg actgctgtt 240
tgacggtgtc aacgagctga tgaaaacct acagtttgca gccacatcc ccaccttctg 300
cctgggcctg ctctcaacc tctggtccat ccattgcttt agaaccttc ttaagaacag 360
gtggccgat tatgctgcca cctccatcta catgatcaac ctggcagttt ttgacctgt 420
gtggtgtctc tccctccat tcaagatggt cctgtccag gtacagtccc ccttccctgtc 480

ctgtgtgcaac ctggttggagt ccttttactt cctcagcactt tacgggaagcg ttttcaaccat 541
 ctggttccatc agcatcgacc gctttcttggc cactccttcc cctctacttg tgacccacat 601
 ccggttccccc aggaacatct ttgggatctc ctgcacatc tgggtctctg tctugacccg 661
 aagcatccct atctacagtt tccatgggaa agtgagagaa tacatcttct tccacaacat 721
 gtctgatgat acctggagcg ccaaggttct ttcccccctc cagggtgttc ccttctctct 781
 tcccatgggc atcatgggtt tctgtgtctc caggagcact caccatcttc tgggcacggc 841
 agaccacacac caggactggg tgcagcagaa agccttcact taccagatcc caccagagct 901
 ggtgtgtcttc ggtgtctctt tcttcccatg ccaacggggg ttcttctctg agttcttggg 961
 gagaaacagc ttctatgtag agtgagagc caagagagc atcagcttct tcttgcaatt 1021
 gtccatgtgt ttctcacaag tcaactgtct cctggatctt ttctgtctct accttgctat 1081
 caaagaattc tccatgaaca tcagggccca cgggtctctc agggctcagc tgggtctgca 1141
 ggacaccacg atctccggg gtaaacggaa ggacatctct ttccaggggaa gaaagccctg 1201
 gccctgaatt ctggttaacg attctggctt ccagggtttt gatgtgttgg gatgatccgc 1261
 accatcttca ctgatgtgt tctcttctgt gccattcag tgcagctttt gctcattata 1321
 ccccaagaa ctttttttca ctgcccagac agcttatccc accaggtgtt cagggtatct 1381
 tgaagaacct acagaccagc tgaattactg attcttaagt ccaaaaaacta tagagcagaa 1441
 gaattgagaa agagaatgag accatgtcaa caaggtgtt tctaaactct cccattttct 1501
 tgttcgactg ggaggttctg gaaagaaaga gaggagagaa aaagaggtaa aggagggagc 1561
 caagagagtc agttattggg gagagtgtct tgggcagagg tgggtgtgga gggatga 1617

<210> 3

<211> 337

<212> PRT

<213> Homo sapiens

<400> 3

Met Asp Glu Thr Gly Asn Leu Thr Val Ser Ser Ala Thr Cys His Asp
 1 5 10 15

Thr Ile Asp Asp Phe Arg Asn Gln Val Tyr Ser Thr Leu Tyr Ser Met
 20 25 30

Ile Ser Val Val Gly Phe Phe Gly Asn Gly Phe Val Leu Tyr Val Leu
 35 40 45

Ile Lys Thr Tyr His Lys Lys Ser Ala Phe Gln Val Tyr Met Ile Asn
 50 55 60

Leu Ala Val Ala Asp Leu Leu Cys Val Cys Thr Leu Pro Leu Arg Val
 65 70 75 80

Val Tyr Tyr Val His Lys Gly Ile Trp Leu Phe Gly Asp Phe Leu Cys
 85 90 95

Arg Leu Ser Thr Tyr Ala Leu Tyr Val Asn Leu Tyr Cys Ser Ile Phe
 100 105 110

Phe Met Thr Ala Met Ser Phe Phe Arg Cys Ile Ala Ile Val Phe Pro

| | | |
|---|-----|-----|
| 115 | 120 | 125 |
| Val Gln Asn Ile Asn Leu Val Thr Gln Lys Lys Ala Arg Phe Val Cys | | |
| 130 | 135 | 140 |
| Val Gly Ile Trp Ile Phe Val Ile Leu Thr Ser Ser Pro Phe Leu Met | | |
| 145 | 150 | 155 |
| Ala Lys Pro Gln Lys Asp Glu Lys Asn Asn Thr Lys Cys Phe Glu Pro | | |
| 165 | 170 | 175 |
| Pro Gln Asp Asn Gln Thr Lys Asn His Val Leu Val Leu His Tyr Val | | |
| 180 | 185 | 190 |
| Ser Leu Val Gly Gly Phe Ile Ile Pro Phe Val Ile Ile Ile Val Cys | | |
| 195 | 200 | 205 |
| Tyr Thr Met Ile Ile Leu Thr Leu Leu Lys Lys Ser Met Lys Lys Asn | | |
| 210 | 215 | 220 |
| Leu Ser Ser His Lys Lys Ala Ile Gly Met Ile Met Val Val Thr Ala | | |
| 225 | 230 | 235 |
| Ala Phe Leu Val Ser Phe Met Pro Tyr His Ile Gln Arg Thr Ile His | | |
| 245 | 250 | 255 |
| Leu His Phe Leu His Asn Glu Thr Lys Pro Cys Asp Ser Val Leu Arg | | |
| 260 | 265 | 270 |
| Met Gln Lys Ser Val Val Ile Thr Leu Ser Leu Ala Ala Ser Asn Cys | | |
| 275 | 280 | 285 |
| Cys Phe Asp Pro Leu Leu Tyr Phe Phe Ser Gly Gly Asn Phe Arg Lys | | |
| 290 | 295 | 300 |
| Arg Leu Ser Thr Phe Arg Lys His Ser Leu Ser Ser Val Thr Tyr Val | | |
| 305 | 310 | 315 |
| Pro Arg Lys Lys Ala Ser Leu Pro Glu Lys Gly Glu Glu Ile Cys Lys | | |
| 325 | 330 | 335 |
| Val | | |

<210> 4

<211> 1358

<212> DNA

<213> Homo sapiens

<400> 4

```

acatttcacac cagualtggg cagcagggtc gtagatcga tttcttgaag acttggaggt 60
tgcttctcag aacaaaagca aaagcagagt aaactgtgga ccttgaagtt agcagcgtgg 120
gcttctctta atattacacc gtaaaaggca ttgataacca taagaaggaa cttttgtgaa 180
ggtactccag tgcagaaaa aggcacaaaag cagacatttg tagagaaaca tggatgaaac 240
aggaaaatctg acagtatctt ctgcacatg ccattgacat attgatgact tccgcaatca 300
agtgtattcc accttgtact ctatgatctc tgttgtaggc tcttttggca atggctttgt 360
gctctatgtc ctacataaaaa cctatcacaa gaagtcagcc ttcacagtat acatgattaa 420
tttagcagta gcagatctac tttgtgtgtg cacttggct ctctgtgtgg tctattatgt 480
tcacaaaaggc atttggctct ttggtgactt ttgtgtgggc ctacgcacct atgctttgta 540
tgtcaacctc tattgtagca tcttctttat gacagccatg agctttttcc ggtgcattgc 600
aattgttttc ccagtcacga acatttattt ggctacacag aaaaaagcca ggtttgtgtg 660
tgtaggtatt tggatttttg tgattttgac cagttctcca tttctaatgg ccaaacccaca 720
aaaaagatgag aaaaataata ccaagtgctt tgagccccc cagacacac aaactaaaaa 780
tcatgttttg gtcttgcatt atgtgtcatt ggttgttggc tttatcctcc cttttgttat 840
tataattgtc tgctacacaa tgatcatttt gaccttacta aaaaaatcaa tgaaaaaaaa 900
tctgtcaagt cataaaaaag ctataggaat gatcatggtc gtgacccgtg cttttttagt 960
cagtttcatg ccattacata ttaaacgtac cattcacctt ctttttttcc acaatgaaac 1020
taaacctctg gattctgtcc ttagaatgca gaagtcctgt gtcataacct tgtctctggc 1080
tgcatccaat tgttgccttg acctctctct atattttctt tctgggggta actttaggaa 1140
aaggctgtct acatttagaa agcattcttt gtccagcgtg atttatgtac ccagaaaagaa 1200
ggcctctttg ccagaaaaag gagaagaaat atgtaaagta tagtttaaac ccatttccag 1260
tccaaaaccaa tgaaaatagt ttcccaata agtattttgt caaatcattt acaaaaaaaaa 1320
taaaaatttt acttaaaaaa aaaaaaaaaa aaggaaaaa 1358

```

<210> 5

<211> 372

<212> PRT

<213> Homo sapiens

<400> 5

```

Met Leu Ala Asn Ser Ser Ser Thr Asn Ser Ser Val Leu Pro Cys Pro
  1                      5                      10                      15

```

```

Asp Tyr Arg Pro Thr His Arg Leu His Leu Val Val Tyr Ser Leu Val
      20                      25                      30

```

```

Leu Ala Ala Gly Leu Pro Leu Asn Ala Leu Ala Leu Trp Val Phe Leu
      35                      40                      45

```

```

Arg Ala Leu Arg Val His Ser Val Val Ser Val Tyr Met Cys Asn Leu
      50                      55                      60

```

```

Ala Ala Ser Asp Leu Leu Phe Thr Leu Ser Leu Pro Val Arg Leu Ser
      65                      70                      75                      80

```

Tyr Tyr Ala Leu His His Trp Pro Phe Pro Asp Leu Leu Cys Gln Thr
85 90 95

Thr Gly Ala Ile Phe Gln Met Asn Met Tyr Gly Ser Cys Ile Phe Leu
100 105 110

Met Leu Ile Asn Val Asp Arg Tyr Ala Gly Ile Val His Pro Leu Arg
115 120 125

Leu Arg His Leu Arg Arg Ala Arg Val Ala Arg Leu Leu Cys Leu Gly
130 135 140

Val Trp Ala Leu Ile Leu Val Phe Ala Val Pro Ala Ala Arg Val His
145 150 155 160

Arg Pro Ser Arg Cys Arg Tyr Arg Asp Leu Glu Val Arg Leu Cys Phe
165 170 175

Glu Ser Phe Ser Asp Glu Leu Trp Lys Gly Arg Leu Leu Pro Leu Val
180 185 190

Leu Leu Ala Glu Ala Leu Gly Phe Leu Leu Pro Leu Ala Ala Val Val
195 200 205

Tyr Ser Ser Gly Arg Val Phe Trp Thr Leu Ala Arg Pro Asp Ala Thr
210 215 220

Gln Ser Gln Arg Arg Arg Lys Thr Val Arg Leu Leu Leu Ala Asn Leu
225 230 235 240

Val Ile Phe Leu Leu Cys Phe Val Pro Tyr Asn Ser Thr Leu Ala Val
245 250 255

Tyr Gly Leu Leu Arg Ser Lys Leu Val Ala Ala Ser Val Pro Ala Arg
260 265 270

Asp Arg Val Arg Gly Val Leu Met Val Met Val Leu Leu Ala Gly Ala
275 280 285

Asn Cys Val Leu Asp Pro Leu Val Tyr Tyr Phe Ser Ala Glu Gly Phe
290 295 300

Arg Asn Thr Leu Arg Gly Leu Gly Thr Pro His Arg Ala Arg Thr Ser
305 310 315 320

Ala Thr Asn Gly Thr Arg Ala Ala Leu Ala Gln Ser Glu Arg Ser Ala
325 330 335

Val Thr Thr Asp Ala Thr Arg Pro Asp Ala Ala Ser Gln Gly Leu Leu
340 345 350

Arg Pro Ser Asp Ser His Ser Leu Ser Ser Phe Thr Gln Cys Pro Gln
355 360 365

Asp Ser Ala Leu
370

<210> 6

<211> 2559

<212> DNA

<213> Homo sapiens

<400> 6

```

ccatgacctc cctctgcttg ttttgggacc atgtctgtac agcctctagg ccccagcccc 60
ggaggtgaat gccatgccat gattctggtg tgcctcatgg catccccagg ctagctccca 120
atcccacttt ggcacgatgt tagccaacag ctctccaacc aacagttctg ttctcccggtg 180
tcttgactac cgacctaccc accgcctgca cttgggtggc tacagcttgg tgcctggctgc 240
cgggtccccc ctcaacgcgc tagccctctg ggtcttctct cggcgctgac ggcctgacct 300
ggcgggtgag gtgtacatgt gtaacctggc ggccagcgac ctgctcttca cctctctgct 360
gcccgttcgt ctctctact accactgca ccaatggccc ttcccagacc tctgtgcca 420
gacgacgggg gccatcttcc agatgaacat gtacggcagc tgcctcttcc tgatgctcat 480
caacgtggac cgtacgcgc gccatcgtgca cccgctgcga ctggccacc ttggcggggc 540
cccgctggcg cggctgctct gccctggcgt gtggcgctc atctgggtgt ttggcggtgc 600
cgccgccccg gtgcacagcg cctcgcttg ccgtaccgg gccctcgagg tgcgctatg 660
cttcgagagg tttagcgagc agctgtggaa aggcaggctg ctgcccctcg tgcctgctgc 720
cgaggcgctg ggcctctctg tgcacctggc ggcggtggtc taactgctcg gcagagtctt 780
ctggacgctg gcgcgcgcgc accccacgca gagccagcgg cggcggaaga ccgtgcgcct 840
cctgctgggt aacctcgcca tctctctgct gtgcttcgt cctacaaca gccagctggc 900
ggtctacggg ctgctgcgga gcaagctggc ggccggccag gtgcctgccc gcgatcgct 960
gcgcgggggt ctgatggtga tggctgctgt gcccggcgc aactgcgtg ttggcccgct 1020
ggtgtactac tttagcgccg agggcttccg caacacctg cggcgctggt gcactccgca 1080
ccgggccagg acctcgcca ccaacgggac gcggcgcgcg ctccggaat ccgaaaggtc 1140
cgccgtcacc accgacgcca ccaggccgga tgcggccagt caggggctgc tccgacctc 1200
cgactccac tctctgtctt ccttcacaca gtgtccccc gattccggcc tctgaacaca 1260
catgccattg cgtgtctcgt gcccgactcc caacgcctc cgtcttggga ggcttacagg 1320
gtgtacacac aagaagggtg gctgggcact tggaccttg ggtggcaatr ccagcttagc 1380
aacgcagaa agtacaaagt gtggaagcca gggccagggt aaggcagtgc tgtggaaat 1440
ggcttcttta aactgtgagc acgcagagca ccccttctcc agcggtggga agtgatgcag 1500
aaagcccacc cgtgcagagg gcagaagagg acgaaatgcc ttgggtgggt caggggcata 1560
aactgctaaa agctggttag atggaccaga aaatgggcat ttggatttt aaccggccac 1620
aggggcttga gacttgaaga gcaccagggt tgggtggaca agctacgag atgctgttc 1680
atctgctgac ttctgtctag gctcatggat gccacccct ttcattttg cctaggtctc 1740
cctgctcac cactgaggcc taatacaaga gtccctatgg acagaactat attctttctc 1800
gcatagtgac ttgtgacaat ttagacttgg catccagcat gggatagttt gggcaaggca 1860
aaactaactt agagtttccc cctcaacaac atccaagtc aaacctttt taggttatcc 1920

```

```

ttttttccat cacatccctt tttccagggc tcttcattt taggtcccta atattctttc 1980
ttttttcttc tctctgggtt ctctcttttc tctctctccc tctctctctc cctctctctc 2040
ctctctctct ctctctctt gtcagagta aggataaatt cttcttacta aagcactggc 2100
tctcaaaatt ttgggtctca gaccacactc tttagaaattg aggatctcaa agagctttgc 2160
ttatatcttg tctcttgat acttaccata ctagaaatta aaqccaatac atttttaaaa 2220
taaatacaca tgcacacatt acattagcca tgggagcaat aatgtcacca caccaccttc 2280
atgaagcttc tggaaaactc tacagtatac ttgtgagaga atgagagtga aaggagacaa 2340
taacatctgt gttagcagta tatgaaaata gcttgacctc gtggacttcc tcagagggtt 2400
ggctccttga tcacactttg agaaccatac ttgtcctgaa gtattggagt tcattgttaa 2460
cttcttccca gggcattatg tacagtctt tttattactg tggggagagg gcagtgttaa 2520
ataaattaat cactactgat agtcaaaaaa aaaaaaaaaa 2559

```

<210> 7

<211> 269

<212> PRT

<213> Unknown

<220>

<223> Description of Unknown Organism: Rhodopsin family
transmembrane receptor

<400> 7

```

Gly Asn Ile Leu Val Ile Trp Val Ile Cys Arg Tyr Arg Arg Met Arg
  1                      5                      10                      15

```

```

Thr Pro Met Asn Tyr Phe Ile Val Asn Leu Ala Val Ala Asp Leu Leu
                20                      25                      30

```

```

Phe Ser Leu Phe Thr Met Pro Phe Trp Met Val Tyr Tyr Val Met Gly
                35                      40                      45

```

```

Gly Arg Trp Pro Phe Gly Asp Phe Met Cys Arg Ile Trp Met Tyr Phe
                50                      55                      60

```

```

Asp Tyr Met Asn Met Tyr Ala Ser Ile Phe Phe Leu Thr Cys Ile Ser
                65                      70                      75                      80

```

```

Ile Asp Arg Tyr Leu Trp Ala Ile Cys His Pro Met Arg Tyr Met Arg
                85                      90                      95

```

```

Trp Met Thr Pro Arg His Arg Ala Trp Val Met Ile Ile Ile Ile Trp
                100                      105                      110

```

```

Val Met Ser Phe Leu Ile Ser Met Pro Pro Phe Leu Met Phe Arg Trp
                115                      120                      125

```

```

Ser Thr Tyr Arg Asp Glu Asn Glu Trp Asn Met Thr Trp Cys Met Ile
                130                      135                      140

```

Tyr Asp Trp Pro Glu Trp Met Trp Arg Trp Tyr Val Ile Leu Met Thr
145 150 155 160

Ile Ile Met Gly Phe Tyr Ile Pro Met Ile Ile Met Leu Phe Cys Tyr
165 170 175

Trp Arg Ile Tyr Arg Ile Ala Arg Leu Trp Met Arg Met Ile Pro Ser
180 185 190

Trp Gln Arg Arg Arg Arg Met Ser Met Arg Arg Glu Arg Arg Ile Val
195 200 205

Lys Met Leu Ile Ile Ile Met Val Val Phe Ile Ile Cys Trp Leu Pro
210 215 220

Tyr Phe Ile Val Met Phe Met Asp Thr Leu Met Met Trp Trp Phe Cys
225 230 235 240

Glu Phe Cys Ile Trp Arg Arg Leu Trp Met Tyr Ile Phe Glu Trp Leu
245 250 255

Ala Tyr Val Asn Cys Pro Cys Ile Asn Pro Ile Ile Tyr
260 265



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|-----------|--|
| (51) International Patent Classification ⁷ : C12N 15/12, C07K 14/705, 16/28, G01N 33/53, C12Q 1/68, A61K 31/70, 38/17, A01K 67/027 | | A3 | (11) International Publication Number: WO 00/23588 (43) International Publication Date: 27 April 2000 (27.04.00) |
| (21) International Application Number: PCT/US99/24368 (22) International Filing Date: 18 October 1999 (18.10.99) (30) Priority Data: 09/173,869 16 October 1998 (16.10.98) US Not furnished 18 October 1999 (18.10.99) US (71) Applicant (for all designated States except US): MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GLUCKSMANN, Maria, Alexandra [AR/US]; 33 Summit Road, Lexington, MA 02173 (US). WEICH, Nadine, S. [US/US]; 70 Park Street #53, Brookline, MA 02446 (US). (74) Agents: BROWN, Anne et al.; Alston & Bird LLP, P.O. Drawer 34009, Charlotte, NC 28234-4009 (US). | | | (81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 27 July 2000 (27.07.00) |
| (54) Title: G-PROTEIN COUPLED RECEPTORS | | | |
| (57) Abstract <p>The present invention relates to newly identified receptors belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptors. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/24368

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C07K16/28 G01N33/53 C12Q1/68
A61K31/70 A61K38/17 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N C12Q A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No |
|------------|---|----------------------|
| X | DATABASE EMBL - EMBEST28 [Online] Entry HSA33905, Acc.no. AA33905, 26 August 1996 (1996-08-26) HILLIER, L ET AL.: "zi05b04.r1 Soares fetal liver spleen 1NFLS S1 Homo sapeins cDNA clone 429871 5'." XP002129413 the whole document --- -/-- | 3-7 |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

25 April 2000

Date of mailing of the international search report

10.05.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer

Smaït, R

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/24368

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | <p>DATABASE EMBL - EMBEST5 [Online] Entry/Acc.no. AA993247, 5 June 1998 (1998-06-05) STRAUSBERG, R.: "ot60c09.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1621168 3' similar to TR:Q60485 Q60485 ACROSOMAL PROTEIN SP32 PRECURSOR. ;," XP002136321 the whole document</p> <p>---</p> | 3,4,6,7 |
| X | <p>DATABASE EMBL - EMBEST3 [Online] Entry/Acc.no. AA769338, 31 January 1998 (1998-01-31) STRAUSBERG, R. ET AL.: "nz30e08.s1 NCI CGAP GCB1 Homo sapiens cDNA clone IMAGE:1289318 3'," XP002136322 the whole document</p> <p>---</p> | 4,6,7 |
| A | <p>O'DOWD B F ET AL: "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,GB,ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 187, no. 1, 10 March 1997 (1997-03-10), pages 75-81, XP004093242 ISSN: 0378-1119 the whole document</p> <p>---</p> | |
| A | <p>WO 98 34948 A (CORNELL RES FOUNDATION INC) 13 August 1998 (1998-08-13) the whole document</p> <p>---</p> | |
| P,X | <p>WO 99 42582 A (ELSHOURBAGY NABIL A ;SMITHKLINE BEECHAM CORP (US); TSUI PING (US);) 26 August 1999 (1999-08-26) the whole document</p> <p>---</p> | 1-32, 37-43 |
| P,X | <p>DATABASE EMBL - EMHTG1 [Online] Entry/Acc.no. AC006087, 7 December 1998 (1998-12-07) MUNZY, D. ET AL.: "Homo sapiens chromosome 12p13.3 clone RPC111-433J6, *** SEQUENCING IN PROGRESS ***, 100 unordered pieces." XP002136323 From nt.131859-134408.</p> <p>-----</p> | 4-7 |

INTERNATIONAL SEARCH REPORT

national application No
PCT/US 99/24368

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons

- 1 ☒ Claims Nos
because they relate to subject matter not required to be searched by this Authority, namely
Although claims 37-39, 42, and 24, 30, 41 in as far as they relate to in vivo use, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
- 2 ☒ Claims Nos 36
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
- 3 ☐ Claims Nos
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a)

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows

see additional sheet

- 1 ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
- 2 ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee
- 3 ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos
1-43, all partially (inventions 1 and 3)
- 4 ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims Nos

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☒ No protest accompanied the payment of additional search fees

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 36

Claim 36 refers to a compound identifiable with a method, without giving a true technical characterization of the compound. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-43, all partially

A G-protein coupled receptor protein, designate REC2838, represented by seq.ID.2, nucleic acids encoding it as represented by seq.ID.1, fragments thereof, antisense thereto, antibody directed against the protein, vector comprising said nucleic acid, host transformed with the vector, and method for producing the protein using the host. Methods for detecting the protein or the nucleic acid in a sample, method for identifying compounds that interact with said protein or said nucleic acid, method for identifying compounds that modulate the level or activity of the protein or the nucleic acid, pharmaceutical compositions of the protein, the nucleic acid, or the modulating compound, transgenic animal expressing said protein and method for producing such an animal.

2. Claims: 1-43, all partially

A G-protein coupled receptor protein, designate REC14618, represented by seq.ID.3, nucleic acids encoding it as represented by seq.ID.4, fragments thereof, antisense thereto, antibody directed against the protein, vector comprising said nucleic acid, host transformed with the vector, and method for producing the protein using the host. Methods for detecting the protein or the nucleic acid in a sample, method for identifying compounds that interact with said protein or said nucleic acid, method for identifying compounds that modulate the level or activity of the protein or the nucleic acid, pharmaceutical compositions of the protein, the nucleic acid, or the modulating compound, transgenic animal expressing said protein and method for producing such an animal.

3. Claims: 1-43, all partially

A G-protein coupled receptor protein, designate REC15334, represented by seq.ID.5, nucleic acids encoding it as represented by seq.ID.6, fragments thereof, antisense thereto, antibody directed against the protein, vector comprising said nucleic acid, host transformed with the vector, and method for producing the protein using the host. Methods for detecting the protein or the nucleic acid in a sample, method for identifying compounds that interact with said protein or said nucleic acid, method for identifying compounds that modulate the level or activity of the protein or the nucleic acid, pharmaceutical compositions of the protein, the nucleic acid, or the modulating compound, transgenic animal expressing said protein and method for producing such an animal.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/24368

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9834948 | A | 13-08-1998 | AU 6149898 A | 26-08-1998 |
| WO 9942582 | A | 26-08-1999 | NONE | |

| | | | |
|--|--|---|--|
| (51) International Patent Classification ⁷ : C12N 15/12, C07K 14/705, 16/28, G01N 33/53, C12Q 1/68, A61K 31/70, 38/17, A01K 67/027 | | A3 | (11) International Publication Number: WO 00/23588 (43) International Publication Date: 27 April 2000 (27.04.00) |
| (21) International Application Number: PCT/US99/24368 (22) International Filing Date: 18 October 1999 (18.10.99) (30) Priority Data: 09/173,869 16 October 1998 (16.10.98) US Not furnished 18 October 1999 (18.10.99) US (71) Applicant (for all designated States except US): MILLENIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GLUCKSMANN, Maria, Alexandra [AR/US]; 33 Summit Road, Lexington, MA 02173 (US). WEICH, Nadine, S. [US/US]; 70 Park Street #53, Brookline, MA 02446 (US). (74) Agents: BROWN, Anne et al.; Alston & Bird LLP, P.O. Drawer 34009, Charlotte, NC 28234-4009 (US). | | (81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i> (88) Date of publication of the international search report: 27 July 2000 (27.07.00) Date of publication of the amended claims: 14 September 2000 (14.09.00) | |
| (54) Title: G-PROTEIN COUPLED RECEPTORS | | | |
| (57) Abstract <p>The present invention relates to newly identified receptors belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptors. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

AMENDED CLAIMS

[received by the International Bureau on 7 July 2000 (07.07.00);
original claims 1-43 replaced by new claims 1-20 (4 pages)]

1. An isolated polypeptide having an amino acid sequence selected from the group consisting of:
- (a) The amino acid sequence shown in SEQ ID NO 5;
 - 5 (b) The amino acid sequence encoded by the cDNA contained in ATCC Deposit No. _____;
 - (c) The amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO 5;
 - (d) The amino acid sequence of an allelic variant of the amino acid
10 sequence encoded by the cDNA contained in ATCC Deposit No. _____;
 - (e) The amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO 5, wherein the sequence variant is encoded by a nucleic acid molecule hybridizing to the nucleic acid molecule shown in SEQ ID NO 6 under stringent conditions;
 - 15 (f) The amino acid sequence of a sequence variant of the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. _____, wherein the sequence variant is encoded by a nucleic acid molecule hybridizing under stringent conditions to the cDNA contained in ATCC Deposit No. _____;
 - (g) A fragment of the amino acid sequence shown in SEQ ID NO
20 5, wherein the fragment comprises at least 8 contiguous amino acids;
 - (h) A fragment of the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. _____, wherein the fragment comprises at least 8 contiguous amino acids;
 - (i) The amino acid sequence of the mature receptor polypeptide
25 from amino acid 6 to amino acid 372, shown in SEQ ID NO 5;
 - (j) The amino acid sequence of the mature polypeptide from amino acid 6 to amino acid 372, encoded by the cDNA clone contained in ATCC Deposit No. _____;
 - (k) The amino acid sequence of the polypeptide shown in SEQ ID
30 NO 5, from amino acid 1 to amino acid 25;
 - (l) The amino acid sequence from amino acid 1 to amino acid 25 in the polypeptide encoded by the cDNA contained in ATCC Deposit No. _____;
 - (m) The amino acid sequence of an epitope bearing region of any one of the polypeptides of (a)-(l).

2. An isolated antibody that selectively binds to a polypeptide of claim 1, (a)-(m).
- 5 3. An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:
- (a) The nucleotide sequence shown in SEQ ID NO 6;
 - (b) The nucleotide sequence in the cDNA contained in ATCC Deposit No. ____;
 - 10 (c) A nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO 5;
 - (d) A nucleotide sequence encoding the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. ____; and
 - (e) A nucleotide sequence complementary to any of the nucleotide
15 sequences in (a), (b), (c), or (d).
4. An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:
- (a) A nucleotide sequence encoding an amino acid sequence of a
20 sequence variant of the amino acid sequence shown in SEQ ID NO 5 that hybridizes to the nucleotide sequence shown in SEQ ID NO 6 under stringent conditions;
 - (b) A nucleotide sequence encoding the amino acid sequence of a sequence variant of the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. ____, the nucleic acid sequence of the sequence variant
25 hybridizing to the cDNA contained in ATCC Deposit No. ____ under stringent conditions; and
 - (c) A nucleotide sequence complementary to either of the nucleotide sequences in (a) or (b).
- 30 5. An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:
- (a) A nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO 5, wherein the fragment comprises at least 8 contiguous amino acids;

(b) A nucleotide sequence encoding a fragment of the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. _____, wherein the fragment comprises at least 8 contiguous amino acids;

(c) A nucleotide sequence complementary to either of the
5 nucleotide sequences in (a) or (b).

6. A nucleic acid vector comprising the nucleic acid sequences in any of claims 3-5.

10 7. A host cell containing the vector of claim 6.

8. A method for producing any of the polypeptides in claim 1 comprising introducing a nucleotide sequence encoding any of the polypeptide sequences in (a)-(m) into a host cell, and culturing the host cell under conditions in which the proteins
15 are expressed from the nucleic acid.

9. A method for detecting the presence of any of the polypeptides in claim 1 in a sample, said method comprising contacting said sample with an agent that specifically allows detection of the presence of the polypeptide in the sample and
20 then detecting the presence of the polypeptide.

10. The method of claim 9, wherein said agent is capable of selective physical association with said polypeptide.

25 11. The method of claim 10, wherein said agent binds to said polypeptide.

12. The method of claim 11, wherein said agent is an antibody.

13. The method of claim 11, wherein said agent is a ligand.
30

14. A kit comprising reagents used for the method of claim 9, wherein the reagents comprise an agent that specifically binds to said polypeptide.

15. A method for detecting the presence of any of the nucleic acid sequences in any of claims 3-5 in a sample, the method comprising contacting the sample with an oligonucleotide that hybridizes to the nucleic acid sequences under stringent conditions and determining whether the oligonucleotide binds to the nucleic acid sequence in the sample.

16. The method of claim 15, wherein the nucleic acid, whose presence is detected, is mRNA.

17. A kit comprising reagents used for the method of claim 15, wherein the reagents comprise a compound that hybridizes under stringent conditions to any of the nucleic acid molecules.

18. A method for identifying an agent that binds to any of the polypeptides in claim 1, said method comprising contacting the polypeptide with an agent that binds to the polypeptide and assaying the complex formed with the agent bound to the polypeptide.

19. The method of claim 18, wherein a fragment of the polypeptide is contacted.

20. A method for modulating the activity of any of the polypeptides in claim 1, the method comprising contacting any of the polypeptides of claim 1 with an agent under conditions that allow the agent to modulate the activity of the polypeptide.